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The inflammatory bowel diseases (IBD) are chronic, relapsing and remitting diseases 
of the gastrointestinal tract. There are two main types of IBD: Crohn’s disease (CD) 
and ulcerative colitis (UC). The prevalence of IBD is highest in the western world, 
approximately 100-200 people per 100,000 are affected. In recent years there has 
been a marked increase in the incidence of CD and UC, in both adults and children 
(Henderson et al., 2012; Molodecky et al., 2012). This is particularly relevant in 
Scotland where recent research shows that there has been a 79% increase in the 
number of cases of paediatric IBD since the 1990’s (Henderson et al., 2012).  
A yeast 2 hybrid screen identified TLE1as an interacting partner of the known CD 
susceptibility gene; Nucleotide- binding oligomerisation protein 2 (Nod2). An initial 
genome wide association study (GWAS) also found an association between the 
rs6559629 SNP, located in Tle1 and ileal CD (p =3.1 x 10-5) and showed that 
carriage of the Tle1 risk allele increases the effects of Nod2 mutations in CD. TLE1 
functions as a transcriptional co repressor in a variety of different cellular and 
developmental pathways   
The work presented in this thesis investigates the potential role of TLE1 in CD. This 
has been approached using four different strategies: sequencing TLE1 in CD patients 
and controls, analysing the effects of knocking down TLE1 on genome wide 
expression, investigating whether the known IBD susceptibility protein XBP1 binds 
to a predicted binding site in TLE1 and investigating TLE1 levels and localisation in 
human intestinal samples from CD patients and controls  
Sequencing TLE1 exons and introns 15/16 and 16/17 in a Scottish cohort of 24 CD 
patients and healthy controls identified a number of potentially pathogenic exonic 
and intronic SNPs. Two exonic SNPs and thirteen intronic SNPs were identified and 
these were further investigated in larger Scottish (203 CD cases, 190 HC) and 
European cohorts (6,333 CD cases and 15,056 HC) but were not present at 
statistically significantly different frequencies.    
 
x  
Secondly, the effects of TLE1 knock down on genome wide expression were 
analysed using an Illumina HT12 expression chip. The results showed that TLE1 
knock down significantly altered expression of 19 loci (Bonferroni) and 526 loci 
(FDR). Four of the 19 Bonferroni significant loci are potentially involved in CD:  
RIOK1 (p=4.3×10-3), SGPL1 (p=4.3×10-3), TUSC3 (p=1.8×10-2) and CCND1 
(p=2.7×10-3). Furthermore, expression of SGPL1 and RIOK1 were shown to be 
differentially expressed at the mRNA level between inflamed patients and controls.   
  
The third approach investigates a predicted binding site for the known IBD 
susceptibility gene, XBP1 in TLE1 which was identified using the Haploreg program. 
This work shows, using chromatin immunoprecipitation, that exogenous XBP1 does 
not appear to bind to this predicted binding site.  
  
Finally, TLE1 expression was analysed in human intestinal resection samples from 
patients of known NOD2 status. This work shows that TLE1 and NOD2 are 
expressed in Paneth cells, however TLE1 expression is not altered in patients 
carrying CD associated NOD2 variants.  
  
In this work TLE1 sequence, expression and potential interacting proteins have been 
analysed. The results presented suggests multiple mechanisms by which TLE1 may 
be influencing susceptibility to CD including: the unfolded protein response 
(TUSC3), S1P signalling and ribosome biogenesis. They also implicate TLE1 in 
Paneth cell function alongside NOD2. The exact means by which TLE1 may play a 































Chapter 1: Introduction                                                                                               2 
1.1 Inflammatory Bowel Disease 
The inflammatory bowel diseases (IBD) are chronic, relapsing and remitting diseases 
of the gastrointestinal tract. In IBD, the most commonly affected regions of the tract 
are the colon and ileum.  There are two main types of IBD: Crohn’s disease (CD) and 
Ulcerative colitis (UC). The symptoms of these disorders are similar and include 
diarrhoea, abdominal pain, gastrointestinal bleeding, weight loss, malnutrition and 
fatigue. Furthermore, UC sufferers have 60% increased risk of developing colorectal 
cancer when compared to that of the general population (Herrinton et al., 2012).The 
key differences between UC and CD are the region of the GI tract affected and the 
degree of inflammation. Clinically, CD can be characterised by discontinuous 
inflammation in any part of the gastrointestinal tract from the mouth to anus. However, 
CD most commonly affects the lower part of the small intestine called the ileum, 
however, approximately 5% of cases affect the mouth. This inflammation is 
transmural; it can affect any layer of tissue. In UC there is usually continuous 
distribution of inflammation which begins in the rectum and can extend to the caecum. 
The inflammation which usually begins in the lamina propria layer of tissue and is 
limited to the mucosal and submucosal layers of the intestinal wall. In a proportion of 
cases with colonic inflammatory bowel disease patients show characteristics of both 
UC and CD, these patients are diagnosed with IBD unclassified (IBD-U).  
 
1.2 Structure of the gastrointestinal (GI) tract 
The gastrointestinal tract contains the organs responsible for the ingestion of food, the 
digestion of food and the excretion of any waste material. The upper GI tract is 
comprised of the oesophagus, stomach and the first part of the small intestine, the 
duodenum. The lower section of the tract comprises the rest of the small intestine 
(jejunum and ileum) and the large intestine (colon, caecum and rectum).  
The process of digestion begins with the mouth and salivary glands which orchestrate 
the mechanical and enzymatic breakdown of food. This process is continued in the 
stomach, where the food is further broken down in the presence of acids and enzymes. 
The partially digested food then passes into the small intestine which contains 
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digestive enzymes secreted by the pancreas. The small intestine has three sections: the 
duodenum, the jejunum and the ileum; these are responsible for the final stages of 
digestion and the absorption of nutrients. To aid absorption of nutrients, the surface of 
the small intestine is comprised of many crypts which provide increased surface area. 
Following digestion in the small intestine, the remaining material passes through the 
ileo-colonic valve into the colon allowing absorption of water and vitamins, leftover 
waste material is stored in the rectum prior to excretion. 
 
Histologically, the GI tract is composed of four layers (from inside to outside): the 
mucosa, submucosa, muscularis externa and the adventitia. These layers are evident 
throughout the GI tract, however their composition varies. In the small intestine, the 
inner mucosal layer consists of three sub-layers the inner epithelial layer, the lamina 
propria and the muscularis mucosa.  
 
The inner epithelial layer acts as a barrier to defend against bacterial invasion, whilst 
facilitating efficient absorption of nutrients and fluids and excretion of waste material. 
In the small intestine the epithelial layer consists of absorptive (epithelial cells) and 
secretory cells (endocrine cells, goblet cells and Paneth cells). Endocrine cells produce 
hormones that are release into the bloodstream through the copious amounts of blood 
vessels in the mucosa. Goblet cells produce glycosylated proteins called mucins. These 
proteins form a mucus which is secreted by the goblet cells and functions to protect 
the epithelial cells from enzymatic and bacterial damage. Paneth cells are involved in: 
bacterial sensing, upon exposure to bacteria or bacterial antigens, they release 
antimicrobial peptides including lysozyme and α defensins. The production of these 
peptides helps to retain the integrity of the epithelial barrier and prevent bacteria from 
entering the intestinal crypts. Microfold cells (MC) and dendritic cells (DC) also form 
part of the epithelial cell layer and along with Paneth cells play a key role in the 
intestinal immune system. In response to the presence of bacteria or defects in the 
epithelial barrier DC’s are activate and migrate to the lymph nodes where they induce 
the differentiation of naïve T cells into T effector and T regulatory cells. The lamina 
propria is a thin layer of connective tissue containing patches of lymphoid tissue which 
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produce macrophages and lymphocytes to protect the GI tract and a vascular system 
which supports the epithelial cell layer. The muscularis mucosa is a thin layer of 
smooth muscle which supports movement of the mucosa.  
 
The sub mucosa is a connective tissue layer containing larger blood vessels as well as 
nerve, lymph and glandular tissue. The muscularis externa is composed of two layers 
of muscle, a circular layer and a longitudinal layer. The function of this layer is to 
enable peristalsis, which pushes food through the gut. The outermost layer of tissue is 
an outer layer of connective tissue, the serosa. 
 
1.2.1 Incidence of IBD 
The prevalence of IBD is highest in the western world, approximately 100-200 people 
per 100,000 are affected. In recent years there has been a marked increase in the 
incidence of CD and UC, in both adults and children (Henderson et al., 2012; 
Molodecky et al., 2012). This is particularly relevant in Scotland as recent research 
shows that there has been a 79%  increase in the number of cases of paediatric IBD 
since the 1990’s (Henderson et al., 2012). The cause of this increase is not known, 
however a number of potential environmental risk factors have been identified, namely 
smoking, diet and exposure to bacteria. 
 
1.2.2 Pathogenesis 
Both UC and CD are polygenic, complex diseases that are thought to be caused by a 
combination of genetic and environmental susceptibility factors.  
The precise aetiology of IBD has yet to be fully elucidated. It is generally thought to 
arise from a dysregulated response to luminal bacteria in the intestinal epithelium in 
genetically susceptible individuals. In line with this, current treatment is limited to 
dietary supplementation, administering of drugs such as immunosuppressant’s and 
anti-inflammatory drugs and surgery. These treatments do not provide a cure and have 
adverse side effects, for example the administration of  immunosuppressant’s has is 
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known  to increase the risk of IBD patients developing skin cancer (Long et al., 2012) 
. 
IBD is a lifelong disease, requiring expensive medication and multiple surgeries, and 
therefore represents a significant burden on health services. Research into the 
molecular genetic basis underlying the cause of this disease is essential in order to 
develop more effective treatments. 
 
1.3 Environmental risk factors for IBD 
Many different environmental factors have been suggested to increase risk of 
developing IBD including smoking, oral contraception, diet, breast feeding, drugs, 
geographical and social status, microbial agents, intestinal permeability and 
appendectomy , ( reviewed in (Molodecky & Kaplan, 2010)). However, it is difficult 
to quantify the individual contribution of each of these factors to disease risk. The most 
widely accepted environmental IBD risk factor is smoking; it has been shown to affect 
both IBD incidence and history. Interestingly, smoking is a risk factor for developing 
CD but a protective factor for UC (M. C. Aldhous & Satsangi, 2010). 
 
1.4 Genetics of IBD 
1.4.1 Heritability 
Epidemiological data provide evidence suggesting that genetics contributes 
significantly to IBD susceptibility (Molodecky et al., 2012). There is variation in 
incidence and prevalence of IBD in different ethnic groups, for  example Ashkenazi 
Jews have a two to four fold higher incidence and prevalence than non-Jewish 
Caucasians (Roth, Petersen, McElree, Feldman, & Rotter, 1989; H. Yang et al., 1993).  
Twin and familial aggregation studies have shown that IBD has a strong genetic 
component, between 5-20% of patients have a family history of IBD which is more 
apparent in CD than UC (Orholm & et al, 1991). There is increased concordance for 
IBD in monozygotic twins than dizygotic twins, and this is higher is CD (20-50% in 
MZ vs 0- 7% in DZ) than in UC (14-19% in MZ vs 0- 5% in DZ) (Halfvarson & et al, 
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2003; Orholm, Binder, Rasmussen, Kyvik, & Hospital, 2000; Thompson, Driscoll, 
Pounder, & Wakefield, 1996; Tysk & Lindberg, 1988).  
It is important to note that overall estimates of heritability in IBD are subject to 
controversy as they do not account for interactions between genes, environmental risk 
factors or interactions between genes and the environment.  
 
1.4.2 Approaches 
Initial approaches to the investigation of the heritability of IBD involved linkage 
analysis which led to the led to the identification of two IBD risk loci in 1996: IBD1 
(Chromosome 16) and IBD9 (Chromosome 3). Further dissection of the IBD1 locus 
led to the identification of the first CD susceptibility gene in 2001: NOD2 (Hugot et 
al., 2001; Ogura et al, 2001; Peter & Muddassar, 2001). Three low frequency 
polymorphisms in the coding region of NOD2 were discovered (R707W, G908R and 
L1007fs) (Figure 4). It has since been shown that these mutations, in their homozygous 
or compound heterozygous states, result in a 20-40 fold increased risk of developing 
CD (Bonen & Cho, 2003). These mutations and the function of NOD2 are central to 
this project and are further discussed in section 1.4.6. Aside from the discovery of 
NOD2, linkage studies found very few replicable IBD susceptibility loci. This may 
have been due to the relatively small sample sizes used in these studies (usually 
between 100 and 400) leading to false findings. This information suggested that the 
genetic architecture of IBD was likely to be much more complex than that of 
Mendelian diseases and was unlikely to be caused by a defect in a single gene. It was 
postulated that complex diseases, such as IBD could be caused by a combination of 
large numbers of common variants of small effect size.  
 
Advances in technology led to the advent of genome wide association studies 
(GWAS). These are large scale studies, typically involving many thousands of cases 
and controls. These studies use a hypothesis free approach and involve comparing the 
frequency of single nucleotide polymorphism (SNP) alleles across the genome in cases 
and controls. This allows identification of SNPs that are associated with a disease, 
SNPs tagging a region of DNA implicated in disease pathogenesis.  GWA studies have 
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led to the identification to 201 susceptibility loci (J. Z. Liu et al., 2015). Of these 201 
loci, the majority (148) are implicated in both CD and UC, 30 are only relevant to CD 
and 23 are specific to UC. Together these loci account for 13.1% and 8.2% of the 
genetic heritability of CD and UC, respectively (J. Z. Liu et al., 2015). These loci are 
involved in many biological pathways including: innate pattern recognition (NOD2/ 
CARD15), differentiation of Th17-lymphocytes (IL23, IL23R), autophagy 
(ATG16L1) and the unfolded protein response (XBP1). GWA studies have not 
replicated many of the loci identified by linkage studies. Although as previously 
discussed this may be due to the limited cohort sizes of linkage studies, it is important 
to note that unlike linkage studies, the number of patients with a family history of IBD 
in GWAS cohorts is low. Additionally, mutations in NOD2, which is the strongest CD 
risk gene identified to date, were identified by linkage studies and have been replicated 
in GWA studies (Hugot et al., 2001; Jostins et al., 2012; Ogura et al, 2001).   
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1.4.3 The differentiation of Th17 lymphocytes in IBD pathogenesis  
Th17 cells are a subset of thymus derived lymphocytes that express the 
proinflammatory cytokine Interleukin 17 (IL 17).  These cells are positive for CD4, a 
glycoprotein present on the cell membrane of certain subtypes of immune cells. They 
are characterised by the synthesis of the cytokines: IL 17A, IL 21A, IL 22 and the 
expression of the receptors: IL23R and CCR6 (Wilson et al., 2007). Th17 cells 
function as part of the adaptive immune response. Upon exposure to antigens, naïve 
Th17 cells differentiate in order to perform a number of effector functions i.e. 
production of proinflammatory cytokines and anti apoptotic proteins (Figure 1). This 
differentiation process is induced by the cytokine IL 23. IL 23 interacts with the 
heterodimeric IL 23 receptor (IL23R). Upon binding of IL 23 to IL 23R, JAK2 is 
autophosphorylated and STAT3 forms an active homodimer and translocates into the 
nucleus to initiate transcription. 
 
GWAS studies have identified variants in the IL 23 receptor as associated with CD 
(Duerr et al., 2006). Duerr et al showed that the Arg381Gln substitution in IL23R has 
a protective effect in CD. More recent work has used deep sequencing of CD patients 
to identify rare variants in IL23R with a protective effect (Balzola, Bernstein, Ho, & 
Russell, 2012).  
 
The cytokines IL17A, IL22 and IL 26 show increased expression in both intestinal 
tissue and serum of IBD patients (Andoh et al., 2005; Fujino et al., 2003). Furthermore, 
a 20 fold increase is seen in the number of active Th17 cells in gut resections taken 
from CD patients when compared to controls. These Th17 cells have been shown to 
promote inflammation in colonic cell lines, treatment of cells with supernatant from 
Th17 cells (containing cytokines released by Th17 cells) leads to increased expression 
of chemokines (CXCL, CXCL8, CCL20) that are involved in maintenance of 
inflammation in CD patients (Kleinschek et al., 2009).  
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Figure 1 T helper (Th) cell differentiation 
Adapted from (Van Limbergen, Wilson, & Satsangi, 2009). Naïve T cells differentiate into 
Th1, Th2 or Th17 cells depending on cytokine stimulation. Th17 cells are induced by 
TGFβ, IL6 and IL23. IL23 binds to the IL23 receptor on the surface of Th17 cells, causing 
JAK2 to be phosphorylated, STAT3 to homodimerise and translocate into the nucleus. 
STAT3 initiates transcription of pro inflammatory cytokines and anti- apoptotic proteins.  
 
1.4.4 The Unfolded protein response in IBD pathogenesis 
The rough endoplasmic reticulum (ER) is the eukaryotic organelle responsible for the 
synthesis, folding and post translational modification of proteins. When the burden on 
the ER is too high, unfolded/misfolded proteins accumulate in the ER, this situation is 
defined as ER stress. The accumulation of unfolded/misfolded proteins initiates the 
unfolded protein response (UPR) which functions to resolve ER stress or induce 
apoptosis. X box protein 1 (XBP1) encodes a transcription factor that functions as part 
of the unfolded protein response. The role of XBP1 in IBD is discussed in detail in 
chapter 3. In brief, both common SNPs in the XBP1 region and four rare variants have 
been associated with IBD (Kaser et al., 2008).  Additionally, XBP1 null mice show 
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increased ER stress, develop spontaneous enteritis and have an exaggerated response 
to pro inflammatory cytokines (IBD inducers) e.g. TNFα and Flagellin in the 
epithelium. They also have an increased susceptibility to colitis as a result of Paneth 
cell absence and malformation (Kaser et al., 2008).  
 
Anterior gradient 2 (AGR2) is a protein disulphide isomerase which aids formation of 
disulphide bonds in the endoplasmic reticulum (ER). AGR2 aids formation of 
disulphide bonds in the cysteine rich Mucin 2 (MUC2) protein. MUC2 is a key 
component of the mucus secreted by goblet cells. Mice lacking Agr2 show decreased 
MUC2 levels and increased expression of the ER stress markers Xbp1(sp) and BiP.  
AGR2 is highly expressed in the ileum and colon and shows decreased expression 
levels in gut biopsies from UC patients when compared to healthy controls (W. Zheng 
et al., 2006). Additionally, FOXA1 and FOXA2 regulate goblet cell differentiation and 
have been shown to activate the AGR2 promoter region using luciferase reporter assays 
(W. Zheng et al., 2006).    
 
1.4.5 IBD and Autophagy 
Autophagy describes the evolutionarily conserved process by which cellular 
components are degraded in lysosomes. It is mediated by the autophagosome which 
consumes portions of cytoplasm. The process of autophagy begins with the formation 
of a phagosome which is (double membraned structure) forming around molecules that 
are to be degraded. This phagosome then expands, elongates and matures, eventually 
fusing with lysosomes resulting in the degradation of components encompassed by the 
autophagosome. Autophagy related gene like-1 (ATG16L1) encodes an autophagy 
protein involved in the formation and expansion of the autophagosome. During 
autophagosome formation, ATG16L1 forms a complex with other autophagy proteins 
(ATG5 and ATG 12) to enable conversion (lipidation) of the microtubule associated 
light chain protein (LC3) to LC3-II. LC3-II is a marker of autophagy and is located on 
the membrane of the mature autophagosome. The ATG16L1 T300A variant has been 
associated with CD, this variant causes a threonine to alanine substitution (Hampe et 
al., 2007) 
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In immune cells, autophagy is important for degradation of pathogens and initiation of 
the immune response. It is up regulated during intracellular infection, oxidative stress 
and upon accumulation of misfolded proteins. 
 
A 20Kb deletion upstream of the Immunity related GTPase M (IRGM) locus has also 
been associated with CD. Similarly to ATG16L1, IRGM has been implicated in the 
conversion of LC3-1 to LC-II. Human macrophages treated with IRGM siRNA do not 
form LC3-II in the presence of the autophagy inducer rapamycin (Singh, Davis, 
Taylor, & Deretic, 2006). Additionally, IRGM is involved in bacterial resistance. 
Increased bacterial survival is seen in human cells transfected with IRGM siRNA when 
compared to control transfections (Singh et al., 2006).  Igrm1 knockout mice exhibit 
increased acute ileal and colonic inflammation in response to DSS treatment when 
compared to controls. Furthermore, Paneth cells from these mice showed altered 
morphology of secretory granules and reduced expression of antimicrobial peptides 
including α defensins (B. Liu et al., 2013).   
 
Other autophagy proteins have also been associated with IBD including:  Leucine 
repeat kinase 2 (LRRK2) and SMAD Specific E3 Ubiquitin Protein Ligase 1 
(SMURF1) (Jostins et al., 2012).  
 
1.4.6 NOD2 (Nucleotide Oligomerisation Domain 2) 
Structure and Function 
Nucleotide oligomerisation protein 2 (NOD2) encodes a member of the Nod like 
Receptor (NLR) protein family. NOD2 functions as an intracellular pattern recognition 
receptor that plays a crucial role in innate immunity and inflammation. It consists of 
three protein domains, two caspase recruitment domains (CARD) at the N terminus, a 
nucleotide binding domain (NBD) and a C terminal leucine rich repeat region (LRR) 
(Figure 2). The LRR is thought to be responsible for ligand detection, it recognises 
bacterial components. NOD2 has been shown to bind to the bacterial cell wall 
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component, Muramyl Dipeptide (MDP) , upon binding a downstream signalling 
cascade initiates pro inflammatory,  immune and anti- microbial signalling pathways 
(Grimes, Ariyananda, Melnyk, & O’Shea, 2012). It is not known whether accessory 
proteins are necessary for the NOD2 –MDP interaction as is the case with Toll-like 
receptor 4 (TLR4) which forms a heterodimer with myeloid differentiation factor- 2 
(MD-2) to recognise lipopolysaccharide (LPS) (Park et al., 2009). The nucleotide 
binding domain of NOD2 contains winged helix (WH) and helix domains (HD) which 
play an important role in NOD2 oligomerisation. X ray crystallography of apoptosis 
protease activator 1 (APAF1) a member of the NOD protein family suggests that when 
inactive, NOD2 is in a monomeric state where the WH domain is bound to ADP and 
the protein has a closed conformation (Riedl, Li, Chao, Schwarzenbacher, & Shi, 
2005). When MDP binds to the LRR, NOD2 protein conformation changes, ADP-ATP 
exchange occurs, NOD2 oligomerises and downstream signalling is initiated (Riedl et 
al., 2005). The suggested functions of the LRR and NOD domains are supported by 
analysis of mutations in these regions which lead to ineffective bacterial sensing (and 
therefore downstream NFκB signalling) and lack of NOD2 inhibition (constitutive 




Figure 2 Structure of NOD2  
Adapted from (Rivas et al., 2012). NOD2 consists of two N terminal caspase recruitment 
(CARD) domains a nucleotide binding domain (NBD) and a leucine rich repeat region 
(LRR). The CARD domains are where protein interactions occur, for example RIP2 binds 
to this region. The NBD is where ATP binds and is metabolised and where NOD2 
oligomerisation occurs. The LRR domain at the carboxyl terminal is where ligands 
including MDP and LPS are recognised.  
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NOD2 functions as part of the innate immune system 
The innate immune system is the human body’s first line of defence upon exposure to 
pathogens. It is a rapidly induced, evolutionarily conserved, response to microbial 
invasion. The human gut is constantly exposed to both harmful and harmless microbes. 
An overactive immune response is thought to be causal in IBD.  The key functions of 
the innate immune system are: recognition of microbes, regulation of inflammation, 
and activation of the adaptive immune response. Pattern recognition receptors (PRRs) 
are responsible for the recognition of microbes. PRRs include the Toll- like family of 
receptors (TLRs) and the Nucleotide oligomerisation domain- like receptors (NODs). 
These PRRs recognise components of microbes called Pathogen- associated microbial 
patterns (PAMPs) which include bacterial/viral DNA, bacterial cell wall components, 
and flagella proteins. PRRs have also been shown to recognise damage-associated 
molecular patterns (DAMP’s), these are molecules that are exposed upon destruction 
of host membranes and are released as a result of necrosis.  
NOD2 and RIPK2 
NOD2 is activated by the binding of the ligand MDP in the cytoplasm. MDP enters 
the cytoplasm through three mechanisms: interaction with solute carrier proteins 
(SLCs), invasive bacteria or cellular absorption of bacterial membrane vesicles 
(reviewed in (Boyle, Parkhouse, & Monie, 2014)) . Activated NOD2 oligomerises and 
interacts with receptor –interacting serine /threonine protein kinase 2 (RIPK2) via its 
CARD domains. Both CARD domains are essential for the NOD2-RIPK2 interaction 
and downstream NFκB signalling (Yasunori Ogura et al., 2001). RIPK2 is necessary 
for downstream NFκB and MAPK signalling. Embryonic fibroblasts derived from 
RIPK2 null mice show diminished NFκB signalling when transfected with a NOD2 
over expression construct whereas cells derived from wild type mice initiate NFκB 
signalling when NOD2 is over expressed (K. Kobayashi et al., 2002). In unstimulated 
cells, where NOD2 is inactive, RIPK2 is bound by MAP Kinase Kinase 4 (MEKK4), 
activated NOD2 competes for RIPK2 resulting in formation of a RIPK2:NOD2 
complex.  
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NOD2 in the NFκB signalling pathway 
The NFκB pathway is a pro inflammatory signaling pathway that is initiated by 
exposure to pro inflammatory cytokines, viruses, bacterial exposure and DNA damage. 
 
Figure 3 NOD2 in the NFκB signalling pathway 
Figure adapted from (Strober, Murray, Kitani, & Watanabe, 2006). Peptidoglycan (PGN) 
from Gram positive bacteria enters the cell. Muramyl dipeptide (MDP), a component of 
PGN is recognised by NOD2. NOD2 is subsequently activated, it oligomerises and 
interacts with the kinase, RIPK2 (also known as RICK). Downstream NFκB signaling is 
initiated, the IKK complex is ubiquitinated leading to proteosomal degradation of the NFκB 
inhibitor IKK. An active NFκB heterodimer (p50/p65) is then able to translocate into the 
nucleus and initiate transcription.    
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The NFκB proteins are a family of nuclear transcription factors: RELA, RELB, c-REL, 
p50 and p52 which are well conserved and functionally related, particularly in the N 
terminal region which contains sequence necessary for nuclear localisation and 
dimerisation. There are two pathways by which the NFκB pathway is activated, the 
canonical pathway and the alternative pathway. The canonical pathway is activated by 
pro inflammatory cytokines such as TNFα whereas the alternative pathway is initiated 
by other cytokines such as RANKL and TNFSF11. The difference between these two 
pathways is that the canonical pathway leads to activation of NFκB RelB/p52 
heterodimers whereas the alternative pathway activates the RelA and c-Rel complexes.  
 
The general post activation mechanism of both the canonical and alternative NFκB 
signaling pathways is similar. When inactive, the NFκB dimers are bound by the IκB 
(Inhibitors of NFκB) proteins, their nuclear localization signal is not exposed and they 
are retained in the cytoplasm. Stimulation of the NFκB pathway leads to dissociation 
of NFκB dimers from their inhibitors, the IκB proteins. This dissociation is mediated 
by the IκB kinase (IKK) complex. This complex consists of catalytic components 
(IKKα, IKKβ, and IKKγ) and adaptor proteins which together phosphorylate the IκB 
inhibitory proteins, targeting them for proteasome mediated degradation. Active NFκB 
dimers can then translocate into the nucleus where they activate a range of genes 
involved in the immune response, cell cycle checkpoints, NFκB inhibition (negative 
feedback loop) and anti-apoptotic genes (Figure 3).  
 
NOD2 activates the NFκB pathway, this activation occurs via the IKK complex. Ogura 
et al showed that HEK293T cells activated the NFκB signaling pathways using a 
luciferase assay, they also showed that decreased NFκB activation in HEK293T cells 
transfected with dominant negative forms of IKKα, IKKβ or IKKγ or IκB (Yasunori 
Ogura et al., 2001). Additionally, RIPK2 is also necessary for NOD2 dependent 
activation of the IKK complex. The activated NOD2:RIPK2 complex is ubiquitinated 
which leads to recruitment of Transforming growth factor β activated kinase 1 
(TAK1). TAK1 interacts with the kinase domain of RIPK2 and the IKK complex binds 
to the intermediate domain of RIPK2. The IKKγ subunit is subsequently ubiquitinated 
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and by TAK1 and undergoes degradation allowing phosphorylation of the NFκB 
inhibitor, IκB by IKKα and IKKβ. This leads to release of the p65 NFκB subunit 
allowing translocation into the nucleus and activation of transcription.  
 
NOD2 levels are tightly controlled, and MDP stimulation of NOD2 initiates a negative 
feedback loop whereby heat shock protein 90 (HSP90) dissociates from NOD2 which 
leads to ubiquitination and proteasome mediated degradation of NOD2 (K.-H. Lee, 
Biswas, Liu, & Kobayashi, 2012).  
 
NOD2 Expression patterns 
In line with its function as a PRR, NOD2 has been shown to be located in the plasma 
membrane and cytoplasm, where it can come into contact with bacterial products such 
as MDP i.e. antigen presenting cells (APCs). This is supported by NOD2 expression 
in macrophages and dendritic cells but not in T or B cells of the immune system 
(Gutierrez et al., 2002). A number of chemicals including TNFα and IFNγ activate 
NOD2 and increase the response of NOD2 to MDP (Rosenstiel et al., 2003).   In the 
intestine, NOD2 expression was first detected in Paneth cells and was originally 
thought to be exclusively expressed in these cells (Y Ogura et al., 2003). The absence 
of a functioning NOD2 antibody has meant that a majority of work has looked at 
mRNA expression levels of NOD2, however recent advances suggest that NOD2 is 
also expressed at the protein level in intestinal epithelial cells and monocyte derived 
cells (dendritic cells) of the immune system (Barnich, Aguirre, Reinecker, Xavier, & 
Podolsky, 2005; Hu & Peter, 2013a). In dendritic cells NOD2 expression is  
upregulated upon exposure to viruses (Hu & Peter, 2013b).  Additionally in mice, 
NOD2 expression has been detected in the stem cells of the intestinal crypts (Nigro, 
Rossi, Commere, Jay, & Sansonetti, 2014).  
Recent work indicates that NOD2 is able to shuffle to the nucleus (Barnich, Aguirre, 
et al., 2005; Kufer, Kremmer, Banks, & Philpott, 2006; Zurek et al., 2012). NOD2 has 
been detected in the nucleus in HeLa cells overexpressing NOD2. There is a 6 fold 
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increase in the concentration of nuclear NOD2 in cells treated with chemicals that 
block nuclear export (Zurek et al., 2012).  
NOD2 in human disease 
NOD2 is a highly conserved gene located on chromosome 16. Three mutations in 
NOD2 were the first genetic risk factors to be associated with CD, particularly ileal 
CD (Economou, Trikalinos, Loizou, Tsianos, & Ioannidis, 2004; Hugot et al., 2001; 
Ogura et al, 2001). These were:  R702W (missense), G908R (missense) and 
L1007fsinsC (frame shift) all of which affect the LRR region of the NOD2 proteins 
(Figure 4) (Hugot et al., 2001; Ogura et al, 2001). The R702W and G908R are point 
mutations leading to amino acid substitutions, arginine to tryptophan and glycine to 
arginine respectively. The L1007fsinsC is an insertion leading to a premature stop 
codon and a 1007 amino acid truncated NOD2 protein. Studies have shown that the 
presence of one of these NOD2 risk alleles confers a 2-4 fold increased risk whereas 
two risk alleles increases the risk of CD development by between 20 and 40 fold 
(reviewed in (Bonen & Cho, 2003)). These mutations are the strongest CD risk factors 




Figure 4 NOD2 mutations associated with Crohn's disease (adapted from (Rivas et 
al., 2012) 
Schematic diagram of the NOD2 protein, the three most common CD mutations are in the 
LRR region (R702W, G908Rand L1007fsInsC (fs1007)). Six additional low frequency 
variants found in CD patients are also shown as identified by deep sequencing analysis 
conducted by (Rivas et al., 2012).    
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In addition to the more common NOD2 variants discussed, Hugot et al identified over 
30 rare NOD2 polymorphisms and recent deep sequencing has revealed six low 
frequency NOD2 risk variants (R311W, S431L, R703C, V793M, N852S and M863V) 
in CD patients. These six variants are not in linkage disequilibrium with the R702W, 
G908R or L1007fsInsC variants. Aside from the L1007fsinsC mutation, all other 
variants result in amino acid substitutions. The N852S, S431L, R702W, G908R and 
fs1007 all affect downstream NFĸB signalling, in the fs1007 mutant signalling is 
abolished (Inohara et al., 2003; Rivas et al., 2012). The S431L and fs1007 mutant 
forms of NOD2 do not localise to the plasma membrane in HEK293 cells, they are 
retained in the cytoplasm, the N852S mutant localises similarly to wild type NOD2 in 
the plasma membrane (Rivas et al., 2012).     
 
Prevalence of mutations 
Although the R702W, G908R and L1007fsinsC variants are the strongest genetic risk 
factor for CD found to date and they are only found in approximately 36 percent of 
European patients (Cuthbert et al., 2002). Approximately 8 to 17 percent of CD 
patients have two NOD2 risk alleles, compared to approximately 1 percent in 
Caucasian healthy controls. In the western population between 30 and 50 percent of 
people carry one NOD2 risk allele. The frequency of these mutant alleles varies 
dramatically across different populations, they are not found in Asian populations and 
are more frequent in southern Europeans than northern Europeans (Hugot et al, 2007). 
Additionally they are only found in approximately eleven percent of Scottish patients, 
suggesting that they are  not attributable for the higher incidence of CD in Scottish 
populations (Arnott et al., 2004).  
 
The exact mechanism by which these mutations contribute to CD susceptibility has 
yet to be fully elucidated. The location of the variants in the LRR region suggests that 
these mutants are defective in sensing microbial ligands and therefore in initiating 
activation of the NOD2 protein and NFκB signalling i.e. the mutations cause loss of 
function. This is supported by data from human monocytes harbouring NOD2 
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mutations which show decreased activation of downstream cytokine signalling 
(Negoro et al., 2005). Additionally, HEK293T cells transfected with NOD2 mutant 
constructs show decreased NFκB signalling (Inohara et al., 2003).  Furthermore, 
macrophages from both NOD2 null and L1007fsInsC homozygous mice exhibit 
reduced NFκB activation following stimulation with MDP (Y.-G. Kim et al., 2011).   
 
An alternative mechanism by which NOD2 mutations may influence CD susceptibility 
is via the autophagy pathway. NOD2 physically interacts with the autophagy protein 
ATG16L1 and recruits it to the plasma membrane. The NOD2 L1007fsInsC protein 
does not recruit ATG16L1 to the plasma membrane (Travassos et al., 2010).  MDP 
stimulation of human cell lines shows increased bacterial killing upon Salmonella 
infection. NOD2 overexpression also results in increased bacterial killing in this 
model, furthermore, siRNA knockdown of ATG16L1 blocks this increase. The R702W 
and G908R NOD2 mutants exhibit decreased bacterial killing and bacterial killing is 
abolished in the L1007fsInsC mutant (Homer, Richmond, Rebert, Achkar, & 
McDonald, 2010). MDP has also been shown to induce autophagy in human dendritic 
cells expressing WT NOD2.  NOD2 knockdown in these cells results in decreased 
levels of the autophagy marker LCIII upon MDP stimulation. Furthermore, although 
CD associated NOD2 mutations were not shown to alter autophagy in monocytic CD 
patient derived cells, they do alter autophagy in the dendritic cells of CD patients 
(Cooney et al., 2010; Homer et al., 2010). Dendritic cells cultured from CD patients 
with either ATG16L1 or NOD2 mutations have defects in bacterial clearance, 
autophagy and antigen presentation (Cooney et al., 2010).  
 
NOD2 gain of function in Blau’s Syndrome 
In addition to LOF mutations in NOD2 being associated with Crohn’s disease, gain of 
function (GOF) mutations have been associated with other auto immune diseases such 
as Blau Syndrome. Blau syndrome is an autosomal dominant disorder characterised 
by arthritis and dermatitis. Three missense mutations in the NOD domain of NOD2 
are associated with Blau syndrome, these are thought to cause increased sensitivity of 
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NOD2 to ligands leading to increased activation of NFκB and other downstream 
signalling pathways (Miceli-Richard et al., 2001).  
 
NOD2 null mice 
The investigation of the functional significance of the CD associated NOD2 mutations 
is complicated by NOD2 null mice. These are mice lacking the NOD domain required 
for activation. These mice do not develop spontaneous inflammation and do not exhibit 
increased sensitivity towards dextran sodium sulphate (DSS) induced colitis. DSS is a 
chemical which destroys mucosal epithelial cells and disrupts the epithelial cell barrier 
therefore allowing bacterial infiltration of the mucosa (Kitajima, Takuma, & 
Morimoto, 1999).  Additionally, there was no difference in bacterial clearance between 
wild type and NOD null mice when exposed to gram positive bacteria by 
intraperitoneal or intravenous injection only when exposed via oral routes  (K. S. 
Kobayashi, Chamaillard, & Ogura, 2005). This phenotype is not necessarily surprising 
as there are numerous PRRs that function as part of the innate immune system, these 
may be compensating for NOD2 inactivation.   
 
Paneth cell dysfunction and decreased expression of α defensins have been observed 
in NOD2 null mice (K. S. Kobayashi et al., 2005). Defensins are antimicrobial 
peptides, in the small intestine they are present in Paneth cells. This, in line with high 
levels of NOD2 expression in human Paneth cells, suggest that NOD2 plays a role in 
maintenance and protection of the intestinal mucosa which may be mediated by 
interaction with α defensins. Reduced expression of α defensins has been seen in ileal 
CD patients compared to healthy controls, however, more recently, this has been 
attributed to inflammation as opposed to NOD2 status (Simms et al., 2008; Wehkamp 
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1.4.7 Yeast 2 Hybrid Assays 
Linkage and GWA studies have identified many different susceptibility loci, the most 
significant of which is the NOD2 locus. In the post GWAS era the research focus has 
shifted towards identifying the mechanisms underlying the associations discovered. In 
our lab one of the approaches was to identify proteins that interact with the known CD 
susceptibility gene: NOD2. 
 
Yeast 2 hybrid assays have been used in other IBD studies to identify potential IBD 
risk genes. The DNA binding domain of a transcription factor (TF) is attached to a bait 
protein (usually the known protein of interest) and DNA activation domain of a TF is 
attached to prey proteins (usually encoded by a cDNA library), when the bait and prey 
interact, the TF DNA binding domain and activation domain form an active TF 
initiating transcription of a reporter gene (Figure 5). GRIM 19 was identified as an 
interacting partner of NOD2 using a yeast two hybrid assay, this interaction was 
confirmed by co immunoprecipitation using GRIM19 and NOD2 over expression 
constructs in COS7 and HEK293 cells (Barnich, Hisamatsu, et al., 2005). In this study 
the N terminal region of NOD2 lacking the CARD domain was used as bait and cDNA 
generated from human bone marrow as prey. ERBIN has also been shown to interact 
with NOD2 using a yeast two hybrid assay. In these experiments, full length ERBIN 
and NOD2 were used and the interaction was confirmed by immunoprecipitation in 
SW480 cells. 
 
TLE1 was not identified by these screens, this may be due to differences in cell lines 
and methodologies used. Nimmo et al used full length NOD2 extracted from SW480 
cells as prey and co immunoprecipitation was confirmed in HEK293 cells.  
 
This approach has also been used to understand pathogenic mechanisms and identify 
susceptibility genes in other diseases. Millar et al used a yeast 2 hybrid assay to 
successfully identify interacting partners of DISC1, which has been implicated in 
schizophrenia. They identified 21 interacting proteins, implicating DISC1 in a novel 
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pathways and identifying it as a potential hub protein (Millar, Christie, & Porteous, 
2003). Interestingly, GWA studies for psychiatric illnesses have not identified DISC1 
as a susceptibility locus. However, GWA studies have identified interacting partners 





Figure 5 Yeast 2 Hybrid Assay 
The bait protein is attached to the DNA binding domain of a transcription factor (TF). The 
prey which will be a protein generated from a large cDNA library is attached to a TF 
activation domain. If the bait and prey proteins interact, then the TF binding domain and 
TF activation domain interact in the yeast cells and function as a transcriptional activator 
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1.5  TLE1 (Transducin- like enhancer of Split) 
1.5.1 TLE1 in Crohn’s Disease 
Recent research by Nimmo et al identified TLE1 as an interacting partner of the known 
IBD susceptibility gene, NOD2 using a yeast-2 hybrid assay. This interaction was 
confirmed by co immunoprecipitation in the colorectal cancer cell line, SW480. 
Furthermore, three SNPs in TLE1 were significantly associated with CD in a combined 
Scottish cohort (Edinburgh and Dundee): rs11139315 (p=0.003), rs2796469 (p=0.004) 
and rs6559629 (p=4×10-4). Statistical analysis on this combined cohort showed that 
the rs6559629 risk allele in TLE1 was required for NOD2 to be a risk factor for CD 
(Nimmo et al., 2011) . However, it is important to note that the latter has not been 
replicated in data from larger UK IBD cohorts (see chapter 6).   
 
1.5.2 Discovery and structure of TLE1  
TLE1 is a transcriptional co repressor and one of the human homologs of the 
Drosophila groucho family of proteins. Groucho is a nuclear protein, mutations in 
which cause the development of extra bristles above the eye, reminiscent of the 
eyebrows of Groucho Marx (Lindsley & Grell, 1968). Groucho was initially classified 
as part of the enhancer of split complex (e(sp)l) due to its location in the densely packed 
e(sp)l chromosomal region. This, combined with sequence similarity to the β subunit 
of the TRANSDUCIN protein lead to the name, Transducin Like Enhancer of split for 
the human groucho/TLE1 family. Further work showed that functionally, groucho was 
not related to β transducin or the e(sp)l complex.  
 
The TLE family consists of four proteins, TLE1-4 (Stifani, Blaumueller, Redhead, 
Hill, & Artavanis-Tsakonas, 1992). These proteins are highly conserved, both groucho 
and TLE proteins have the same five protein domains (Q, GP, CcN, SP and WD) as 
shown in Figure 6. The Q and WD domains are particularly well conserved between 
Groucho and TLEs, they share between 70% and 88% sequence identity. The WD and 
Q domains are where the majority of protein interactions take place. The coil structures 
in the Q domain are essential for oligomerisation of groucho/TLE, mutations in this 
region prevent oligomerisation and repression of target genes (Song, Hasson, Paroush, 
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& Courey, 2004). A number of proteins interact with the Q domain including the 
TCF/LEF transcriptional regulators (Chodaparambil et al., 2014). Along with the 
glycine/proline rich GP domain, the Q domain is also the site for binding histone 
deacetylases (Chen, Fernandez, Mische, & Courey, 1999; Choi, Kim, Kwon, & Kim, 
1999; Palaparti, Baratz, & Stifani, 1997; Wang, Chen, & Ouyang, 2011).  
 
The central CcN domain contains nuclear localisation signals and phosphorylation 
sites. The two serine residues in this domain are phosphorylated by cell cycle 
dependant kinase 2 (CDC2) and Casein Kinase 2 (CK2). Phosphorylation of serine 
residues in the CcN domain has also been shown to be important for efficient 
transcriptional repression and nuclear localisation of TLE1 (H. N. Nuthall, Joachim, 
& Stifani, 2004). Inhibition of CDC2 causes dephosphorylation of TLE1 (H. Nuthall, 
Husain, & McLarren, 2002; H. N. Nuthall, Joachim, Palaparti, & Stifani, 2002). 
 
The role of the SP domain of TLE proteins is also regulatory, cofactors such as HES1 
induce phosphorylation of serine residues in this region. Mutations affecting serine 
286 (SP domain) of TLE1 bind to chromatin with less strength that wild type TLE1, 
although TLE1 is still recruited to the chromatin (Buscarlet et al., 2009). HIP2K and 
MAPK  have also been shown to induce hyperphosphorylation of serine residues in 
the SP domain, this phosphorylation is thought to alter the conformation of TLE1, 
exposing additional serine residues as well as negatively impacting transcriptional 
repression (Ciarapica et al., 2014; Hasson et al., 2005).  
 
The WD domain is the site where a majority of protein interactions take place. This 
region has a β propeller structure with seven blades (WD repeat motifs) that has been 
resolved by X ray crystallography (Pickles, Roe, Hemingway, Stifani, & Pearl, 2002). 
The central pore region of the WD repeat region is where a majority of protein 
interactions occur (Pickles et al., 2002). The WRPW and Eh1 (Engrailed Homology 
region 1) motifs in this domain are essential to most of the TLE1 protein interactions. 
The WRPW motif is the recognition site for proteins from the basic helix loop helix 
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(bHLH) family (HES) and the Runt homology domain protein family (RUNX) (Ali et 
al., 2010; Grbavec & Stifani, 1996; McLarren, Theriault, & Stifani, 2001).  The Eh1 
site is where proteins including PAX and FOXD bind (Dastidar, Narayanan, Stifani, 
& D’Mello, 2012; Eberhard, Jime, Heavey, & Busslinger, 2000). 
 
 
Figure 6 Structure of Groucho and full length TLE1 proteins 
Protein domain structure of Drosophila groucho and human TLE proteins. Amino acid 
numbers are shown above each schematic diagram. The Q domain is the glutamine rich 
domain, the GP domain is glycine proline rich, the CcN is the central domain containing 
nuclear localisation signals, the SP is serine rich and the WD domain contains WD repeat 
sequences necessary for protein-protein interactions.  
 
1.5.3 Expression patterns in different tissues 
Human TLE (hTLE) proteins are ubiquitously expressed in human tissues. hTLE1 is 
highly expressed in the brain, liver and muscle, as determined by northern blot analysis 
(Stifani, Blaumueller, Redhead, 1992). TLE1 is primarily a nuclear protein, in line 
with its function as a transcriptional co repressor, however it has also been detected to 
a lesser extent in the cytoplasm in HeLa and HEK 293 cell lines (Nimmo et al., 2011; 
Stifani, Blaumueller, Redhead, 1992).  
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Overexpression of the TLE1 homolog, Grg1, causes defects in neuronal differentiation 
and pituitary gland development in mice. In Medaka embryos, overexpression leads to 
developmental defects including left/right asymmetry (reviewed in: (Buscarlet & 
Stifani, 2007)) 
 
1.5.4 TLE1 transcripts 
TLE1 is located on chromosome nine, the full length transcript is 3893 base pairs in 
length and encodes a protein composed of 770 amino acids.   
 
There are five TLE1 transcripts described by the Ensembl genome browser, these are 
shown in Figure 7. The Transcript Support Level (TSL) ranges from one to five, TSL1 
indicates that all splice junctions are supported by RNA evidence, TSL2 means that 
the best supporting mRNA is suspect or support is from more than one expressed 
sequence tag (EST), TSL3 means there is only support from the transcript from one 
EST, TSL4 indicates the best supporting EST is suspect and TSL5 means no single 
transcript supports the model structure. Only transcript one has a TSL of 1, the other 
transcripts have TSL scores between 2 and 5 and have therefore not been properly 
validated yet.  
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Figure 7 TLE1 transcripts 
TLE1 predicted transcripts, data from Ensembl genome browser. Transcript support level 
(TSL) shown for each transcript, definitions of each TSL level as described in text.  
 
 
1.5.5 TLE1 function 
TLE1 is a transcriptional co repressor, it lacks the ability to bind DNA directly but 
influences transcription by interacting with other DNA binding proteins. It is thought 
to be involved in long range repression, although the exact mechanisms underlying 
this repression are unclear. They are hypothesised to involve both chromatin 
remodelling and direct inhibition of transcription and translation (Courey & Jia, 2001). 
TLE1 appears to cause chromatin remodelling via interactions with the H3 subunit of 
histones, Histone deacetylase 1 (HDAC1) and Histone deacetylase 3 (HDAC3). The 
Drosophila histone deacetylase, rpd3 interacts with groucho via the GP domain of the 
groucho protein. Cells overexpressing TLE1 recruit HDAC1 and knockdown of 
HDAC3 results in increased expression of TLE1 intestinal epithelial cell lines (Mario 
F Fraga et al., 2008a; Godman et al., 2008). TLE1 has been shown to associate with 
H3 in human cell lines, this interaction is thought to occur at the amino terminus of H3 
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(Palaparti et al., 1997).  TLE1 inhibits protein translation via interaction with the 
RUNX2 proteins, RUNX2 and TLE1 form a complex which represses transcription of 
rRNA genes. It has also been shown that loss of TLE1 leads to increased global protein 
synthesis (Ali et al., 2010).  
 
1.5.6 TLE1 in different signaling pathways  
TLE1 functions as a transcriptional co-repressor in a variety of different cellular and 
developmental pathways e.g. NFκB, Wnt, TGFβ and Notch signalling pathways 
(Fisher, Ohsako, & Caudy, 1996; Levanon et al., 1998; McLarren et al., 2001). TLE 
proteins cannot bind DNA directly, they influence transcription via interaction with 
DNA bound transcription factors and the recruitment of histone deacetylases e.g. Sirt-
1 (Ghosh, Spencer, Ng, McBurney, & Robbins, 2007a).  
 
TLE1 in the Transforming growth factor β   (TGFβ) signalling pathway 
Maintaining a balance between pro-inflammatory and anti-inflammatory factors is one 
of the essential functions of the immune system, disturbance of this balance leads to 
inflammation. As previously mentioned, chronic inflammation is one of the major 
characteristics of IBD. In the GI tract the maintenance of this balance is dependent on 
effective communication between intestinal epithelial cells and the mucosal immune 
system. One of the ways in which this is achieved is via signalling molecules such as 
cytokines. Pro-inflammatory cytokines, for example, TNFα are important for the 
maintenance of inflammation in IBD patients, as shown by the use antibodies against 
these cytokines as treatment for IBD e.g. Infliximab. TNFα is a pro inflammatory 
cytokine that is overexpressed in the mucosa of IBD patients. It is primarily produced 
by macrophages, monocytes and T cells and TNFα receptors are broadly expressed. In 
response to TNFα stimulation, the MAP kinase and NFκB signalling pathways are 
initiated and inflammatory cells are recruited. In IBD patients, Infliximab (TNFα 
antibody) is used to sequester TNFα and reduce inflammation. Infliximab is also used 
to treat other autoimmune diseases including rheumatoid arthritis and ankylosing 
spondylitis.  
 
Chapter 1: Introduction 29 
TGF β is a regulatory cytokine and has a variety of functions which include 
suppressing local immune responses to antigens in the lumen, enhancing barrier 
function and increasing production of immunoglobulins in the mucosa. TGF β binds 
to TGFβ cell surface receptors, leading to activation of the receptor complex. This in 
turn causes downstream phosphorylation and activation of TGF β – associated 
signalling molecules (SMAD’s). Activated SMAD complexes then translocate into the 
nucleus and activate or repress specific target genes (Figure 8). One of these target 
genes is Brinker; this gene is down regulated by the SMAD complex. Brinker been 




Figure 8 TGFβ signalling pathway  
TGFβ binds to cell surface receptor molecules which leads to phosphorylation and 
subsequent activation of downstream SMAD molecules. There are three types of SMAD’s: 
receptor regulated (R SMAD’s 2, 3), co-mediator (Co SMAD’s 4) and inhibitory SMAD’s 
(SMAD 7). Upon binding of the TGFβ ligand to cell membrane receptors, an activated 
SMAD complex, consisting of an R SMAD and Co SMAD is formed. This complex 
translocates into the nucleus and interacts with DNA and other regulatory proteins to 
influence transcription.   
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Analysis of colonic biopsies from healthy controls has suggested that TGFβ is 
important in down regulation of inflammation, exposing these biopsies to TGFβ 
antibodies increased production of pro-inflammatory cytokines e.g. TNFα (Reimund, 
Wittersheim, Dumont, & Muller, 1996). However, colonic biopsies from IBD patients 
have shown increased TGF β expression. Recent research has shown that this is due to 
over expression of SMAD7, this inhibitory SMAD binds to the TGF β receptor which 
in turn stops activation of SMAD 3 and the formation of an activated SMAD complex. 
Inhibition of SMAD3 has been shown to restore normal TGF β signalling.   
 
TLE1 in the Notch signalling pathway  
The Notch signalling pathway is an evolutionarily conserved pathway that controls 
cell fate determination during development e.g. haematopoiesis, somitogenesis, 
vasculogenesis and neurogenesis. These processes involve maintenance of stem cell 
self-renewal, proliferation, specification of cell fate or differentiation and apoptosis. 
Mutations that alter Notch signalling have been implicated in a number of 
developmental disorders and cancers including colorectal cancer (Qiao & Wong, 
2009).  
 
Notch signalling is initiated by binding of ligands e.g. DELTA and JAGGED to the 
NOTCH transmembrane receptor. Upon NOTCH activation γ secretase cleaves the 
Notch intracellular domain (NICD). The NICD translocates into the nucleus where it 
interacts with the CSL protein and other regulatory proteins to activate transcription 
of target genes including the HES genes (Figure 8). Research in Drosophila 
melanogaster has shown that groucho is a notch antagonist; when notch is inactive, 
groucho inhibits transcription of the csl proteins  (Nagel et al., 2005). TLE1 has been 
shown to interact with HES proteins to mediate transcriptional repression (Grbavec & 
Stifani, 1996).  
 
Maintenance and renewal of the intestinal epithelium is governed by intestinal stem 
cells, Notch is highly expressed in these cells (Okamoto et al., 2009). These cells are 
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situated at the base of the intestinal crypt, they progressively differentiate, migrate and 
proliferate along the crypt villus axis, eventually becoming functional absorptive, 
goblet or epithelial cells of the villus. In inflamed mucosa of IBD patients this process 
is often dysregulated and an excess of dedifferentiated or differentiated cells can be 
seen (Dahan et al., 2008). In mice, notch is essential for the proliferation and 
differentiation of intestinal epithelial cells it and inhibition of notch causes increased 
severity of colitis (Okamoto et al., 2009). NOTCH binds to TNFα and is a target of 
anti TNFα therapies such as Infliximab that are used to treat IBD. Additionally, Notch 




Figure 9 Notch signalling pathway 
Notch is a transmembrane receptor protein that is activated by ligands of the Serrate/Lag2 
family which include the DELTA and JAGGED proteins. Ligand binding results in cleavage 
of the Notch intracellular domain (NICD). The NICD translocates from the cytoplasm into 
the nucleus where it interacts with CBF/Su(H)/Lag2 (CSL) proteins. The NICD and CSL 
along with other co-activators form a complex which binds DNA and functions as a 
transcriptional activator. Targets of this complex include the HES genes.  
 
Recent research has further implicated the Notch pathway in IBD pathogenesis, the 
activated form of NOTCH has been shown to be over expressed in the epithelium of 
CD patients when compared to controls (Dahan et al., 2008). CD patients have fewer 
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goblet cells than healthy controls (Gersemann et al., 2009). Furthermore, over 
expression of the NICD in goblet cell lines causes an abnormal goblet cell phenotype 
to develop, further confirming the importance of the Notch pathway in IBD (X. Zheng 
et al., 2011).  
 
TLE1 in the Wnt signalling pathway  
The Wnt–β-catenin signalling pathway plays a critical role in development, cell fate 
determination and adult stem cell proliferation. The abnormal activation of the Wnt–
β-catenin signalling pathway has been found to be associated with a number of human 
cancers, including colorectal cancer (Jin et al., 2003; Korinek, 1997; Krings et al., 
2000; Morin, 1997; Polakis, 2012; Rubinfeld, 1997).  
The Wnt signalling pathway is activated by the presence of Wnt glycoproteins which 
bind to and activate FRIZZLED, and low density lipoprotein receptors (LDL 5 and 6). 
This causes accumulation of β CATENIN in the nucleus which forms a complex with 
the TCF/LEF proteins and other co-activators to initiate transcription activation 
(Figure 10). In the absence of Wnt signalling the TCF/ LEF proteins are bound by 
TLE1 and Histone deacetylase 1 (HDAC 1) in a transcriptional repression complex 
(Daniels & Weis, 2005).  
 
The Wnt signalling pathway has been found to be dysregulated in UC. The mucosa of 
UC patients has shown over expression of a number of Wnt pathway related genes 
including the Wnt receptor FRIZZLED (Uthoff et al., 2001). Additionally both 
epigenetic and genetic alterations in this pathway have been shown to be involved in 
the development in colorectal cancer in UC patients (Dekken et al., 2007). 
 
 
Chapter 1: Introduction 33 
 
Figure 10 Wnt signalling pathway 
Wnt’s are glycoproteins that interact with the cell surface receptors FRIZZLED and low 
density lipoprotein receptors 5 and 6 (LDL 5 and 6). Activation of these Wnt receptors 
leads to accumulation of the transcriptional co activator β CATENIN in the nucleus. In the 
absence of Wnt signalling the TCF/LEF proteins are bound by histone deacetylase 1 
(HDAC1) and TLE1. In the presence of Wnt signalling, TLE1 and HDAC1 are displaced by 
β CANTENIN and a transcriptional activation complex is formed.  
 
TLE1 in the NFκB signalling pathway  
TLE1 proteins have been implicated in the NFκB pathway, TLE1 directly interacts 
with and represses transcription activity of the p65 subunit of NFκB dimers (Tetsuka 
et al., 2000). Additionally Groucho interacts with Dorsal, the Drosophila NFκB 
homolog, converting Dorsal into a transcriptional repressor (Dubnicoff et al., 1997). 
A yeast 2 hybrid screen identified TLE1 as an interacting partner of the deacetylase 
and NFκB inhibitor, SIRT1. This finding was confirmed by co-immunoprecipitation 
of TLE1 and SIRT1 in HeLa cells. Furthermore, although SIRT1 does not directly 
influence expression of TLE1 or vice versa, TLE1 is necessary for NFκB inhibition by 
SIRT1 (Ghosh, Spencer, Ng, McBurney, & Robbins, 2007b).  
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Inflammation is a hallmark of IBD, it is seen in affected regions of the GI tract in both 
CD and UC patients. As the NFκB pathway is a pro-inflammatory pathway it has been 
well studied in IBD and is a therapeutic target for IBD treatments. NFκB (p65) is 
overexpressed in the inflamed intestines (macrophages and epithelial cells) of IBD 
patients and the extent of NFκB (p65) expression correlates with the extent of 
inflammation (Rogler et al., 1998). The known IBD susceptibility gene NOD2 also 
induces NFκB activation through CARD domain interactions with RICK, as discussed 
earlier in this chapter (Yasunori Ogura et al., 2001).  
 
A number of current IBD treatments including anti TNFα antibodies (Infliximab) and 
corticosteroids are thought to alleviate IBD symptoms by targeting the NFκB pathway. 
The anti-inflammatory effects of anti-TNFα treatments are at least partially 
attributable to inhibition of the NFκB p65 subunit and increased expression of catalytic 
components of the IKK complex (Guidi et al., 2005). Corticosteroids are also thought 
to increase expression of the catalytic components of the IKK complex, therefore 
increasing inhibition of NFκB proteins and preventing translocation into the nucleus, 
they have also been shown to directly interact with the NFκB p65 subunit (Auphan, 
Nathalie, Didonato, Joseph, Caridad, Rosette, Helmburgh, 1995).  
 
1.6 Dysregulation in cancer 
TLE1 expression has been studied in a range of cancers including: breast, bone/joints 
(sarcomas), lung, colon and pancreatic cancer (Allen et al., 2006; Hamidov et al., 2011; 
Knösel et al., 2012; Kosemehmetoglu, Vrana, & Folpe, 2009). In hematologic 
malignancies TLE1 has been shown to undergo promoter hypermethylation (Mario F 
Fraga et al., 2008b).  
 
UC and CD predispose to colorectal cancer (CRC) and lead to a poorer prognosis 
(reviewed in: (Kim & Chang, 2014)).  In approximately half of the CRC cases histone 
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deacetylase 3 (HDAC3) is overexpressed. In the CRC cell lines, it has been shown that 
inhibition of  HDAC3 causes increased expression of TLE1 and other members of the 
Wnt signalling pathway (Godman et al., 2008).   
 
1.6.1 TLE1 deletion in model organisms  
Groucho null Drosophila melanogaster develop extra bristles above the eyes and 
their eyes a show developmental abnormalities. Groucho mutants also show 
abnormalities in neurogenesis and sex determination (Paroush et al., 1994). Gro null 
mice are born healthy, however they show growth abnormalities from three days old 
onwards with a survival of 50% by the age of four weeks when compared to healthy 
control littermates. In response to TLR ligand stimulation, macrophages derived 
from these mice show increased levels of TNFα and IL6 when compared to 
macrophages derived from healthy littermates (Ramasamy, Chen, Wang, Ding, & 
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1.7 Aims  
As discussed in this chapter, TLE1 has been implicated in CD pathogenesis by way 
of its interaction with NOD2 and association with CD in a case control GWA study 
(Nimmo et al., 2011). Additionally TLE1 functions in signalling pathways that 
NOD2 has been implicated in such as the NFκB pathway. Furthermore TLE1 
functions as part of the Wnt, Notch and TGFβ pathways, all of which have 
previously been implicated in IBD. The aim of this thesis is to elucidate the 
mechanism by which TLE1 may be influencing susceptibility to CD. The work 
presented analyses TLE1 sequence, expression and interacting proteins in order to 
further understand the function of TLE1 and its potential role in CD pathogenesis. 
This in turn may allow for identification novel therapeutic targets leading to 
improved quality of life for CD patients and lessening the current burden on the 
NHS. 
 
The specific aims of each results chapter of this thesis are as follows: 
1. To analyse the effect of down regulating TLE1 expression on genome 
wide expression to identify mechanisms by which TLE1 may be 
influencing susceptibility to CD. 
 
2. To examine the potential TLE1/ XBP1 interaction and its role in the 
unfolded protein response (UPR). 
 
3. To determine TLE1 expression and localisation in ileal tissue taken 
from healthy controls and CD cases. 
 
4. To sequence regions of the TLE1 gene to identify causative mutations 
underlying the association between TLE1 and CD in the Scottish 
population.
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2.1 Buffers and solutions 
2.1.1 Bacterial culture 
Table 1 Solutions required for bacterial culture 
2.1.2 Cell culture 
Table 2 Cell culture buffers and solutions 
Blocking Buffer 0.1% Tween (Sigma) 
5% w/v powdered milk (Marvel) 
10ml PBS 
L Agar 50g Tryptone 
25g Yeast extract 
50g NaCl 





25g Yeast extract 
25g NaCl 
5L dH20,  pH 7.2 
Glycerol freezing medium 100ml L Broth 
25% glycerol 




DMSO freezing medium 10% Dimethylsulfoxide (DMSO) 
90% Fetal calf serum (FCS) 
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PBS- Tween (PBS-T) PBS supplemented with 0.1% tween  
Table 3 Buffers and solutions for protein analysis 
2.1.3 Chromatin Immunoprecipitation 
ChIP Dilution Buffer 16.7mM TrisHCL pH8.1 (3.3ml, 0.5M) 
1.2mM Ethylinediamenetetraacetic acid (EDTA) (0.34ml, 
0.5M) 
167mM NaCl (4.15ml,4M) 
1.1% Triton  
0.01% Sodium dodecyl sulphate (SDS) (0.1ml, 10%) 
91.1 ml H2O 
ChIP Lysis Buffer 50mM TrisHCl pH8.1 (10ml, 0.5M) 
10mM EDTA (2ml, 0.5M) 
1% SDS (10ml, 10%) 
78ml distilled H2O 
ChIP Elution Buffer 0.1M NaHCO3 (0.084g) 
1% SDS (1ml, 10%) 
9ml H2O 
TSEI 20mM TrisHCl pH8.1 (4ml, 0.5M) 
2mM EDTA (0.4ml, 0.5M) 
150mM NaCl (3.8ml, 4M) 
1% Triton (1ml) 
0.1% SDS (1ml, 10%) 
89.9 ml H2O 
TSE II 20mM TrisHCl pH8.1 (4ml, 0.5M) 
2mM EDTA (0.4ml, 0.5M) 
500mM NaCl (12.5ml, 4M) 
1% Triton (1ml) 
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0.1% SDS (1ml, 10%) 
81.3ml H2O 
TE 50mM Tris HCL pH8.1 (10ml, 0.5M) 
Buffer III 1mM TrisHCl pH8.1 (2ml, 0.5M) 
1mM EDTA (0.2ml, 0.5M) 
1% NP40 (5ml, 5%) 
1% 2-4 dimethyoxy-4 –chloramphetamine (DOC) (10ml, 10%) 
dH2O (7.8ml) 
Table 4 Buffers used in chromatin immunoprecipitation experiments (ChIP) 
2.1.4 Antibodies 
















Table 5 Primary antibodies used in this thesis 
Name/Target Concentration Application 
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2.1.5 Expression vectors 
  Vector Promoter Resistance Source 
Empty vector   CMV Ampicillin (Nimmo et al., 
2011) 
TLE1  CMV Ampicillin (Nimmo et al., 
2011) 
NOD2  CMV Ampicillin (Nimmo et al., 
2011) 
XBP1(unspliced)  CMV Ampicillin (Kaser et al., 2008) 
XBP1 (spliced)  CMV Ampicillin (Kaser et al., 2008) 
Table 7 Summary of expression constructs used in this thesis 
 
2.2 Bacterial Culture 
Plasmids were transformed into competent E.Coli cells (Life Technologies) for 
amplification. Cells were transformed with 1ul of plasmid. Briefly, 50µl of cells were 
mixed with 1µl plasmid DNA (approximately 20ng), the mixture was incubated in ice 
for 30 mins, heat shocked at 42˚C for 30 seconds, 1ml LB broth was added and mixture 
was incubated in a shaking incubator for 90 minutes (37˚C, 369G) 100µl of this 
mixture was then spread onto agar plates containing the relevant antibiotic. The 
following day a single colony was picked and added to 250ml LB broth supplemented 
with the relevant antibiotic and incubated in a shaking incubator overnight (37˚C, 
369G).  Plasmid DNA was extracted using a Qiagen midiprep kit according to standard 
protocols. Plasmid concentration was analysed using a Nanodrop 1000 
spectrophotometer (Thermo Fisher). Plasmid DNA was stored at -20˚C. Glycerol 
stores were made for long term storage of each plasmid by spinning down 1 ml of 
single colony bacterial culture, resuspending in 1ml glycerol freezing medium and 
storing at -80˚C.  
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2.3 Cell culture 
2.3.1 Maintenance of cell lines  
Cells were kept in a Galaxy 170S incubator at 37°C in a humidified environment of 
5% CO2 and 95% air. HEK293, HCT116, HT29 and SW480 cells were originally 
purchased from the American Type Culture Collection (ATCC). Cells were kept in 
75cm or 125cm flasks and passed every 3-5 days (80% confluency). Unless otherwise 
stated, all cell treatments including transfection, stimulation and passing was 
conducted in a sterile hood with laminar air flow. Passing cells involved aspiration of 
media, washing in 10ml Phosphate Buffered Saline (PBS) and 5 minute TrypLE 
Express treatment (37˚C/ 5% CO2) (Life Technologies). Media and PBS were kept at 
4°C but were heated to 37°C in a water bath prior to use.  Following treatment with 
either 2ml (25cm flask) or 5ml (75cm flask) trypsin either 10 or 20ml of the appropriate 
media was added to the flask to quench the trypsin. Cells were passaged at dilutions 
specified in Table 2. Cells were cultured in media purchased from life technologies 
according to Table 8. All glassware was autoclaved prior to use, all plastic ware was 
purchased pre-sterilised. Cells were tested for mycoplasma once a month, no cells were 
positive. Additionally cell morphology was analysed every week using a light 
microscope (Leica).  
 
2.3.2 Cell counting 
Prior to an experiment, once cells had been re suspended in media following TrypLE 
express treatment they were counted using a Cellometer X1 (Nexcelom). According 
to standard protocols, 20µl of cell solution was pipetted into each well of the counting 
chamber, the slide was placed in the cellometer, the image focused and the cell type 
chosen and counted. The software returned cell images which were analysed for 
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Cell Line  Description  Dilution factor 
(passaging) 
Media  
HEK 293 Human Embryonic Kidney  1:20 DMEM + 10% FCS 
HCT 116 Colorectal carcinoma 1:10 Mc Coy’s + 10% FCS 
HT 29 Colorectal carcinoma 1:10 DMEM + 10% FCS 
SW 480 Colorectal carcinoma 1:10 Leibovitz +10% FCS 
Table 8 Cell lines, Culture medium and passing dilution factor 
2.3.3 Long term storage of cells 
For long term storage, a T75 flask of cells was trypsinised and resuspended in the 
relevant media. The cell solution was precipitated (4°C, 1000RPM) and cells were 
resuspended in 1ml DMSO freezing medium and stored in cryovials. Vials were placed 
in a Mr Frosty containing isopropanol (Thermo Fisher) and kept at -80°C for 2-3 days. 
Vials were then transferred to liquid nitrogen stores at the Human Genetics Unit 
(HGU).  
Cell stocks were thawed for use in a 37°C water bath for 3 minutes. Cell solution was 
then transferred to a T75 flask containing 10ml normal cell media. The following day, 
media was replaced to remove DMSO containing media.  
 
2.3.4 Transient transfection 
Cells were plated 24 hours prior to transfection in 10cm plates at a confluencies of: 
2×106 (24 hour transfection), 1×106 (48 hour transfection) 5×105 (72 hour 
transfection). All transfections were carried out in 10cm plates. Lipofectamine 369G0 
(Life Technologies) was used as a transfection reagent. 10µg of DNA construct was 
mixed with 500µl of Opti-MEM (Life Technologies), the solution was incubated for 5 
mins (room temperature (RT), sterile hood). Simultaneously, 18µl of Lipofectamine 
was added to 500µl of Opti-MEM and incubated for 5 minutes (RT, sterile hood). The 
DNA solution was then mixed with the Lipofectamine solution and incubated for 20 
minutes (RT, sterile hood). During this the media of cells to be transfected was 
removed and replaced with 9ml of the appropriate fresh media. Following 20 minute 
incubation, the DNA-Lipofectamine mix was added dropwise to the 10cm plate of 
cells.  
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After the relevant time period for transfection had passed, cells were washed in PBS 
at the bench, scraped in 2ml PBS and pelleted by centrifugation 9167G). PBS was 
removed and pellets were stored in Eppendorf tubes at -20°C prior to RNA, DNA or 
protein extraction.        
 
2.3.5 MDP stimulation  
Cells were plated in 10cm plates according to standard protocols 24 hours prior to 
stimulation. The following day, media was aspirated from the cells and replaced with 
10ml of the relevant media supplemented with 10µl L18 MDP (Invitrogen). 
Following 6 or 24 hour incubation in a humidified incubator (37˚C, 5% CO2) cells 
were washed in PBS. Cells were scraped into 2ml PBS using a cell scraper and 
pelleted by centrifugation (4˚C, 10,000 RPM).   
 
2.4 Protein analysis 
2.4.1 Sample preparation 
Cell pellets were lysed by addition of 200µl Lamelli loading buffer (Biorad). The 
solution was sonicated for at a 10 micron amplitude for 1 minute on ice and then heat 
treated at 45°C for 10 minutes. Finally, samples were vortexed for 30 seconds, ready 
for loading.  
 
2.4.2 Western Blotting 
Electrophoresis 
20µl of cell lysate was loaded onto a 10% NuPage SDS-PAGE gel (Invitrogen) 
alongside PageRuler plus protein ladder (Thermo Fisher). The western blotting tank 
gel chamber was filled to the brim and the tank was half filled with NuPage buffer 
(Invitrogen). This was run at 150V (mA set to maximum) for 10 minutes and then 
120V for approximately 45 minutes, until the 25KDa ladder was at the end of the gel.  
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Transfer 
Following electrophoretic separation of proteins on the gel, proteins were transferred 
to a nitrocellulose membrane (GE Healthcare). This was performed using the Mini 
Trans Blot system (Biorad). Briefly, nitrocellulose membrane, two sponges and two 
pieces of filter paper were soaked in 1X transfer buffer (Invitrogen). A sponge was 
placed on one side of the plastic cassette, followed by a piece of filter paper. The gel 
was extracted from its plastic cassette and placed on the filter paper. The nitrocellulose 
membrane was placed on top of the gel, then an additional piece of filter paper and the 
final sponge. Any bubbles in the “sandwich” were removed by rolling a 10ml plastic 
stipette over it. The cassette was then placed in the transfer apparatus. An ice block 
was placed in the tank alongside the transfer cassette. The entire transfer tank was 
filled to the brim with transfer buffer. Gels were transferred for 90 mins (RT). Protein 
transfer was confirmed by staining the nitrocellulose membrane with Ponceau S.  
 
Figure 11 Western blot transfer 
Adapted from Biorad. Schematic diagram of western blot transfer “sandwich”. Assembled 
using filter paper, sponges, nitrocellulose membrane and polyacrylamide gel.  
 
Immunoblotting 
Ponceau S stain was removed by washing with PBS. Membranes were incubated in 
blocking buffer for 1 hour (RT). Membranes were then incubated in 10ml PBS 
supplemented with 5% milk powder and primary antibody, overnight at the 
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concentrations specified. The following day the membrane was washed in PBS-tween 
(PBS-T) for 5 mins, three times (RT). HRP conjugated secondary antibody was added 
at a concentration of 1:1000 (DAKO) for 1 hour (RT). Membranes were washed in 
PBS-T for 5 minutes, three times (RT). This was followed by chemiluminescent 
detection of proteins using an ECL kit (GBI Labs) with standard protocols. The 
membrane was wrapped in cling film and placed in a light poof cassette and was 
exposed to X-ray film for periods of 30seconds, 1 minute and 5 minutes. X-ray film 
was developed using a Curix 60 film processor (AGFA Healthcare).   
 
 
2.5 RNA analysis 
2.5.1 RNA extraction and cDNA conversion 
RNA was extracted on the bench using an All Prep RNA/DNA kit (Qiagen) with 
standard protocols. At the final stage RNA was eluted in 30µl DEPC treated water. 
Extraction was performed on the bench, samples were kept on ice at all times. RNA 
was quantified using the Nanodrop spectrophotometer 1000 (Thermo Fisher) and RNA 
was converted to cDNA using a Superscript cDNA VILO kit (Invitrogen). RNAse free 
Eppendorf tubes were used at all stages of the conversion. Briefly, 1µg RNA was 
mixed with 2µl Superscript enzyme and 4µl 5X VILO reaction mix, DEPC treated 
water was added to 20µl. The mixture was incubated at 25˚C (10 mins) and 42˚C (60 
mins). The reaction was terminated by incubation at 85˚C (5mins).    
 
2.5.2 Real-time Quantitative PCR (RT qPCR)  
RT qPCR was performed using a Rotor gene 6000 (Corbett Life Sciences/Qiagen). All 
water used in dilutions and RT qPCR negative controls was obtained from a Milli-Q 
Integral dispenser (Merck Millipore). Taqman expression assays were used to analyse 
NOD2 (hs00223394_m1), TLE1 (hs00896130_g1) and GAPDH (hs02758991_g1) 
expression (Thermo Fisher). Serial dilutions of cDNA (1:10-1:1000) were used in 
these assays. Briefly, 4µl diluted cDNA or ultrapure water (negative control) was 
added to a mixture containing: 1µl 20X Taqman Gene Expression Assay, 10µl 2X 
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Taqman gene expression master mix and 4µl ultrapure water. cDNA was added to the 
mixture in RT qPCR tubes and pipetted up and down. Taqman reagents and cDNA 
were kept on ice throughout the experiment. RIOK1, SGPL1, TUSC3, CCND1, TBP, 
GAPDH (not used when analysing TLE1 or NOD2 expression), UBC, β ACTIN 
expression and the XBP1 ChIP DNA enrichment RT qPCRs were analysed using a 
SYBR green based assay (DyNAmo Flash, Thermo Fisher). In the SYBR green assays 
reaction mixtures consisted of 10µl 2X master mix, 1µl 10µM of each primer (forward 
and reverse), 2µl of cDNA dilution/undiluted DNA (ChIP DNA enrichment) and 
ultrapure water to 20µl.  RT qPCR reaction mixtures were prepared on a cooled rack. 
For each gene expression assay a standard curve was also run using serial cDNA 
dilutions ranging from 1-1:10000. The same standard curve samples were used for all 
runs of an experiment. RT qPCR reactions were placed in the Rotor gene 6000 and run 
on programs detailed in Table 9 and Table 10.   
 
 
 Temp Time 
Hold 95˚C 7 mins  




Melt 60-98˚C 90 secs per 1˚C step 
5 secs between each step 
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 Temp Time 
Hold 95˚C 7 mins  




Melt 60-98˚C 90 secs per 1˚C step 
5 secs between each step 
Table 10 ChIP RT qPCR program 
 
RT qPCR data was analysed using Rotor gene analysis software (Corbett Life 
Sciences/Qiagen). A standard curve was used to generate concentration values for each 
sample. Concentrations were standardised to the relevant controls i.e. samples 
overexpressing TLE1 were standardised to empty vector transfections. If negative 
controls showed contamination results for the run were discarded and re run.  
 
2.6 DNA Analysis 
2.6.1 DNA Extraction  
DNA was extracted from cell lines using an All Prep DNA/RNA kit (Qiagen) with 
standard protocols. DNA pellets were resuspended in 30µl TE and was quantified 
using a Nanodrop spectrophotometer 1000 (Thermo Fisher).  
DNA patient samples had already been extracted using the blood DNA Nucleon 
extraction kit (Hologic) 
 
2.6.2 Polymerase Chain Reaction (PCR) 
DNA samples to be used in PCR reactions were kept at 4˚C. DNA was used at a 
concentration of 100ng/µl. PCR reagents were defrosted and kept on ice during the 
experiment. A Hot start Taq polymerase kit (New England Biosciences) was used to 
set up PCR reactions. The reaction mixture contained: 2.5µl Taq reaction buffer, 
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0.5µl 10mM dNTPs, 0.5µl 10µM forward primer, 0.5µl 10µM reverse primer, 
0.125µl Hot start Taq polymerase, 1µl 100ng/µl DNA and DEPC treated water to 
25µl. When more than one PCR reaction was being performed, a master mix without 
primers or DNA was made up and pipetted into the PCR plate containing the relevant 
primers and DNA in each well. Thermocycling conditions are shown in Table 11.  
 
 Temperature  Time  
Initial denaturation 95 ˚C 30 






Final extension 68 ˚C 5 mins 
Hold 4 ˚C  
Table 11 PCR program specifications 
2.6.3 Sanger sequencing 
PCR products were sent for PCR cleanup and sequencing at the Human Genetics 
unit. 10µM primer stocks were provided with each sample. Primers sequences are 
shown in Appendix 1. Sequence chromatograms were analysed using Geneious 7.1.4 
software. 
2.7 Statistical Analysis  
All statistical analysis was conducted using Microsoft Excel or R. All error bars 
represent the standard error of the mean, unless otherwise stated. Data from samples 
sizes less than 5 was assumed to have non- normal therefore non- parametric 
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3.1 Introduction  
3.1.1 Identification of direct and indirect TLE1 targets 
As previously discussed, TLE1 is a transcriptional corepressor that has been implicated 
in IBD pathogenesis (Nimmo et al., 2011) . Transcriptional cofactors such as TLE1 
influence transcription of large numbers of target genes ; TLE1 functions as part of 
numerous developmental signalling pathways: NFĸB, Wnt and TGFβ (Fisher et al., 
1996; Levanon et al., 1998; McLarren et al., 2001).  
 
In the first part of this chapter, TLE1 expression was altered in a human cell line and 
the effect of this on genome wide expression were analysed using an Illumina HT12 
expression chip.  Analysis of the effect of TLE1 knockdown will allow for 
identification of novel direct and indirect targets as well as novel pathways that TLE1 
may be involved in. This in turn may help to elucidate the mechanisms and signalling 
pathways by which TLE1 may be influencing susceptibility to CD.  
 
3.1.2 Functional characterisation of the relationship between TLE1 
and NOD2 
MDP and NOD2 stimulation 
NOD2 is a pattern recognition receptor (PRR). When activated, it initiates downstream 
signalling pathways including the NFκB signalling pathway (as discussed in chapter 
1). Muramyl dipeptide (MDP) is a peptidoglycan, which is a component of the 
bacterial cell wall of both gram positive and negative bacteria. MDP has been shown 
to bind to NOD2 and stimulate NOD2 expression (Marian C Aldhous et al., 2011; 
Girardin et al., 2003; Grimes et al., 2012; Rosenstiel et al., 2003). The NOD2 promoter 
contains NFκB regulatory sites and stimulation of cells with MDP initiates a positive 
feedback loop (Rosenstiel et al., 2003).   
Giradin et al showed that MDP initiated NOD2 dependant NFκB signalling. This was 
shown using a luciferase assay. In brief, this assay involved cloning the NFκB 
promoter region into a luciferase reporter plasmid. This plasmid was then transfected 
into HEK293T cells. Upon binding of RNA polymerase to the NFκB promoter, 
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luciferase is transcribed. Binding is quantified by lysing the cells, adding the luciferase 
substrate, luciferin and quantifying chemiluminescence. A 14 fold increase in NFκB 
activation was observed in cells transfected with NOD2 and stimulated with MDP 
versus unstimulated cells transfected with NOD2 (Girardin et al., 2003).  MDP has 
been used successfully as NOD2 stimulant in previous work conducted in our lab. A 
two fold increase in NOD2 expression in cell lines stimulated with MDP for 4 hours 
was observed using RT qPCR (Marian C Aldhous et al., 2011).  
 
As previously discussed, TLE1 was shown to interact with NOD2 using a Y2H assay. 
The pathological significance of this interaction has yet to be fully elucidated (Nimmo 
et al., 2011). As MDP is a component of bacterial cell walls, MDP was used as a NOD2 
stimulant in order to mimic the response of the host organism to bacterial exposure.   
 
In the second part of this chapter MDP was used as a NOD2 stimulant in human cells 
to determine whether increasing NOD2 expression directly alters TLE1 expression and 
then to analyse the effect of stimulating NOD2 expression on genome wide expression.  
MDP stimulation was also combined with TLE1 knockdown to identify any novel 
pathways that both NOD2 and TLE1 influence and to see whether any of the effects of 
NOD2 stimulation rescue TLE1. These experiments may suggest a mechanism by 
which the NOD2/TLE1 interaction may be influencing susceptibility to CD.  
 
3.1.3 Illumina HT12 Expression chip 
The Illumina HT12 expression chip (beadchip) is an established method of analysing 
genome wide expression. The chip contains over 48,000 gene specific, 50 base pair 
probes representing the genome. Analysis of hybridization of RNA from experimental 
samples to these probes allows for quantification of genome wide expression. Briefly, 
the methodology involves, preparation of experimental samples, RNA extraction, in 
vitro synthesis of cRNA, biotin labelling of cRNA, hybridization of cRNA to the 
Illumina HT 12 bead chip and analysis of data (Figure 12).  
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This HT12 beadchip has been used successfully in many different contexts and 
diseases to analyse genome wide expression. Recently it was used to determine the 
mechanisms by which BRAF mutations affect tumorigenicity in colorectal cancer cell 
lines. Analysis of data obtained using the bead chip showed that BRAF inhibition 
results in loss of stemness and increased expression of differentiation markers such as 




Figure 12 Illumina HT12 Beadchip  
Figure adapted from http://www.illumina.com/technology/beadarray-technology/direct-
hybridization-assay.html) 
A) Schematic representation of a 50bp probe attached to a bead on the Illumina HT12 
beadchip. Biotin labelled cRNA binds to probe and extent of hybridisation is quantified. B) 
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3.2 Aims 
There are two key aims to this chapter, the first was to analyse the effect of altering 
TLE1 expression on genome wide expression. The second aim was to combine altering 
TLE1 expression with stimulation of NOD2 expression. These aims can be broken 
down as follows: 
 
1. Optimise assays for altering (decreasing) TLE1 expression in an appropriate 
cell line  
 
2. Analyse the effect of knocking down TLE1 on genome wide expression 
 
3. Analyse the effect of stimulating NOD2 expression on genome wide 
expression  
 
4. Analyse the effect of combining TLE1 knockdown with NOD2 stimulation to 
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3.3 Results 
3.4 Optimisation Experiments 
3.4.1 Choice of cell line 
Levels of TLE1 were measured in four cell lines: HEK293, HCT116, HT29 and 
SW480 (Figure 13). Relative TLE1 expression was standardised to expression in 
HCT116 cells. HEK293 cells were shown to have the highest level of TLE1 
expression, whereas SW480 cells had the lowest levels. Both HEK293 cells and 
SW480 cells have been used extensively in IBD research.  Initially the SW480 cell 
line was chosen to be used in these experiments as MDP has been shown to stimulate 
NOD2 expression in this cell line previously (Marian C Aldhous et al., 2011). My 
experiments showed transfection efficiencies for the control shRNA and TLE1 shRNA 
were low and knockdown was undetectable by RT qPCR in SW480 cells. Hence, the 
HEK293 cell line was used in further experiments as it had the highest levels of TLE1 
(88% higher than SW480 cells) and transfection efficiency was much higher. Although 
it is not an intestinal epithelial cell line, it has been used in much IBD research (Nimmo 
et al., 2011; Stevens et al., 2013).  
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Figure 13 RT qPCR analysis of TLE1 expression in HCT116, HT29, SW480 and HEK293 
cells  
TLE1 expression was analysed in three intestinal epithelial cell lines: HCT116, HT29, 
SW480 and one embryonic kidney cell line, HEK293. TLE1 expression was quantified by 
RT qPCR and levels shown are relative to TLE1 expression in HCT116 cells. This 
experiment was based on one replicate. 
 
HEK293 cells were transfected with a mixture of four scrambled shRNA’s (control) 
and four TLE1 shRNA purchased from Genecopia. Cells were plated at 30% 
confluency in 6cm plates and transfected the following day. The total concentration of 
shRNA used per transfection was 2.5µg. Optimisation experiments were conducted at 
three different time points: 24, 48 and 72 hours, as recommended by the manufacturer. 
Levels of TLE1 were measured by RT qPCR and normalised to GAPDH expression. 
Normalised TLE1 levels at 24, 48 and 72 hours were compared in HEK293 cells 
transfected with control shRNA or TLE1 shRNA (Figure 14). The 48 hour time point 
was most efficient for knockdown showing a 65% decrease in TLE1 expression when 
compared to a cells transfected with a control construct for the same period of time. 
This was the time point used for cells in the final experiment. 
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3.4.2 Optimisation of MDP mediated stimulation of NOD2 
In these experiments, MDP was used to stimulate NOD2 expression. Previous work 
has suggested that MDP stimulation of NOD2 is most effective between 4 and 24 hours 
post stimulation (Marian C Aldhous et al., 2011). Figure 15 shows that MDP 
stimulation is highest at 24 hours post transfection, with a fold change of +2.51 (151% 
increase) between unstimulated and MDP stimulated cells.  
A summary of the four different conditions (involving TLE1 shRNA and MDP 
stimulation of NOD2) used in this experiment is shown in  
Table 12.  
 
 
Figure 14 TLE1 knockdown using shRNA is most effective 48 hours post transfection 
TLE1 knockdown efficiency was analysed at 24, 48 and 72 hours post transfection of TLE1 shRNA in 
HEK293 cells. Each time point is shown from left to right on the X axis. The Y axis shows fold 
change in TLE1 expression, this is the fold change in TLE1 expression between cells transfected 
with control shRNA construct and cells transfected with TLE1 shRNA. Expression was quantified by 
RT qPCR. Each bar represents the average fold change in expression across three replicates. Error 
bars represent the standard error of the mean.  
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Table 12 Summary of experimental conditions used on Illumina HT12 Expression chip 
The table shows the four experimental conditions analysed using the Ilumina HT12 
Expression chip. 
 Unstimulated  
(24 hours) 






Control shRNA  
MDP (NOD2) stimulated 
TLE1 shRNA 
(48 hours) 
TLE1 shRNA  
Unstimulated 
TLE1 shRNA  




Figure 15 MDP stimulation of NOD2 expression is most effective 24 hours post stimulation. 
MDP stimulation of NOD2 expression was optimised in HEK293 cells at 6 and 24 hour time points. 
These time points were based on previous work in our laboratory (Marian C Aldhous et al., 2011). 
Fold change in expression was calculated by comparing unstimulated control cells and MDP 
stimulated cells. Expression was quantified by RT qPCR. Each bar represents the average fold 
change in NOD2 expression across three replicates. Error bars represent the standard error of the 
mean.  
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3.4.3 Reference gene optimisation for TLE1 quantification 
In order to determine the optimal reference genes to be used to quantify gene 
expression by RT qPCR, the stability of a panel of five reference genes was analysed. 
The reference genes used were Ubiquitin C (UBC), Glyceraldehype-3-phosphate 
dehydrogenase (GAPDH), β Actin (β ACT), Tata box Binding Protein (TBP) and 
Succinate Dehydrogenase (SDHA). These are well characterized reference genes that 
have been used previously in our laboratory and in other studies. Levels of each 
reference gene were analysed by RT qPCR. All optimisation conditions were analysed 
i.e. HEK293 cells transfected with: empty vector, empty vector and stimulated with 
MDP (6 and 24 hours), TLE1 shRNA, TLE1 shRNA and stimulated with MDP (6 and 
24 hours). The qBase+ software (Biogazelle) which uses the geNorm algorithm was 
used to analyse the stability of each reference gene across all four samples 
(Vandesompele et al., 2002). The GAPDH, UBC and βACT reference genes were most 
stable and these were used in further RT qPCR experiments (Figure 16).  
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Figure 16 Average expression stability of RT qPCR reference genes 
Line graph showing average expression stability of the five reference genes used in this 
project: TBP (Tata box binding protein), SDHA (Succinate dehydrogenase), UBC 
(Ubiquitin C) and β Actin. Average expression stability was calculated based on RT qPCR 
expression levels of all reference genes in HEK293 cells transfected with: empty vector 
construct, TLE1 shRNA (24 and 48 hours), TLE1 shRNA stimulated with MDP (6 and 24 
hours) and empty vector construct stimulated with MDP (6 and 24 hours). GeNorm 
software was used to calculate average expression.  
 
3.5 Final Experiment 
3.5.1 Data Analysis  
In the final experiment, each of the optimised experimental conditions described in  
Table 12 was set up in triplicate and run on an Illumina HT12 expression chip. The 
experiment was performed by Dr Elaine Nimmo and the HT12 expression chip was 
run by the Welcome Trust Clinical Research Facility (Western General Hospital, 
Edinburgh). Data was analysed with the kind help of Dr Nicholas Kennedy and Dr 
Alex Adams using the Lumi and Limma packages in the statistical program, R.  
 
The first stage of data analysis involves normalising the data. Data is normalised in an 
attempt to compensate for the systematic differences between samples run across 
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different beadchips, to aid the identification of systematic biological differences 
between samples and eliminate any anomalies and spurious data trends.  The data 
obtained from the HT12 expression chip was normalised using the VST transformation 
algorithm as part of the Lumi package in R. This method of normalisation was chosen 
based on evidence demonstrating that it improves detection of differentially expressed 
genes and reduces the number of false positive results when compared to other 
normalisation methods (Lin, Du, Huber, & Kibbe, 2008). It has been designed 
specifically for the Illumina platform and takes full advantage of the within array 
control probes (Lin et al., 2008).   
 
Figure 17 shows the intensity of all the probes across the arrays, each line corresponds 
to a different sample number.Figure 17 (A) shows the density of the signal intensity 
across all the probes on the beadchip prenormalisation. Each line and therefore sample, 
is distinguishable, peak heights vary and the range of intensity also varies across 
samples. If this unnormalised data was used to anaylse the effect of TLE1 knockdown 
we would expect many more spurious results due to variation between chips and array 
positions not being filtered out. Figure 17 (B) shows the data post normalisation, only 
one curve is visible as the samples all have equal ranges and intensities.  
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Figure 17 Log2 intensity of density of probes on the HT12 expression chip pre and post 
normalisation  
Line graph showing density of ~47000 probes on the HT12 expression chip. There were four 
experimental samples and each experiment was conducted in triplicate. Each line on the graph 
represents one experimental replicate. A) shows the probe density across all unnormalised samples. 
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3.5.2 Confirmation of TLE1 and NOD2 expression by RT qPCR in 
samples used on Ilumina HT12 expression chip. 
RT qPCR was used to determine whether TLE1 knockdown and MDP stimulation of 
NOD2 expression had been successful, all three technical replicates were analysed. 
Figure 18 shows that RT qPCR analysis revealed a 48% decrease in TLE1 expression 
in cells transfected with TLE1 shRNA compared to those transfected with control 
shRNA. Cells transfected with TLE1 shRNA and stimulated with MDP showed a 43% 
decrease in expression when compared with those transfected with control shRNA and 
stimulated with MDP.  
 
 
Figure 18 Confirmation of TLE1 knockdown by RT qPCR in three technical replicates 
used on HT12 expression chip 
RT qPCR analysis of TLE1 expression across all three technical replicates of HEK293 
cells transfected/ stimulated according to  
Table 12 as per results from optimisation experiments (Figure 14 and Figure 15) Each bar 
represents average TLE1 expression across three technical replicates. From left to right 
samples are: control shRNA (no MDP), control shRNA (with MDP), TLE1 shRNA (no 
MDP), TLE1 shRNA (with MDP). Error  bars are calculated as ± SEM 
 
 
Figure 19 shows RT qPCR analysis of NOD2 expression in the same samples used in 
the expression chip. On average there was a 243% increase in NOD2 expression in 
cells transfected with control shRNA and stimulated with MDP compared to 
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unstimulated cells. There was a lower average increase of 56% in NOD2 expression in 
cells transfected with TLE1 shRNA and stimulated with MDP when compared to 
untransfected controls. However, as shown by the error bars in Figure 19, there were 
large amounts of variation in NOD2 expression levels between technical replicates of 
MDP stimulated cells. This variation makes this data very difficult to interpret and no 
definite conclusions can be drawn. This is further emphasised in Figure 21 which 
shows no detectable change in NOD2 expression between unstimulated and stimulated 
samples according to results from the beadchip.  
 
 
Figure 19 RT qPCR analysis of NOD2 expression across the three technical replicates 
used on HT12 expression chip 
Quantification of NOD2 expression by RT qPCR on all three technical replicates of 
HEK293 cells transfected/ stimulated according to  
Table 12, as per results from optimisation experiments (Figure 14 and Figure 15) Each bar 
represents the average NOD2 expression across three technical replicates. From left to 
right samples are: control shRNA (no MDP), control shRNA (with MDP), TLE1 shRNA (no 
MDP), TLE1 shRNA (with MDP). Error bars are calculated as ± SEM. 
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Figure 20 Differentially expressed genes following TLE1 knockdown of HEK293 cells 
Manhattan plot showing –log10 p values for all probes on the expression chip. Each colour along the X axis represents a different chromosome, 
chromosome number is shown below the X axis. P values shown relate to the differential expression between HEK293 cells transfected with an 
empty vector and TLE1 shRNA. The first line indicates the threshold for False discovery rate (FDR) significance and the second denotes 
Bonferroni significance. Labelled genes reach the latter threshold. 
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Figure 21 Differentially expressed genes following MDP stimulation of HEK293 cells 
Manhattan plot showing –log10 p values for all probes on the expression chip following MDP stimulation. P values shown relate to differential 
expression between unstimulated and MDP stimulated HEK293 cells. Each colour along the X axis represents a different chromosome 
(chromosome number is shown below the X axis).  The first line indicates the threshold for False discovery rate (FDR) significance and the 
second denotes Bonferroni significance. Labelled genes reach the latter threshold. 
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3.5.3 Differentially expressed genes following TLE1 knockdown  
TLE1 knockdown was successful as indicated by results from RT qPCR analysis ( 
Figure 18) and results from the HT12 expression chip (Figure 20). Overall, 10 known 
genes reached Bonferroni significance and 526 genes FDR significance (Figure 20). 
Nine additional loci reached Bonferroni significance, however, actively transcribed 
regions have not been found near these loci. The focus of the following section was to 
analyse genes that were differentially expressed following TLE1 knockdown 
according to the HT12 expression chip and identify any genes that may provide a link 
between TLE1 and CD for follow up analysis. Differentially expressed genes were 
defined as genes with a Bonferroni corrected p value of less than 0.05. Identification 
of CD relevant genes was conducted by two separate means. A Pubmed search for 
each significant gene was carried out, with focus placed on identifying genes involved 
in inflammation, intestinal homeostasis, IBD, autoimmune disease, autophagy and 
bacterial exposure. Each gene was also input into the Search Tool for Interacting Genes 
(STRING) database. This database contains information about confirmed and 
predicted, direct and indirect protein interactions obtained from four sources, genomic 
context, high throughput and co expression experiments and data from Pubmed. All 
known IBD susceptibility loci were analysed for inclusion or proximity to Bonferroni 
corrected genes (Jostins et al., 2012). 
 
Four genes were identified for follow up analysis: SGPL1, TUSC3, RIOK1 and 
CCND1. Expression of each of these genes was analysed by RT qPCR following TLE1 
overexpression or TLE1 knockdown in HEK293 cells. This was to confirm results 
from the beadchip and to further examine the relationship between each of these genes 
and TLE1. Each experiment was conducted in three biological replicates for both TLE1 
knockdown and overexpression. TLE1 overexpression and downregulation was 
confirmed in each replicate, the Student’s t test showed significant differences in 
expression between HEK293 cells overexpressing and down regulating TLE1 (Figure 
22) (p=2.5 ×10-3) 
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3.5.4 RIO Kinase 1 (RIOK1) 
RIO kinase 1 (RIOK1) is a serine/ threonine kinase that forms part of the protein 
arginine methyl transferase (PRMT) complex (Guderian et al., 2011). The PRMT 
complexes are involved in the post translational modification of proteins; they are 
function in the addition of methyl groups to arginine residues. This leads to epigenetic 
modifications of histone proteins and alteration of protein–protein interactions. RIOK1 
is thought to be involved in the recruitment of substrate proteins for methylation by 
the PRMT complex. Proteins predicted to interact with it include a large number of 
 
Figure 22 TLE1 expression in cells with overexpressing and downregulating TLE1 
RT qPCR analysis of TLE1 overexpression and TLE1 knockdown in three biological replicates. TLE1 
overexpression and TLE1 knockdown bars represent average log fold change in expression. TLE1 
overexpression and knockdown data was normalised to expression of the reference genes: UBC, 
GAPDH and βACTIN.  The bar labelled expression chip shows the log fold change in RIOK1 expression 
as determined by the HT12 expression chip.  Error bars represent the standard error of the mean. * p 


































*p = 4.5× 10-3
**p = 4.5× 10-11
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ribosomal proteins, implying a role in ribosomal biogenesis and RNA processing 
(Guderian et al., 2011). More specifically it has been implicated in 18S rRNA 
processing and cytoplasmic maturation of the 40S ribosomal subunit (Vanrobays, 
Gelugne, Gleizes, & Caizergues-ferrer, 2003; Widmann et al., 2012).  
 
An IL-6 mediated role for ribosomal biogenesis has been implicated in UC, which 
suggests a possible mechanism by which RIOK1 may be involved in inflammation and 
IBD (Brighenti et al., 2014).  Additional evidence suggesting a role for RIOK1 in IBD 
is provided by the STRING tool which predicts that RIOK1 interacts with the known 
IBD susceptibility proteins mTOR and VIMENTIN  (Nimmo et al., 2011; Stevens et 
al., 2013). The interaction between RIOK1 and mTOR has been confirmed in 
HEK293T cells; the mTORC1 complex confirms interactions between RIOK1, 
RIOK2 and mTOR. 
 
The PRMT complex has also been implicated in other autoimmune diseases and 
numerous cancers, including colorectal cancer (Y. Yang & Bedford, 2013; 
Zakrzewicz, Zakrzewicz, Preissner, Markart, & Wygrecka, 2012).  
RIOK1 is a regulator of the PRMT complex and a by-product of protein arginine 
methylation is the production of ADMA (asymmetric dimethyl arginine). Increased 
ADMA levels have been attributed to defective PRMT complex and ADMA levels 
have been shown to be increased in IBD patients (Owczarek, Cibor, & Mach, 2010).  
This is a second mechanism by which decreased TLE1 expression, which in turn 
downregulates RIOK1 expression could cause accumulation/ deregulation of 
methylated proteins and increased ADMA. A similar pathogenic mechanism has been 
proposed in asthma (Zakrzewicz et al., 2012). 
 
The Illumina HT12 expression chip showed significant down regulation of RIOK1 
upon TLE1 knockdown. A log fold change of -0.12 was observed with a p value of 
4.3×10-3. RT qPCR analysis of RIOK1 expression on three biological replicates of 
HEK293 cells down regulating TLE1 confirmed this trend with an average log fold 
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change of -1.19 Overexpression of TLE1 showed an average of +2.78 log fold change 




RIOK1 expression in human intestinal biopsies 
RIOK1 expression was analysed using RNA extracted from the terminal ileum of 53 
CD patients and 31 healthy controls. Biopsies were taken from inflamed and non 
inflamed regions of each study participant. These experiments were conducted by 
Colin Noble as described in Noble et al, 2010. Briefly, total RNA from each biopsy 
 
Figure 23 RIOK1 expression in cells with overexpressing and downregulating TLE1 
RT qPCR analysis of the effect of TLE1 overexpression and TLE1 knockdown on RIOK1 
expression across three biological replicates. TLE1 overexpression and TLE1 knockdown 
bars represent average log fold change in expression. TLE1 overexpression and 
knockdown data was normalised to expression of the reference genes: UBC, GAPDH and 
β ACTIN.  The bar labelled expression chip shows the log fold change in RIOK1 
expression as determined by the HT12 expression chip.  Error bars represent the 
standard error of the mean. * p value as determined by Student’s t test. ** p value as 







































*p = 5.6 ×10-2
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was extracted, converted to cRNA (complementary RNA) and purified, a reference 
cRNA genome was labelled with the fluorophore cyanine 3 (Cy3) and the test cRNA 
genome was labelled with cyanine 5 (Cy5), samples were then hybridized to an Agilent 
whole genome expression array, washed and then scanned for fluorescence. The 
microarray data was analysed with the help of Dr Nick Kennedy and Dr Alex Adams. 
RIOK1 was a statistically significant marker of inflammation in healthy controls 
(repressed in inflamed tissues- p=0.007) but not in CD patients (p=0.907). There was 
a statistically significant increase in RIOK1 expression between non inflamed controls 
and CD patients (p=0.02) and a statistically significant decrease in average RIOK1 
expression between inflamed healthy controls and CD patients (p=0.003) (Figure 24). 
In summary, RIOK1 is a marker for inflammation in healthy controls but not CD 
patients and is differentially expressed between both inflamed and non inflamed CD 
patients and controls, however the change seen in between inflamed patients and 
controls is in the opposite direction to that seen in no inflamed patients and controls.  
 
Chapter 3: Analysing the effect of knocking down TLE1 and stimulating NOD2 on 
genome wide expression                                                                                          72 
 
Figure 24 RIOK1 mRNA expression in human intestinal biopsies 
RIOK1 expression in human inflamed and non inflamed intestinal biopsies from healthy 
controls and CD patients. Sample collection, experiment and data analysis were 
performed by Colin Noble (Noble et al., 2010). Boxplots describe average RIOK1 
expression across the 53 CD patients and 31 controls used by Noble et al. Genome wide 
expression was analysed using Agilent whole genome microarrays. Bonferroni corrected p 
values represent differences between inflamed and non inflamed individuals in controls 
and CD patients.  Black circles represent outliers.    
 
 
3.5.5 Cyclin D1 (CCND1) 
CCND1 encodes CYCLIN D1, a protein involved in cell cycle regulation. The cyclins 
are a group of proteins involved in progression of a cell from the G1 to the S phase of 
the cell cycle. Cyclins function via interaction with their catalytic counterparts the 
cyclin dependent kinases (cdk’s), CYCLIN D1 interacts with CDKs 4 and 6. Binding 
of cyclins to cdk’s results in phosphorylation of downstream signalling molecules 
including the retinoblastoma (Rb) protein. Rb is a cell cycle inhibitor, which is 
inhibited upon phosphorylation. This leads to initiation of DNA replication and 
movement from G1 to the S phase of the cell cycle. Hence cyclins play a key role in 
the promotion of cell proliferation.  
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Recent evidence suggests that CYCLIN D1 also has cdk independent functions. It 
interacts with over 30 different transcription factors and co factors. These 
transcriptional regulators are involved in cell differentiation, apoptosis, cell migration, 
metabolism (mitochondrial function) and cell growth.  
 
CCND1 expression is induced by growth factors including: TGFβ, various hormones 
e.g. gastrin in the GI tract, IGF1 and II and a variety of other extracellular signalling 
molecules. The promoter region of CCND1 contains binding sites for a number of 
known oncogenic proteins such as RAS, β CATENIN and STATs.  
 
CCND1 was identified as a gene of particular interest to study due to, its functional 
relevance to IBD and interactions with proteins implicated in IBD pathogenesis and 
evidence for its role in IBD. STRING analysis showed that CCND1 is predicted to 
interact with TLE1 and MTOR. Mechanistic target of rapamycin (MToR) is a 
serine/threonine kinase that is activated in response to cellular stress. It regulates 
translation of specific mRNAs via interaction with transcription factors. mTOR 
inhibitors such as rapamycin are being explored as IBD therapeutics, as they have 
immunosuppressant effects in patients with IBD. (Massey, Bredin, & Parkes, 2008) 
 
The intestinal epithelium is one of the most rapidly proliferating tissues of the body 
and maintenance of mucosal homeostasis is dependent on precise control of cell 
proliferation in the intestinal crypts. As previously discussed CYCLIN D1 is essential 
for cell division and the progression of a cell from the G1 to S phase of the cell cycle, 
hence it is crucial to intestinal homeostasis. CCND1 is highly expressed at sites of 
inflammation; in IBD models, CCND1 has been shown to be upregulated in both 
epithelial and immune cells (Taylor, 2006). In line with this, immunhistochemical 
analysis of intestinal biopsies has revealed increased expression of CYCLIN  D1 in 
IBD (both UC and CD) (Ioachim, Michael, & Agnantis, 2004). There is also some 
evidence for a contribution of CCND1 to IBD related colorectal carcinoma, however 
the evidence is mixed (Dekken et al., 2007; Ioachim et al., 2004; Kanaan et al., 2011).   
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Given the dysregulation of CCND1 expression in IBD, it has been the target of 
therapeutic strategies for IBD. The use of siRNA to silence cyclin D1 expression in 
the gut specific leukocytes of mouse models has shown down regulation of CCND1 
can reverse DSS induced colitis (Peer, Park, Morishita, Carman, & Shimaoka, 2008). 
More recent work has confirmed the therapeutic potential of cyclin D1 inhibitors in 
IBD treatment (Kriegel & Amiji, 2011).  
 
The Illumina HT12 expression chip showed significant up regulation of CCDN1 upon 
TLE1 knockdown. A +0.54 log fold change was observed with a p value of 2.7 ×10-3. 
Analysis of CCND1 expression on three biological replicates of HEK293 cells down 
regulating TLE1 confirmed this trend with an average log fold change of +0.63. 
Overexpression of TLE1 showed an average of +0.42 log fold change in CCDN1 
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CCND1 mRNA expression in human intestinal biopsies 
CCND1 was a statistically significant marker of inflammation in CD patients 
(p=0.007), the same trend is seen in healthy controls although the p value does not 
reach significance (p=0.17), this is likely to be due to small sample sizes. There was 
no difference in CCND1 expression between inflamed healthy controls and CD 
patients (p=0.16) or non inflamed healthy controls and CD patients (p=0.80) (Figure 
26).  In summary, CCND1 seems to be a marker for inflammation in CD patients and 
healthy controls and is not differentially expressed between healthy controls and CD 
patients regardless of inflammation status (Figure 26). 
  
Figure 25 CCND1 expression in cells with overexpressing and downregulating TLE1  
RT qPCR analysis of the effect of TLE1 overexpression and TLE1 knockdown on CCND1 
expression across three biological replicates. TLE1 overexpression and TLE1 knockdown 
bars represent average log fold change in expression. TLE1 overexpression and 
knockdown data was normalised to expression of the reference genes: UBC, GAPDH and 
βACTIN.  The bar labelled expression chip shows the log fold change in CCND1 
expression as determined by the HT12 expression chip.  Error bars represent the 
standard error of the mean. * P value as determined by Student’s t test. ** P value as 




































**p = 2.71× 10
-3
 





Chapter 3: Analysing the effect of knocking down TLE1 and stimulating NOD2 on 
genome wide expression                                                                                          76 
 
Figure 26 CCND1 mRNA expression levels in human intestinal biopsies 
CCND1 expression in human inflamed and non inflamed intestinal biopsies from healthy 
controls and CD patients. Sample collection, experiment and data analysis were 
performed by Colin Noble (Noble et al., 2010). Boxplots describe average CCND1 
expression across the 53 CD patients and 31 controls used by Noble et al. Genome wide 
expression was analysed using Agilent whole genome microarrays Bonferroni corrected p 
values represent differences between inflamed and non inflamed individuals in controls 
and CD patients. Black circles represent outliers.   
 
3.5.6 Sphingosine 1 Phosphate Lyase (SGPL1) 
SGPL1 is a ubiquitously expressed enzyme which is responsible for the conversion of 
sphingosine 1 phosphate (S1P) to 2-hexadecenal and phosphoethanolamine. Hence it 
is thought to be essential for homeostasis of S1P levels. S1P accumulation causes 
normal cells to be transformed into cancerous cells. S1P is a lipid signalling molecule 
which binds to the G protein coupled receptors: S1P1, S1P2, S1P3, S1P4 and S1P5. 
Binding of S1P to S1P1-S1P6 results in inhibition of apoptosis, increased angiogenesis 
and amplified NFκB and STAT3 signaling.  
 
The JAK/STAT signalling pathway has previously been implicated in IBD. 
Polymorphisms in members of the pathway including signal transducing and activator 
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of transcription  (STAT3) (Barrett et al., 2008) The STAT proteins are cytoplasmic 
transcription factors that are activated following phosphorylation of tyrosine residues. 
STAT3 activation leads to release of pro inflammatory cytokines including Il-6. 
Activation of STAT3 and release of pro inflammatory cytokines results in 
differentiation of Th17 cells. S1P signalling is part of a reciprocal positive feedback 
loop with STAT3, this signalling is thought to play a crucial role in inflammation and 
cancer, and could also provide a mechanism by which TLE1/SGPL1 influence CD 
susceptibility. 
 
S1P signaling is particularly relevant to IBD as epithelial cells in the small intestine 
are exposed to the breakdown products of sphingolipids; for example S1P is broken 
down by SGPL1 to 2-hexadecenal and phosphoethanolamine, these products would be 
exposed to the intestinal epithelium. In normal, healthy gut tissues sphingosine 
molecules enter the gut and are phosphorylated to S1P and then S1P is rapidly 
degraded by SGPL1. In this normal tissue rapid degradation is dependent upon high 
expression of SGPL1 in enterocytes.  
 
The Illumina HT12 expression chip showed significant up regulation of SGPL1 upon 
TLE1 knockdown. A log fold change of +0.48 was observed with a p value of 4.3 ×10-
3. RT qPCR analysis of CCND1 expression on three biological replicates of HEK293 
cells down regulating TLE1 confirmed this trend with an average log fold change of 
+0.47. Overexpression of TLE1 showed an average of +1.83 log fold change in SGPL1 
expression across three biological replicates (Figure 27). 
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SGPL1 mRNA expression in human intestinal biopsies 
SGPL1 is a marker for inflammation in CD patients (repressed in inflamed tissue 
p=0.04) but not in healthy controls (p=0.98). There was no difference in SGPL1 
expression between inflamed healthy controls and CD patients (p=0.98) or non 
inflamed healthy controls and CD patients (p=0.14) (Figure 28).  In summary, SGPL1 
is a marker for inflammation in CD patients but not healthy controls and is not 
differentially expressed between healthy controls and CD patients regardless of 
inflammation status (Figure 28). 
 
 
Figure 27 SGPL1 expression in cells with overexpressing and downregulating TLE1 
RT qPCR analysis of the effect of TLE1 overexpression and TLE1 knockdown on SGPL1 
expression across three biological replicates. TLE1 overexpression and TLE1 knockdown 
bars represent average log fold change in expression. TLE1 overexpression and 
knockdown data was normalised to expression of the reference genes: UBC, GAPDH and 
βACTIN.  The bar labelled expression chip shows the log fold change in SGPL1 
expression as determined by the HT12 expression chip.  Error bars represent the 
standard error of the mean. * P value as determined by Student’s t test. ** P value as 
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Figure 28 SGPL1 mRNA expression in human intestinal biopsies 
SGPL1 expression in human inflamed and non inflamed intestinal biopsies from healthy 
controls and CD patients. Sample collection, experiment and data analysis were 
performed by Dr Colin Noble, Dr Nick Kennedy and Dr Alex Adams (Noble et al., 2010). 
Boxplots describe average SGPL1 expression across the 53 CD patients and 31 controls 
used by Noble et al. Genome wide expression was analysed using Agilent whole genome 
microarrays. Bonferroni corrected p values represent differences between inflamed and 
non inflamed individuals in controls and CD patients. Black circles represent outliers.     
 
3.5.7 Tumour suppressor candidate 3 (TUSC3) 
Tumour suppressor candidate 3 (TUSC3) is the human homologue of the yeast ostp3 
gene which functions as part of the oligosaccharyltransferase complex (OST). The 
human OST complex is composed of seven different subunits, one of which is TUSC3. 
It has been shown that TUSC3 is present in the rough ER (RER) and binds to core 
proteins of the OST complex: STT3A and STT3B in ovarian cancer and kidney cell 
lines respectively (Horak et al., 2014; Vaňhara et al., 2013).  
 
The OST complex is essential for N-linked glycosylation of proteins in the ER. N 
linked glycosylation is an essential post translational modification of eukaryotic 
proteins that moderates protein folding and structure, stops proteins from being 
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degraded and alters function and immunogenicity. Defects in N linked glycosylation 
can lead to the accumulation of unfolded or misfolded proteins in the ER. This causes 
ER stress and initiates the unfolded protein response (UPR). The UPR is composed of 
three pathways: the Ire1α pathway, the ATF6α pathway and the PERK signalling 
pathway (Figure 29). As discussed in (see Chapter 4), proteins in all three UPR 
pathways have been implicated in IBD and ER dysfunction has been shown to 
influence IEC function and IBD pathogenesis. Dysregulation of TUSC3 alters the ER 
structure and the ER stress response (Horak et al., 2014; Kratochvílová et al., 2015).  
The ER chaperone, Binding immunoglobulin protein (BiP) and the transcription factor 
C/EBP homologous protein (CHOP), which are essential to the PERK, IRE1α, ATF6 
and PERK UPR pathways respectively, are down regulated in response to TUSC3 
silencing (Kratochvílová et al., 2015). Down regulation of TUSC3 by shRNA leads to 
reduced expression of Ire1α.     
 
The most widely accepted environmental IBD risk factor is smoking; it has been 
shown to affect both IBD incidence and history. TUSC3 methylation has been shown 
to decrease in smokers (Imboden et al., 2012). Alteration of methylation at this locus 
could disrupt expression of the gene or alter binding of transcriptional regulators 
thereby influencing susceptibility to CD. 
 
 The Illumina HT12 expression chip showed significant up regulation of TUSC3 upon 
TLE1 knockdown. A log fold change of -0.44 was observed with a p value of 1.8 ×10-
2. RT qPCR analysis of TUSC3 expression on three biological replicates of HEK293 
cells down regulating TLE1 confirmed this trend with an average log fold change of -
1.42. Overexpression of TLE1 showed an average of -0.73 log fold change in TUSC3 
expression across three biological replicates (Figure 30).   
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Figure 29 Summary of UPR signalling pathways (Wu & Kaufman, 2006) 
Schematic diagram showing the sensor, transducer and effector proteins of the three UPR 
pathways: PERK, Ire1α and ATF6.    
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TUSC3 mRNA expression in human intestinal biopsies 
Data for TUSC3 expression was not available, two TUSC3 probes had been removed 






Figure 30 TUSC3 expression in cells with overexpressing and downregulating TLE1 
RT qPCR analysis of the effect of TLE1 overexpression and TLE1 knockdown on TUSC3 
expression across three biological replicates. TLE1 overexpression and TLE1 knockdown 
bars represent average log fold change in expression. TLE1 overexpression and 
knockdown data was normalised to expression of the reference genes: UBC, GAPDH and 
β ACTIN.  The bar labelled expression chip shows the log fold change in TUSC3 
expression as determined by the HT12 expression chip.  Error bars represent the 
standard error of the mean. * P value as determined by Student’s t test. ** P value as 
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3.5.8 Differentially expressed genes following MDP stimulation of 
NOD2 expression   
Although the average levels of NOD2 expression were increased upon MDP 
stimulation, confidence limits imply that the difference was not statistically 
significant. Additionally NOD2 did not reach statistical significance and was not 
detectably differentially expressed in MDP stimulated versus unstimulated cells as 
assessed by the HT12 expression chip. This may be because NOD2 levels in these cell 
lines are low and below the levels of detection on the HT12 expression chip. In line 
with this, no further pathway analysis or follow up of other differentially expressed 
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3.6  Discussion  
In this chapter the effects of TLE1 knock down in HEK293 cells, on genome wide 
expression were analysed using an Illumina HT12 expression chip. Of the 10 known 
loci that were differentially expressed, 5 were identified as particularly relevant to IBD 
pathogenesis: RIOK1, CCND1, SGPL1 and TUSC3. Expression of each of these genes 
was then analysed at the mRNA level in ileal biopsies from 53 CD patients and 31 
controls.  
 
It is important to note that the expression data from ileal biopsies has a number of 
limitations and hence the p values presented should be interpreted with caution. The 
healthy control and CD patient group sizes were both relatively small, 53 and 31 
respectively and were not identical in size. Furthermore, although age matching was 
attempted for the samples when conducting the study, all samples are not age matched 
which may hinder interpretation of the results. Finally, of particular relevance to the 
genes identified as markers of inflammation in healthy controls, the inflamed healthy 
controls may have had another inflammatory disease, resulting in altered expression 
of the genes in question. The biopsy expression analysis results shown in this chapter 
can be interpreted as preliminary results and may be the focus of future research in 
larger Scottish cohorts.  
 
RIOK1 is a serine/threonine kinase that is involved in the post translational methylation 
of arginine residues. It has been implicated in ribosomal biogenesis and is predicted to 
interact with VIMENTIN and mTOR, both of which have been implicated in IBD. 
Overexpression of TLE1 lead to an increase in RIOK1 expression whereas TLE1 
knockdown had the opposite effect, causing a decrease in RIOK1 levels. This is 
interesting as TLE1 is transcriptional co repressor and you would expect the opposite 
effect. However, there is some evidence that TLE1 may also behave as a transcriptional 
activator. TLE1 has been shown to interact with Estrogen Related Receptor γ and when 
co expressed in kidney cells TLE1 results in increased expression of ERRγ as 
determined by a luciferase assay (Hentschke & Borgmeyer, 2003). In addition to 
 
Chapter 3: Analysing the effect of knocking down TLE1 and stimulating NOD2 on 
genome wide expression                                                                                          85 
RIOK1 being differentially expressed upon TLE1 knockdown (p=2.71×103) the 
difference between RIOK1 mRNA expression between cells over expressing TLE1 and 
cells down regulating TLE1 was statistically significant (p=5.6×10-2). RIOK1 appears 
to be a marker for inflammation for CD patients but not healthy controls, implying a 
CD specific role in inflammation. However it is not differentially expressed between 
healthy controls and CD patients regardless of inflammation status.  
 
CCND1 is a cell cycle regulator that is involved in inflammation and has been shown 
to be over expressed in intestinal biopsies from IBD patients, CCND1 siRNA has been 
shown to have therapeutic potential in mice (Ioachim et al., 2004; Kriegel & Amiji, 
2011).  Both overexpression and knockdown of TLE1 led to an increase in CCND1 
expression, this difference was not statistically significant (p=0.89).  Additionally 
CCND1 mRNA was not differentially expressed between healthy controls and CD 
patients (p= 0.89). The latter is in contrast to results from other studies which analysed 
CCND1 levels by immunohistochemistry of human intestinal biopsies this could be 
attributable to the differences in methodology between the two studies (Ioachim et al., 
2004).  
 
SGPL1 is an enzyme which functions as part of S1P signalling and in turn JAK/STAT 
signalling. S1P signalling interplays with JAK/STAT signalling, members of the 
JAK/STAT pathway including STAT3 have been implicated in IBD (Barrett et al., 
2008). SGPL1 mRNA expression was increased upon both TLE1 knock down and 
overexpression, this may be due to additional SGPL1 regulators that are compensating 
for TLE1 dysregulation. SGPL1 was differentially expressed between inflamed 
controls and CD patients but not their non- inflamed counterparts. It is also 
differentially expressed between inflamed and non-inflamed CD patients (p=0.00097). 
This suggests that SGPL1 is a Crohn’s specific marker of inflammation and is 
differentially expressed between inflamed CD patients and controls.  
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TUSC3 is involved in the UPR, a pathway that has already been implicated in IBD. 
Data for TUSC3 expression in ileal biopsies was not available, future work could focus 
on analysis expression in patient samples to confirm whether TUSC3 expression is 
important in IBD. Interestingly, TUSC3 expression patterns suggest that TLE1 
functions as an activator, similarly to the situation with RIOK1.    
 
The second part of this chapter aimed to address the effects of MDP mediated NOD2 
stimulation. However, this was not possible as NOD2 was excluded from the beadchip 
results as it did not meet the quality control criteria. Additionally, RT qPCR analysis 
did not confirm that NOD2 stimulation was successful. The exact reasons underlying 
ineffective stimulation are not clear, they may be a result of a technical difficulties in 
mRNA quantification. Some difficulties have been experienced with the NOD2 
quantification in our laboratory due to low absolute expression levels, this was also 
observed in the beadchip data. MDP is a well characterised NOD2 stimulant however 
other NOD2 stimulants, such as TNFα could be used alongside MDP in future 
experiments. Additionally, NOD2 overexpression constructs could be used. This 
would allow for confirmation of NOD2 stimulation using multiple mechanisms and 
comparisons between activation of downstream signalling pathways. Recent work 
shows that MDP mediated stimulation of NOD2 leads to dissociation of NOD2 from 
the chaperone protein, Hsp90 and subsequent proteasome mediated degradation of 
NOD2. This suggests that even though MDP stimulation upregulates NOD2 
expression, this may not directly correlate with NOD2 protein levels. Hence, NOD2 
mRNA and protein expression may not correspond and analysis of expression at both 
levels is essential to future work.  
 
In these experiments the HEK 293 cell line was used, as previously discussed this cell 
line has been used extensively in IBD research. Research using this cell line primarily 
focuses on analysing the effects of NOD2 stimulation as endogenous NOD2 expression 
is low. In this chapter the effects of NOD2 stimulation were analysed by comparing 
unstimulated and stimulated cells. In theory, the use of a cell line with very low NOD2 
expression would allow us to analyse the difference between unstimulated and 
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stimulated cells more easily as the differences would be expected to be more dramatic. 
However, the use of this cell line may have also prevented these experiments from 
detecting/effectively quantifying NOD2 expression leading to NOD2 probes on the 
expression chip failing to meet quality control criteria. Future work could focus on 
analysing NOD2 expression in primary culture cells from the intestinal ileum, these 
cells have been shown to express NOD2 at detectable levels, and furthermore, the 
results would provide a clearer insights into IBD pathogenesis.  
 
It is important to note that in this study expression of all the genes discussed has been 
analysed at the mRNA level, this may not be a true representation of protein levels of 
the genes in question. It is thought that in human cell lines, mRNA expression can 
explain approximately 27% of the variance in protein concentration hence further work 
analysing protein levels is necessary to confirm these findings. Additionally, analysis 
of gene expression and localisation in different cell types of the ileum is necessary to 
fully understand the role of these genes in IBD. 
 
 
Figure 31 Contribution of mRNA concentration to variance in protein concentration 
in human medulloblastoma cell line 
Pie chart showing factors influencing protein abundance adapted from Vogel et al, 2012. 
Data is based on the human medulloblastoma cell line, DAOY. mRNA expression is 
shown to account for approximately 27% of variance in protein expression and hence 
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4.1 Introduction  
4.1.1 XBP1 and IBD 
As discussed in the introduction, SNPs in the XBP1 gene have been associated with 
IBD. Deep sequencing of the XBP1 gene region revealed 4 variants that were only 
present in IBD patients, two of which are nonsynonymous SNPs that lead to 
hypomorphic forms of XBP1 (Kaser et al., 2008).  
 
Cre recombinase based transgenic mouse models have shown that conditional deletion 
of XBP1 in intestinal epithelial cells results in ER stress, characterised by increased 
splicing of XBP1 mRNA and increased expression of the ER chaperone, Binding 
Immunoglobulin Protein (BiP). This ER stress results in reduced numbers of Paneth 
and Goblet cells. The few remaining Paneth cells are malformed, they lack the 
expanded ER seen in normal Paneth cells and have fewer granules which contain 
antimicrobial peptides such as α defensins. In summary, XBP1 null mice show 
increased ER stress, develop spontaneous enteritis and an exaggerated response to 
proinflammatory cytokines (IBD inducers) e.g. TNF α and flagellin in the epithelium. 
They also have an increased susceptibility to colitis as a result of Paneth cell absence 
and malformation (Kaser et al., 2008).  
 
4.1.2 A potential XBP1 binding site in TLE1 
As discussed in previous chapters, the rs6559629 SNP in TLE1 is associated with IBD. 
One of the principal aims of this thesis is to investigate the pathological significance 
of this association.  
 
Haploreg is a program developed by the Broad institute, it uses data from the 1000 
genomes project to provide information about chromatin state, conservation and 
regulatory/transcription factor binding motifs alterations for a given SNP (Ward & 
Kellis, 2012a). It has been used to classify the functional significance of GWAS SNPs 
in many different contexts (Berndt et al., 2013; Bønnelykke et al., 2014; Chung et al., 
2013; Cui et al., 2013; Hinds et al., 2013; Rhie et al., 2013).  
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Using the Haploreg program we identified that rs6559629 interrupts two potential 
XBP1 binding sites in TLE1 (Figure 32).Figure 33 shows the XBP1 core binding 
motifs, the rs6559629 site interrupts the ACGT and UPRE core binding motifs. It is 
important to note that the core motifs of these sequences only differ by a single base 
pair. The result of this SNP is to change a CpG site. This site is created in the presence 







Figure 32 Schematic diagram showing XBP1 binding site in TLE1 
Schematic diagram showing TLE1 gene, exons are represented by blue boxes, introns are 
represented by black line joining exons. The rs6559629 SNP is shown as a purple line 
located in intron 15/16. The box shows the XBP1 core binding motif in yellow and the 
rs6559629 in purple.  
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4.1.3The Endoplasmic reticulum (ER) and the Unfolded Protein Response 
(UPR) 
The rough endoplasmic reticulum (ER) is the eukaryotic organelle responsible for the 
synthesis, folding and post translational modification of proteins. Following synthesis 
and folding in the ER, proteins are transported to the Golgi apparatus in transition 
vesicles. Proteins are then secreted in vesicles to their final destination. Under normal 
conditions, any unfolded/incorrectly folded proteins are targeted for ER associated 
degradation (ERAD) in the ER and then transported to the cytoplasm where they are 
degraded by proteasomes. ER chaperones responsible for correct protein folding as 
well as ERAD chaperones and enzymes are constitutively expressed in order to process 
nascent proteins. When the ERAD cannot cope with all the unfolded/misfolded 
proteins, they accumulate in the ER, this situation is defined as ER stress. Prolonged 
ER stress initiates apoptosis. A number of factors including viral infection, glucose 
depletion and alterations in ion concentration have been shown to cause ER stress. 
Glucose depletion is thought to alter N linked glycosylation of proteins in the ER and 
activation of the PERK pathway  (De La Cadena, Hernández-Fonseca, Camacho-
Arroyo, & Massieu, 2014).  Viral infection and replication increases the burden on ER 
protein synthesis chaperones leading to ER stress and apoptosis (Tardif, Mori, & 
 
Figure 33 XBP1 core binding motifs 
Figure adapted from (Acosta-Alvear et al., 2007). Table showing names and sequences of 
core XBP1 binding motifs. These motifs were identified as over represented in XBP1 
targets in a chip on chip experiment conducted by Acosta-Alevear et al.   Both ACGT and 
UPRE binding sites are interrupted by the rs6559629 SNP in TLE1. 
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Siddiqui, 2002). The ER is a calcium rich environment and many ER chaperones are 
Ca2+ dependant, alterations in Ca2+  concentration lead to protein misfolding and 
therefore UPR activation (reviewed in (Michalak, Parker, & Opas, 2002) . In response 
to ER stress, the unfolded protein response (UPR) is activated to restore homeostasis 
(reviewed in (Ma & Hendershot, 2001). The UPR initiates signalling pathways in order 
to resolve this stress. These pathways function to inhibit protein translation, produce 
more ER chaperones and ERAD components, increase production of secretory cells 
and initiate apoptosis in damaged cells. 
 
The UPR signalling pathways  
There are three UPR signalling pathways: the Ire1α pathway, the ATF6α pathway and 
the PERK signalling pathway. A summary of these three pathways is shown in Figure 
29.  
 
The presence of misfolded proteins in the ER is detected by ER sensors and leads to 
activation of the three UPR signalling pathways. All three pathways are activated by 
dissociation from the ER chaperone, Binding immunoglobulin protein (BiP). When 
PERK is released from BiP it oligomerises and undergoes phosphorylation becoming 
an active serine/threonine kinase. PERK initiates downstream signalling pathways 
leading to activation of transcription factors such as C/EBP homologous protein 
(CHOP), Activating transcription factor 6 (ATF6) and Eukaryotic initiation factor 2α 
(E1F2α). These transcription factors activate transcription of antioxidative, ER 
chaperone and apoptosis genes. 
 
In the ATF6α pathway, dissociation from BiP allows ATF6α to translocate to the Golgi 
apparatus and be cleaved by the site 1 and site 2 proteases (S1P and S2P). ATF6α 
moves from the cytosol into the nucleus where it initiates transcription of genes 
involved in protein folding and ER associated degradation (ERAD). 
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The most evolutionarily conserved of the three UPR signalling pathways is initiated 
by inositol requiring transmembrane kinase endoribonuclease 1 (IRE1). IRE1 has 
two isoforms; IRE1α which is ubiquitously expressed and IRE1β which is expressed 
in the intestinal epithelium. Under normal conditions IRE1 is inactive as it is bound 
by the chaperone BiP. IRE1 is a sensor/transducer of ER stress and is activated in the 
presence of misfolded/unfolded proteins and released from BiP. IRE1α oligomerises 
and undergoes autophosphorylation, this activated form of IRE1α is an endonuclease 
and kinase. Activated IRE1α cleaves 26nt from the mRNA transcript of the inactive, 
unspliced form of XBP1 (Calfon et al., 2002).  Unlike the unspliced form of XBP1 
(XBP1us), the spliced form of XBP1 (XBP1s) is an active transcription factor that 
binds to the promoter regions of target genes. XBP1 has 545 known target genes, of 
which a “core” of 95 genes are found in more than one cell type (Acosta-Alvear et 
al., 2007). These target genes were identified in both ER stressed and unstressed cells 
in an XBP1 chip on chip experiment using a mouse promoter array (Acosta-Alvear et 
al., 2007). These promoter arrays covered DNA up to 800bp upstream and 300bp 
downstream of approximately 14,000 known mouse genes. A large proportion of 
XBP1 target genes were shown to be UPR related, they are involved in protein 
folding, trafficking, secretion and synthesis. However, XBP1(s) targets are not 
limited to UPR related genes, XBP1 (s) also activates transcription of genes involved 
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Figure 34 Summary of UPR signalling pathways  
Summary of the PERK, Ire1α and ATF6 UPR signalling pathways. Binding 
Immunoglobulin protein (BiP) is the chaperone protein that in response to ER stress 
dissociates from the sensors of all three pathways. 
In the PERK pathway dissociation of BiP from PERK leads to phosphorylation and 
oligomerisation of PERK, converting it to an active serine/threonine kinase. In response to 
activation, PERK phosphorylates E1F2α which stops translational initiation, thereby 
decreasing the protein folding load on the ER. Downstream signalling also leads to 
activation of the transcription factors: NRF2 (Nuclear factor 2), ATF6 (Activating 
transcription factor 6) and CHOP (C/EBP homologous protein). These initiate transcription 
of antioxidative, ER chaperone and apoptosis genes respectively.   
IRE1α is activated similarly to PERK, activated IRE1α is an endonuclease which cleaves 
26nt from the unspliced XBP1 mRNA transcript. The cleaved XBP1 mRNA transcript is 
translated into an active transcription factor, initiating transcription of genes involved in 
protein synthesis, degradation, folding and ER expansion.  
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The ATF6α protein translocates to the Golgi apparatus upon activation and is cleaved by 
the site 1 and site 2 proteases (S1P and S2P). It then moves from the cytosol into the 
nucleus where it initiates transcription of genes involved in protein folding and ER 
associated degradation (ERAD). 
 





Figure 35 Summary of XBP1 target genes  
Figure adapted from Acosta et al, 2007. A) Pie chart summarising number of XBP1 target 
genes in each Gene Ontology (GO) category. The percentage represents the proportion of 
genes in each GO category out of a total of 545 target genes. B) Venn diagram showing 
the number of XBP1 target genes that are specific to each of the three cell types used in 
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4.1.4 ER stress, the UPR and IBD 
ER stress and the UPR dramatically impact the function of the intestinal epithelium; 
Paneth and Goblet cells are highly secretory cells and therefore need to produce 
correctly folded proteins. A defective UPR has a dramatic impact on the secretory 
capacity of these cells. 
 
ER stress and activation of the UPR has been shown in both CD and UC. For example, 
in CD increased expression of BiP and XBP1(s) has been shown by 
immunohistochemistry in intestinal biopsies (Deuring et al., 2011; Kaser et al., 2008). 
IRE1β has also been implicated in IBD; IRE1β-/- mice show increased BiP expression 
and sensitivity to DSS induced colitis (Iqbal et al., 2009). Associations between other 
UPR related genes such as AGR2 and ORMDL3 are discussed in Chapter1. 
 
4.1.5 Chromatin Immunoprecipitation  
Chromatin Immunoprecipitation (ChIP) is a technique used to determine whether a 
protein binds to a specific region of DNA. Briefly it involves, cross linking protein to 
DNA, sonication of DNA, immunoprecipitation with an antibody to the protein of 
interest, purification of DNA and PCR using primers for the region of interest. ChIP 
has previously been used to identify XBP1 target genes such as Xbp1 and Atf6 in 




























Figure 36 Chromatin Immunoprecipitation 
Schematic diagram showing the key stages of chromatin immunoprecipitation.1) Cells are 
treated with a fixing agent such as paraformaldehyde to cross link the protein to the DNA. 
2) Cells are lysed, DNA/protein complexes are harvested. 3) DNA and bound proteins are 
sonicated (usually to approximately 500bp). 4) and 5) Antibodies to the protein of interest 
(in this case XBP1) are used to isolate DNA bound to the protein. Following 
immunoprecipitation of DNA bound to the protein of interest, the DNA/protein cross links 
are reversed. DNA is isolated from the protein, this is the DNA that the protein of interest 
binds to. 6) Primers for the site of interest (in this case the rs6559629 site) are used in RT 
qPCR to determine whether the protein of interest binds to the site.  
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4.2 Aims 
One of the principal aims of this thesis is to elucidate the mechanism by which 
rs6559629, a SNP associated with ileal CD, may be contributing to disease 
pathogenesis. This SNP has been shown to interrupt a potential XBP1 binding site. 
XBP1 is involved in the unfolded protein response and is a known IBD susceptibility 
gene (Kaser et al., 2008). The aim of this chapter was to determine whether XBP1 
binds to this predicted binding site. This aim can be broken down into several stages: 
1. Design a ChIP assay for XBP  
a. Optimise DNA sonication 
b. Identify and characterise a correctly functioning antibody 
c. Characterise positive and negative controls 
d. Design and validate primers for the rs6559629 binding site 
 
2. Determine whether XBP1 binds to the predicted rs6559629 binding site 
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4.3 Results 
4.3.1 Sequencing rs6559629 in cell lines 
Primers were designed for the rs6559629 region in TLE1 in order to determine the 
rs6559629 genotype in HCT116, HT29, SW480 and HEK293 cells ( 
Table 13). Cells were plated and harvested the following day at 80% confluency. 
DNA was extracted using a Qiagen Dneasy kit and amplified by PCR using primers 
for the rs6559629 region (see Appendix for details) and standard PCR protocols ( 
seen Chapter 2). Sanger sequencing technology was used to sequence the resultant 
PCR products. Sequence was analysed using Geneious r7 software. The three cell 
lines used in this experiment were HEK 293, HCT116 and SW480 cells each of 
which have a different rs6559629 genotype. The use of cell lines with all three 
different genotypes allows us to determine whether XBP1 binds differentially to 
different alleles of the rs6559629 SNP. All three cell lines have been used 
extensively in IBD research.  
 
Cell Line Description Rs6559629 genotype 
HEK293 Human Embryonic kidney GG 
HCT116 Human colonic carcinoma GA 
SW480 Human colonic carcinoma AA 
 
Table 13 Cell lines and rs6559629 genotype 
Description and rs6559629 genotype of the three cell lines used in this experiment: 
HEK293, HCT116 and SW480.  
 
4.3.2 Optimisation of sonication conditions 
The first stage of ChIP involves cross linking DNA to protein and sonicating the 
DNA/protein complexes (Figure 36). The optimal size of DNA fragments to be used 
in ChIP experiments is between 200-800bp, for this experiment an average DNA 
fragment size of 500bp was used. 
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Cells were plated in 10cm plates, the following day (80% confluency) DNA bound 
proteins were cross linked to DNA by incubating cells in 10mls DMEM supplemented 
with 1% formaldehyde  (10 mins, 37˚C, 5% CO2). Following crosslinking, the 
formaldehyde solution was aspirated and cells were incubated with 10mls of DMEM 
supplemented with 0.125M glycine (Sigma) (10 mins, room temperature on a rocking 
platform). Cells were washed twice in ice cold PBS and scraped into 1ml PBS. 
Samples were centrifuged (5 mins, 5000 RPM, 4˚C) and PBS was removed. Each cell 
pellet was lysed in 200µl fresh ChIP lysis buffer (see Chapter 2) on ice for 10 mins. 
Samples was  sonicated using a Bioruptor standard water bath sonicator (Diagenode) 
for 10, 15 and 20 cycles of sonication (30 seconds on, 30 seconds off at 4˚C). 
Following sonication, samples were centrifuged (15 mins, 13000 RPM, 4˚C). In order 
to determine the size of sonication fragments, cross links were reversed at this stage, 
for the full ChIP experiment following sonication there was no reversal of cross links 
and samples were used for XBP1 immunoprecipitation. To reverse cross links and 
check DNA fragment size all samples were phenol chloroform treated. This involved: 
adding 5µl 4M sodium chloride, incubating at 65˚C overnight, adding a mixture of 50 
µl phenol, 48 µl chloroform and 2 µl isoamyl alcohol vortexing (10 mins) and  
centrifuging (5 mins, 13000 RPM, 4˚C). The upper phase of the resulting mixture 
contains DNA, 10 µl of 2M sodium acetate and 220 µl ice cold ethanol was added to 
100 µl of the upper phase. Samples were centrifuged (5 mins, 13000 RPM, 4 ˚C) and 
the supernatant was discarded. The resulting DNA pellet was washed in 1ml ethanol, 
centrifuged (5 mins, 10000 RPM, 4 ˚C) and air dried. Each DNA pellet was 
resuspended in 30 µl TE buffer. The sample was vortexed and incubated at -80 ˚C (1 
hour). Each sample (10 µl) was run on a 1.5% agarose gel as shown in Figure 37. The 
optimal average sonication size of 500bp was achieved after 20 cycles of sonication 
(Figure 37).  
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Figure 37 Optimisation of sonication conditions 
Image of 1.5% agarose gel showing Hyperladder V (Invitrogen), DNA digested with 
Lamda HindIII, sonicated DNA (10, 15 and 20 sonication cycles of 10 seconds off, 10 
seconds on) and unsonicated DNA. The 500bp mark is shown on the left hand side. 
 
 
4.3.3 Immunoprecipitation of XBP1 (spliced and unspliced) 
Following cross linking of protein to DNA, cell lysis and sonication the fourth stage 
of ChIP involves immunoprecipitation (IP) of DNA bound to the protein of interest 
(XBP1) (Figure 36). In order to determine whether the XBP1 antibody recognised the 
XBP1(s) and XBP1 (us) proteins, cells were transfected with XBP1 over expression 
constructs and incubated with anti XBP1 antibody on a western blot. Plasmids 
containing either XBP1 spliced (pXBP1SP) or XBP1 unspliced (pXBP1US) were a 
kind gift from Professor Arthur Kaser (Kaser et al., 2008). 
 
Cells were plated and transfected the following day with 10µg of empty vector, 
pXBP1SP or pXBP1US according to standard transfection protocols and incubated for 
24 hours (37˚C, 5% CO2). Cells were sonicated, cross linked and lysed as described 
above. Prior to setting up the IP, 30µl of cell lysate was kept as input sample. Protein 
G agarose beads (Roche) used in this experiment were washed in ChIP dilution buffer 
(see Chapter 2) and centrifuged (5mins, 10000RPM, 4 ˚C) prior to use. Before 
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immunoprecipitation, 100 µl of protein lysate was incubated with 50µl protein G 
agarose beads, 1 µl rabbit IgG (Sigma), 2 µl salmon sperm DNA (Roche) and 20 µl 
purified water. Samples were pre cleared for 6 hours on a rotating wheel at 4 ˚C to 
remove any components of the reaction mixture that may bind to the agarose beads 
nonspecifically. Samples were centrifuged (5 mins, 2000RPM, 4 ˚C) and the 
supernatant transferred to a new Eppendorf tube. Following preclearing, DNA bound 
to XBP1 was immunoprecipitated overnight. The IP reaction contained:  5µl anti 
XBP1 antibody (M186, Santa Cruz), 30µl protein G agarose beads, 100µl cell lysate 
and 965µl purified distilled water. For the purposes of characterising the M186 XBP1 
antibody, 30 µl loading dye was added to 30 µl of each sample and the samples was 
heated for 10 mins at 45 ˚C. Samples were run on a 10% polyacrylamide gel according 
to standard protocols and blotted with M186 anti XBP1 antibody at a concentration of 
1/1000, overnight. Figure 38 shows that both the unspliced (55KDa) and spliced forms 
of XBP1 (35KDa) are detected on a western blot in HEK293 cells transfected with the 
relevant constructs. In cells transfected with the unspliced XBP1 construct, the spliced 
construct can also be detected at 55KDa. These results confirmed that the M186 XBP1 
antibody could detect the XBP1 protein on a western blot. In addition, the lack of bands 
in the empty vector transfection shows that XBP1 does not detect any nonspecific 
proteins on a western blot. The M186 XBP1 antibody has previously been shown to 
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4.3.4 XBP1 promoter region as a positive control 
XBP1 has previously been shown to bind to the XBP1 promoter region as part of a 
positive feedback loop (Acosta-Alvear et al., 2007). In order to confirm that the M186 
XBP1 antibody was binding to XBP1 and the ChIP assay was working, the XBP1 
promoter region was used a positive control for this ChIP experiment. Although the 
XBP1 promoter region has previously been used as a positive control for ChIP 
experiments, the exact co-ordinates of the region where XBP1 binds to the XBP1 
promoter were not available. In order to identify the region in question the UCSC 
genome browser was used to analyse histone acetylation of the promoter region 
(Figure 39B). Histone acetylation is a marker for open chromatin which indicates 
transcriptionally active regions of DNA, as would be expected of a promoter region. 
Primers for regions between 200 and 250 bp long were designed for the XBP1 
promoter region, where histone acetylation appeared most dense (29,196,500-
29,198,500).   
 
To determine whether XBP1 was binding to this site, the entire ChIP experiment was 
conducted on HEK293 cells transfected with an empty vector, pXBP1S or pXBP1US 
 
Figure 38 Confirming immunoprecipitation of XBP1 protein 
Image showing western blot using 10% agarose gel. Top image was blotted with anti 
XBP1 (S) and (US) antibody (M186, Santa Cruz).Three samples were run on each gel (left 
to right): Mock (empty vector) transfected HEK 293 cells, HEK293 cells transfected with 
pXBP1SP and HEK293 cells transfected with pXBP1US. Bands at 55KDa show XBP1 
(US), bands are 35KDa show XBP1(S).  
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construct. Samples were lysed, sonicated and immunoprecipitated overnight as 
described above. Following immunoprecipitation, samples were centrifuged (5 mins, 
2000RPM, 4 ˚C) and the supernatant was discarded. Beads were washed in 1ml of the 
following buffers: TSE, TSEII, buffer III and twice in TE. Each wash lasted 5 mins on 
a rotating wheel, in between washes beads were centrifuged (5 mins, 2000RPM, 4 ˚C) 
and the supernatant was removed. After the final wash, the DNA was eluted from the 
protein G agarose beads in 250µl freshly made 1% sodium bicarbonate solution for 15 
mins on a rotating wheel at 4˚C. Supernatant was removed (kept in a separate 
Eppendorf) and elution was repeated in 200µl 1% sodium bicarbonate solution (15 
mins, 4 ˚C). The solution from both elution’s (450µl) was collected in one Eppendorf 
and 25µl of 4M sodium chloride was added (1.75µl was added to input samples). 
Samples were heat treated at 65 ˚C overnight. See Chapter 2 for further details on 
buffers used. The following day, 30µl of each sample was purified using a QIAquick 
PCR purification kit (Qiagen). DNA was quantified by RT qPCR using standard 
protocols and undiluted DNA samples. 
 
Results from this XBP1 ChIP experiment of the XBP1 promoter show that XBP1 binds 
to the XBP1 promoter region and that this region can be used as a positive control 
(Error! Reference source not found.). Error! Reference source not found. shows 
RT qPCR analysis of HEK 293 cells transfected with empty vector or pXBP1SP for 
the 29,198,500 to 29,196500 region of the XBP1 promoter. Fold enrichment was 
calculated by calculating concentration values (2(-CT)) and normalising all 
concentrations to the empty vector transfection. Each bar represents average fold 
enrichment across three replicates. A fold enrichment of between 6.8 and 7.5 (± SEM 
0.03-0.21) fold is seen between co-ordinates 29,197,700 and 29,196,900.  
Two positive control regions (region 1 = 29,197,500-700, region 2= 29,196,900-7100) 
were used in the final ChIP experiment in HEK 293, HCT 116 and SW 480 cells. 
Error! Reference source not found. shows the results from this experiment, all three 
cell lines were transfected with either an empty vector, pXBP1S or pXBP1US 
construct. Bars show average fold enrichment normalised to the empty vector 
transfection. Results shown are representative of three biological replicates. In HEK 
 
Chapter 4: Investigating the potential TLE1/XBP1 interaction                                106 
293 cells transfected with a pXBP1US there was an average fold enrichment of 1.41 
(± SEM 0.29) in region 1 and 1.73 (± SEM 0.47) in region 2. In HEK 293 cells 
transfected with pXBP1SP there was an average fold enrichment of 7.57 (± SEM 0.75) 
in region 1 and 6.24 (± SEM 2.95) in region 2. . In HCT 116 cells transfected with 
pXBP1US there was an average fold enrichment of 1.94 (± SEM 0.45) in region 1 and 
1.65 (± SEM 0.33) in region 2.  In HCT 116 cells transfected with pXBP1SP an 
average fold enrichment of 6.14 (± SEM 1.08) for region 1 and 8.56 (± SEM 0.25) for 
region 2 was observed. In SW 480 cells transfected with pXBP1US there was an 
average fold enrichment of 1.16 (± SEM 0.11) in region 1 and 1.80 (± SEM 0.40) in 
region 2. In SW 480 cells transfected with pXBP1SP there was an average fold 
enrichment of 7.85 (± SEM 1.41) for region 1 and 11.11 (± SEM 2.13).  
 
Overall, all three cell lines, when transfected with unspliced XBP1, showed a fold 
enrichment between 1.16 and 1.94 (± SEM 0.11-0.45) for region 1 and between 0.85 
and 1.80 (± SEM 0.33-0.47) for region 2. On average, all three cell lines, when 
transfected with spliced XBP1, showed a fold enrichment between 6.14 and 7.85 (± 
SEM 0.75-1.41) for region 1 and between 6.24 and 11.11 (± SEM 0.25-2.95) for region 
2.  
 
4.3.5 Negative controls for XBP1 ChIP 
In order to show that the XBP1 antibody was binding specifically to XBP1 targets, 
negative control regions were used in the final ChIP experiment. Two regions were 
used as negative controls (region 3 = 29,197,700-900, region 4= 29,196,700-900) in 
HEK293, HCT116 and SW480 cells. As above, bars show average fold enrichment 
normalised to the empty vector transfection and are representative of three biological 
replicates. In HEK 293 cells transfected with pXBP1US there was an average fold 
enrichment of 0.84 (± SEM 0.26) in region 3 and 1.73 (± SEM 0.41) in region 4. In 
HEK 293 cells transfected with pXBP1SP there was an average fold enrichment of 
0.69 (± SEM 0.26) in region 3 and 1.90 (± SEM 0.85) in region 4. In HEK 293 cells 
transfected with pXBP1US there was an average fold enrichment of 0.84 (± SEM 0.26) 
in region 3 and 1.73 (± SEM 0.41) in region 4. In HCT 116 cells transfected with 
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pXBP1US there was an average fold enrichment of 2.05 (± SEM 1.31) in region 3 and 
0.98 (± SEM 0.20) in region 4. In HCT 116 cells transfected with pXBP1SP there was 
an average fold enrichment of 2.00 (± SEM 0.47) in region 3 and 0.85 (± SEM 0.10) 
in region 4. In SW 480 cells transfected with pXBP1US there was an average fold 
enrichment of 0.91 (± SEM 0.17) in region 3 and 0.94 (± SEM 0.17) in region 4. In 
HCT 116 cells transfected with pXBP1SP there was an average fold enrichment of 
1.06 (± SEM 0.55) in region 3 and 1.46 (± SEM 0.27) in region 4.     
Overall, all three cell lines, when transfected with unspliced XBP1, showed a fold 
enrichment between 0.84 and 1.31 (± SEM 0.17-1.31) for region 3 and between 0.94 
and 1.73 (± SEM 0.16-0.41) for region 4. On average, all three cell lines, when 
transfected with spliced XBP1, showed a fold enrichment between 0.69 and 2.00 (± 
SEM 0.26-0.54) for region 3 and between 0.85 and 1.90 (± SEM 0.10-0.85) for 
region4,  
 











Figure 39 Identification and characterisation of XBP1 binding site in XBP1 promoter region 
Figure showing the XBP1 gene (A), corresponding H3K9 acetylation track (B) (UCSC) and graph results from an XBP1 ChIP experiment on this 
region (C). This region has been used as a positive control in XBP1 ChIP experiments (Acosta-Alvear et al., 2007). Bars represent average fold 
enrichment normalised to empty vector (EV) transfection. Blue bars show fold enrichment from HEK 293 cells transfected with an empty vector (EV)j, 
grey bars show fold enrichment for HEK 293 cells transfected with spliced XBP1 construct. Error bars show the standard error of the mean across 
three biological replicates. Numbers 1, 2, 3 and 4 correspond to positive and negative control regions used in final experiments. 
 
1 2 3 4 
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HEK 293  
SW 480  
HCT 116 
XBP1 ChIP results for the XBP1 promoter region (19,196,300-29,197,700) are shown as 
average fold enrichment, normalised to empty vector (EV) transfections. Blue bars (EV) 
represent cells transfected with an empty vector, green bars (US) represent cells with 
pXBP1US construct and grey bars pXBP1SP. Each bar shows average fold enrichment 
across three biological replicates. Error bars represent the standard error of the mean. 
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4.3.6 XBP1 does not bind to the rs6559629 site 
Error! Reference source not found. shows positive and negative controls for this 
XBP1 ChIP experiment for the three cell lines to be used in this experiment. These 
same samples were used to determine whether XBP1 binds to its predicted binding 
site, the rs6559629 site in TLE1. Each of these cell lines has a different rs6559629 
genotype to allow quantification of differential binding ( 
Table 13). Figure 8 shows average fold enrichment of the 1Kb region surrounding 
the rs6559629 SNP. This 1Kb region was chosen as results from analysis of the 
XBP1 promoter region showed that XBP1 bound a region approximately 500bp away 
from the core binding motif (Error! Reference source not found.). 
 
Figure 41 shows the XBP1 ChIP results for the rs6552629 region (84,206,860-207860) 
in HEK 293, HCT 116 and SW480 cells transfected with either empty vector, 
pXBP1US or pXBP1SP constructs. Bars show the average fold enrichment normalised 
to empty vector transfections, as described earlier. In HEK 293 cells (rs6559629 
genotype, GG) transfected with pXBP1US, there was an average fold enrichment 
between 0.98 and 1.31 (± SEM 0.20-0.53) across the rs6559629 region. In HEK 293 
cells transfected with pXBP1SP there was an average fold enrichment between 0.87 
and 1.44 (± SEM 0.06-0.56). In HCT 116 cells (rs6559629 genotype, GA) transfected 
with pXBP1US there was an average fold enrichment between 0.75 and 1.12 (± SEM 
0.15-0.43). In HCT 116 cells transfected with pXBP1SP there was an average fold 
enrichment between 0.87 and 1.33 (± SEM 0.11-0.33) across the rs6559629 region. In 
SW480 cells (rs6559629 genotype, AA) transfected with an pXBP1US there was an 
average fold enrichment between 1.11 and 2.06 (± SEM 0.33-0.46) .In SW480 cells 
transfected with pXBP1SP there was an average fold enrichment between 0.73 and 
1.41 (± SEM 0.04-0.66) across the rs6559629 region. 
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XBP1 ChIP results for the rs6559629 region (84,207,860-84,206,860) are shown as 
average fold enrichment, normalised to empty vector (EV) transfections. Blue bars (EV) 
represent cells transfected with an empty vector, green bars (US) represent cells with 
pXBP1US construct and grey bars pXBP1SP. Each bar shows average fold enrichment 
across three biological replicates. Error bars represent the standard error of the mean. 
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4.4 Discussion  
The aim of this chapter was to determine whether XBP1 binds to a predicted binding 
site in TLE1. This predicted binding site was of particular interest as it is interrupted 
by the rs6559629 SNP which is associated with Crohn’s disease (Figure 32) (Nimmo 
et al., 2011).  
 
This was achieved by designing a ChIP assay using an anti XBP1 antibody and RT 
qPCR to quantify DNA enrichment. Three cell lines were used in these experiments 
to quantify differential binding of XBP1 according to rs6559629 genotype ( 
Table 13). The XBP1 promoter region was shown to be a positive control for this 
assay in all three cell lines. Adjacent negative control regions were also used. Both 
unspliced and spliced forms of XBP1 were over expressed in each cell line as 
endogenous levels of XBP1 are low. The results described show that XBP1 does not 
bind to the rs6559629 site in TLE1 in any of the cell lines used.  
 
The rs6559629 site is not in a known promoter region, the nearest transcriptional start 
site (TSS) is the TLE1 TSS which is approximately 10Kb downstream of the XBP1 
recognition motif, in intron 15/16 of TLE1. Many studies have focused on the binding 
of XBP1 to promoter regions for example XBP1 has been shown to bind to promoter 
regions of GPR43, CHOP and BECLIN1 using ChIP assays (Ang, Er, & Ding, 2015; 
Margariti et al., 2013; Shao et al., 2015). Although the potential binding site 
interrupted by rs6559629 was not close to a TSS it was targeted by this study as it had 
sequence overlap for two core XBP1 binding motifs. Additionally although Acosta et 
al suggest that many a majority of XBP1 binding motifs occur at transcriptional start 
sites, their work used proximal promoter arrays and hence a long range transcriptional 
activation mechanism for XBP1 cannot be ruled out. Many transcriptional regulators 
have been shown to have long range effects in addition to short range ones. For 
example, the transcriptional activator, estrogen receptor (ER) has only 22% of its 
targets near TSS, the remaining targets are long range targets, some of which are up to 
100Kb away from a TSS. Furthermore these distal ER binding sites are functional and 
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activate transcription of downstream genes  (Carroll et al., 2006).  Although according 
to this work XBP1 does not bind the rs6559629 site, it would be of future interest to 
explore long range effects of XBP1 to further elucidate its role in IBD pathogenesis.  
 
In this work, binding of both the spliced and unspliced forms of XBP1 were analysed. 
Recent work has shown that the XBP1 (us) is a functional interacting protein. It has 
been shown to interact with the autophagy protein, FoxO1 by co immunoprecipitation 
and co- localisation was shown using immunocytochemistry. It was also suggested 
that XBP1(us) facilitates degradation of FoxO1 by the proteasome (Zhao et al., 2013). 
Although the work presented suggests XBP1 (us) does bind to the same positive 
control regions as XBP1 spliced, it is possible that XBP1 (us) has different targets and 
mechanisms of action to XBP1 (s). However, it is important to note, that over 
expression of XBP1 (us) induces ER stress and expression of XBP1(s) and therefore 
the XBP1 promoter region may not have been a positive control for XBP1 (us). 
Therefore it could be the case that this ChIP assay did not accurately detect the XBP1 
(us) targets. The use of high throughput technologies such as chip on chip to identify 
XBP1 (us) targets would be of interest, to identify whether XBP1 (us) binds to the 
rs6559629 site as well as to compare XBP1 (s) and XBP1 (us) functionality.  
 
The rs6559629 SNP interrupts a CpG site and the methylation status of this CpG site 
may influence XBP1 binding. As part of this project, the methylation status of this site 
was investigated in these cell lines however it was not possible to design an appropriate 
pyrosequencing assay following four attempts with various primers. Other work in our 
laboratory has analysed global methylation in IBD patients vs controls, which included 
four sites in TLE1, these sites did not include the rs6559629 site and were not 
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5.1 Introduction 
5.1.1 Immunohistochemistry  
Immunohistochemistry is a powerful technique used to analyse protein expression and 
localisation in tissues. It has previously been used to analyse the role of proteins 
implicated in IBD including TNFα, IL17A and SIRTUIN (SIRT1) (Honzawa et al., 
2014; Melhem et al., 2015; Murch, Braegger, Walker-Smith, & MacDonald, 1993). 
SIRT1 is an ER stress regulator that has been implicated in the development of colitis 
(Melhem et al., 2015). Colonic biopsies showed decreased SIRT1 expression in the 
colonic crypts of UC patients when compared to non IBD controls (Melhem et al., 
2015).  
 
The IHC protocol involves tissue collection, fixing, embedding in paraffin (for 
storage), deparaffinisation (for analysis), antigen retrieval, staining with an antibody 
to the protein of interest and analysis of this staining using microscopy.  Antibody 
staining consists of two stages, staining with a primary antibody (in this case anti 
TLE1) and staining with a secondary antibody linked to horseradish peroxidase (HRP). 
The HRP enzyme mediates a chemical reaction using diaminobenzene (DAB) as a 
substrate. The addition of DAB in the final stages of the IHC experiment results in 
brown staining in regions of tissue where HRP is present.  
 
 
5.1.2 Immunohistochemical analysis of NOD2 expression  
As discussed in the chapter 1, NOD2 is a pattern recognition receptor and a known 
IBD susceptibility gene. Mutations in NOD2 have been associated with CD and a 
yeast-2 hybrid assay showed NOD2 interacts with TLE1. Initial evidence indicated 
that the TLE1 rs6559629 risk increases the effect of these mutations in CD, however 
subsequent work has not replicated this finding  (Hugot et al., 2001; Nimmo et al., 
2011; Y Ogura et al., 2003).   
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In the intestine, NOD2 expression was first detected in Paneth cells and was originally 
thought to be exclusively expressed in these cells (Y Ogura et al., 2003). The absence 
of a functioning NOD2 antibody has meant that a majority of work has looked at 
mRNA expression levels of NOD2, however recent advances suggest that NOD2 is 
also expressed at the protein level in intestinal epithelial cells and monocyte derived 
cells (dendritic cells) of the immune system (Barnich, Aguirre, et al., 2005; Hu & 
Peter, 2013a).  
 
Pattern recognition receptors such as NOD2 are generally thought to be cytoplasmic. 
However, recent evidence indicates that NOD2 can also shuttle to the nucleus, where 
TLE1 is primarily expressed (Zurek et al., 2012).   
 
5.1.3 Immunohistochemical analysis of TLE1 expression  
TLE1 expression has been well studied in a number of different cancers. Synovial 
sarcomas section show replicable, strong nuclear staining and TLE1 has been proposed 
as a  diagnostic marker to differentiate synovial sarcoma from other tumors (Knösel et 
al., 2010). TLE1 has also been shown to stain other tumor tissues to a much lesser 
extent, for example malignant peripheral nerve sheath tumors (MPNT’s) and Ewing’s 
sarcoma (Kosemehmetoglu et al., 2009). Although TLE1 expression has not been 
analysed in normal intestinal tissue or IBD tissue, it has been shown to be expressed 
in gastrointestinal stromal tumors (Kosemehmetoglu et al., 2009).  
 
In healthy tissues TLE1 is expressed in a range of cell types including endothelial cells, 
keratinocytes and adipocytes (Kosemehmetoglu et al., 2009). The Human Protein 
Atlas suggests that TLE1 is expressed in most healthy tissues, including the colon 
where strong nuclear expression can be observed (Uhlen et al., 2015).  
 
In addition to nuclear staining TLE1 has also been shown the be expressed in the 
cytoplasm in HEK293 and HeLa cells, where NOD2 is primarily seen (Nimmo et al., 
2011; Stifani, Blaumueller, Redhead, 1992). 
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5.2 Aims  
As previously discussed, TLE1 interacts with the known IBD susceptibility gene 
NOD2. The general aim of this chapter was to analyse the expression of TLE1 in 
intestinal biopsies from healthy controls and IBD patients with and without CD 
associated NOD2 variants. Specific focus was placed on cells of the intestinal crypts 
as Paneth cells located in the intestinal crypts show highest levels of NOD2 expression.  
More precisely, the aims of this work were to: 
1. Identify and characterise an anti-TLE1 antibody 
a. Optimise IHC staining protocols for TLE1 
b. Replicate TLE1 staining seen in the literature 
2. Determine TLE1 expression patterns in healthy ileal tissue. 
a. Analyse the expression and cellular localisation of TLE1 in the 
intestinal crypts of healthy ileal tissue 
3. Analyse TLE1 expression in CD patients and healthy controls 
a. Quantify TLE1 expression in the ileal crypts of healthy controls and 
CD cases, identify any differences in TLE1 expression and localisation.  
4. Analyse TLE1 expression in CD patients with and without CD associated 
NOD2 variants 
a. Determine whether there are any differences in TLE1 expression or 
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5.3 Results 
5.3.1 Identification and optimisation of an anti-TLE1 antibody 
Two anti-TLE1 antibodies were tested for use in this work, M101 and N18 (Santa 
Cruz). Ileal pinch biopsies were used for optimisation experiments, these had been 
collected as part of previous work conducted by Dr Craig Stevens and Dr Paul 
Henderson. Slides were cut from paraffin embedded sections by the pathology 
department at the Western General Hospital.  
 
A standard IHC protocol was used for both optimisation and further experiments. 
Slides were rehydrated in glass tanks containing xylene (5 mins, twice), 100% ethanol 
(5 mins, twice) and 70% ethanol (5 mins, twice). Following these washes the slides 
were placed in a tank of distilled water. Cells were then subjected to antigen retrieval 
using either citric acid or trypsin. For citric acid antigen retrieval, slides were placed 
in a 1.5L beaker containing 10mM citric acid solution, pH6.8 (citric acid monohydrate, 
Sigma). Slides were heated in a 200W microwave for 20 minutes and then cooled on 
the bench. For trypsin treatment, slides were placed in a glass slide holder in 0.5% 
trypsin solution at 37˚C for 20 minutes and cooled on the bench. Once slides had 
cooled they were washed in a glass tank filled with water. Hydrogen peroxide solution 
(3%) was prepared in distilled water, slides were incubated in 300mls solution at room 
temperature on a rocking platform. Slides were washed in PBS and then assembled in 
a Sequenza slide rack (Thermo-Fisher). Slides were incubated in rabbit serum (1:5, 10 
mins) (Sigma). Slides were then incubated in 100µl of antibody/rabbit serum/PBS 
(negative control) overnight at 4˚C and the following day washed three times in PBS. 
Secondary antibody was applied using a PoLink-2 plus HRP detection kit (GBI labs) 
using standard protocols. Following incubation with DAB, slides were washed in 
running water. Harris haemotoxylin (Sigma) was applied as a counterstain for 30 
seconds, following this slides were washed in: running water, 68 mM lithium 
carbonate solution (30 secs) and running water. Finally, samples were dehydrated in 
glass tanks containing: 70% ethanol (twice), 100% ethanol (twice) and xylene (twice). 
Slides were mounted individually using Pertex mounting medium (HistoLab), air dried 
and analysed using a Zeiss Axioplan 2 microscope at the specified magnifications.           
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Optimisation of Antigen retrieval  
The M101 and N18 anti-TLE1 antibodies were used at concentrations of 1:10, 1:20 
and 1:50 with citric acid antigen retrieval. These concentrations were determined by 
analysis of the relevant literature. No staining was seen in negative control slides 
(secondary antibody only) or in any slides stained with the N18 antibody, strong 
nuclear staining was achieved with the M101 antibody at a 1:10 dilution. (Figure 42). 
  
Trypsin antigen retrieval was used at a wider concentration of 1:20-1:500 as it had not 
been used in previous TLE1 IHC studies. No staining was seen in negative controls 
(secondary antibody only) or in sections stained with the N18 antibody. Staining was 
observed at the 1:20, 1:50 and 1:100 M101 anti-TLE1 antibody concentrations (Figure 
43). Strong cytoplasmic and nuclear staining was observed at all three concentrations, 
this is in contrast to strong nuclear and weak cytoplasmic staining described in other 
tissues the literature. As the observed staining was determined to have high 
background and non- specific staining, citric antigen retrieval was used in further 
experiments.  This conclusion was confirmed by the pathologist, Professor Donald 
Salter.  
 
As staining was not achieved using two antigen retrieval methods the N18 antibody 
was not used in any further work. The M101 antibody was used in these experiments 
as optimisation experiments showed strong nuclear reactivity, as expected. 
Furthermore, the M101 antibody has been used extensively for IHC in previous 
published work involving analysis of TLE1 expression in synovial sarcoma and 
Ewing’s sarcoma (Foo, Cruise, Wick, & Hornick, 2011; Jagdis, Rubin, Tubbs, 
Pacheco, & Nielsen, 2009; Knösel et al., 2010; Lino-Silva, Flores-Gutiérrez, Vilches-
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Figure 42 Optimisation of M101 anti- TLE1 antibody using citric acid antigen retrieval  
The M101 anti-TLE1 antibody was used at concentrations of 1/10, 1/100 and 1/50 following citric acid antigen retrieval. A negative control image is 
shown on the right (secondary antibody only). Sections are DAB stained, counterstain is haematoxylin. Images have been taken at 20X 
magnification. 
 
Chapter 5: Immunohistochemical analysis of TLE1 expression in IBD patients of known NOD2 status.                                                                                           
122                                                                                                                                                                                                                                                                                                                                                                                                                                                         
 
Figure 43 Optimisation of M101 anti-TLE1 antibody using trypsin antigen retrieval 
The M101 antibody was used on ileal pinch biopsy slides at concentrations of 1/20, 1/50 and 1/100 following trypsin antigen retrieval. A negative 
control image is shown in the right (secondary antibody only). Sections are DAB stained, counterstain is haematoxylin. Images are taken at 20X 
magnification.  
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5.3.2 Replicating TLE1 staining observed in published work 
A literature search was used to identify published work which had analysed TLE1 
expression by IHC. In order to further characterise the M101 anti-TLE1 antibody, the 
tissues identified were analysed for TLE1 staining.  
 
As discussed, synovial sarcoma tissue has been analysed for TLE1 staining in many 
different research papers. Five synovial sarcoma slides from different patients were 
obtained from the pathology service at the Western General Hospital with the kind 
help of Dr Catherine Black and Dr Andrew Wood. Each slide was stained according 
to standard protocols described above. Citric acid antigen retrieval was used and the 
M101 anti-TLE1 antibody was used at a concentration of 1:10. Figure 44A shows 
negative control slides (secondary antibody only) do not show any staining for TLE1 
at 20X, 40X or 60X magnification. Figure 44B shows a synovial sarcoma slide stained 
with M101 anti-TLE1 antibody (1:10) positive nuclear staining can be seen in addition 
to very weak cytoplasmic staining. Figure 44C shows synovial sarcoma slides 
incubated with rabbit serum (1:20) overnight in order to determine whether the 
secondary antibody bound to any non-specific proteins in rabbit serum. Weak, diffuse 
primarily cytoplasmic staining can be seen. These staining patterns see using the M101 
anti-TLE1 antibody replicate those seen in the literature.  
 
Ewing’s sarcoma tissue was used to further characterise the M101 anti-TLE1 antibody. 
Research shows that although some staining is observed in Ewing’s sarcoma the 
degree of staining is much lower than that seen in synovial sarcoma. Slides from two 
Ewing’s sarcoma cases were obtained from resources at the Western General Hospital. 
Figure 45A shows Ewing’s sarcoma tissue negative controls, stained with secondary 
antibody alone, no staining is observed at either 20X, 40X or 60X magnification. The 
brown staining observed was present on the slides prior to deparrafinisation and was a 
result of sample processing by pathology, it does not represent positive staining. 
Ewing’s sarcoma sections stained with M101 anti-TLE1 antibody are shown in Figure 
45B, some nuclear staining is observed, however this is to a lesser extent to that seen 
in synovial sarcoma. Cytoplasmic staining is also visible in Ewing’s sarcoma slides 
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stained with M101 anti-TLE1 antibody. At 60X magnification very diffuse staining 
cytoplasmic staining can be seen, no nuclear staining is visible.    
 
 
Figure 44 TLE1 expression in synovial sarcoma  
A) Synovial sarcoma tissue, negative control (secondary antibody only) at 20X, 40X and 
60X magnification (left to right). B) Synovial sarcoma tissue stained with M101 anti-TLE1 
antibody (1/10) 20X, 40X and 60X magnification (left to right). C)  Synovial sarcoma tissue 
incubated with rabbit serum (1/10) 20X, 40X and 60X magnification (left to right).  Sections 
are DAB stained, counterstain is haematoxylin. 
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Figure 45 TLE1 expression in Ewing’s sarcoma  
A) Ewing’s sarcoma tissue negative control (secondary antibody only) at 20X, 40X and 
60X magnification (left to right). B) Ewing’s sarcoma tissue stained with M101 anti-TLE1 
antibody (1/10) 20X, 40X and 60X magnification (left to right). C)  Ewing’s sarcoma tissue 
incubated with rabbit serum (1/10) 20X, 40X and 60X magnification (left to right). Sections 
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5.3.3 TLE1 staining in healthy human tissue 
TLE1 expression was analysed using a paraffin tissue panel purchased from 
Biochain. The array was analysed using standard IHC protocols as described above. 
Staining was quantified as low (0-30% of positive cells), moderate (30-60% positive 
cells and highly positive (60%+ positive cells). Cytoplasmic and nuclear staining 
were quantified separately. Tissues analysed using this panel were: heart, brain, liver, 
kidney, lung, pancreas, spleen and skeletal muscle (Figure 47). The age and sex of 
these samples is shown in  
Table 14. Varied staining was seen across different tissues, pancreatic tissue showed 
the highest levels of nuclear expression, all other tissues showed low nuclear 
expression levels. Brain tissue had the highest cytoplasmic expression, expression in 
other tissues as low or moderate with heart, lung, spleen and skeletal tissue showing 
the lowest expression  
Table 14).  
 
 
Chapter 5: Immunohistochemical analysis of TLE1 expression in IBD patients of 
known NOD2 status.                                                                                           127                                                                                                                                                                                                                                                                                                                                                                                                                                                         




Heart F 61 Low Low 
Brain F 87 Low High 
Kidney  F 66 Low Moderate 
Liver M 71 Low Moderate 
Lung M 50 Low Low 
Pancreas M 71 Moderate Moderate 
Spleen M 24 Low Low 
Skeletal muscle M 24 Low Low 
 
Table 14 TLE1 staining in healthy tissues 
Healthy tissues were stained for TLE1 protein expression. Sex, age, clinical diagnosis and 
extent of staining in the nucleus and cytoplasm are shown. Low staining is classified as 
less than 30% positive, moderate is between 30 and 60% and high is over 60%.  
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Figure 46 TLE1 expression in healthy tissues 
TLE1 expression in human skeletal muscle, spleen, liver. Brain, heart, pancreas, kidney and lung. Images are shown at 10X and 40X 
magnification. Sections are DAB stained, counterstain is haematoxylin. 
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5.3.4 TLE1 staining in ileal resections from healthy controls and CD patients 
of known NOD2 status 
 
Ileal resection samples were requested from the pathology department of the Western General 
Hospital for two healthy controls and twenty IBD patients of known NOD2 status (10 with 
NOD2 variants, 10 without NOD2 variants) with the help of Dr Catherine Black and Dr Andrew 
Wood. Paraffin embedded samples were processed according to standard hospital protocols 
and cut into 4µM slides by the pathology department.  
 
Prior to starting the experiment, slides from all groups (healthy controls, CD with no NOD2 
variants, CD with NOD2 variants) were randomised and numbered with the help of another 
scientist. This was to blind the experiment and prevent any unconscious bias during both the 
experiment and the analysis.  Each slide was subject to TLE1 staining as described above and 
analysed using a Zeiss Axioplan 2 microscope. Five frames from each slide were imaged at 
both 20 and 40 times magnifications and grouped according to TLE1 expression (low 0-30% 
of positive cells, moderate 30-60% positive and highly positive 60%+). TLE1 expression was 
quantified in 100 cells, using images taken at 40X magnification. Cytoplasmic and nuclear 
staining were quantified separately. All images analysed consisted of approximately 50% 
intestinal crypts as this region was of particular interest in this study. No slides showed overall 
staining higher than 85%. This protocol was has been used in other immunohistochemistry/ 
IBD studies and was advised by Professor Donald Salter.  
 
5.3.5 TLE1 is highly expressed in the ileal crypts of healthy controls 
TLE1 expression was analysed in ileal resections from two healthy controls. The exact details 
of diagnosis are not available to us under the conditions of the relevant ethical review, however 
they were confirmed to be uninflamed, non-cancerous and non IBD samples. Representative 
images of TLE1 staining in these samples is shown in Figure 47. Strong nuclear and limited 
cytoplasmic staining was observed in both healthy controls (A= 90%, B-85% of cells in the 
intestinal crypts). This staining was observed in the nucleus and cytoplasm of a majority of 
Paneth cells analysed i.e. 74% of Paneth cells analysed were positive for TLE1 staining.    
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Figure 47 TLE1 expression in the ileal tissue of healthy controls 
TLE1 staining in healthy ileal tissue obtained from two healthy controls. The top panel represents images taken from one healthy control, from left to right, 
10X, 20X and 40X images showing villi and crypts respectively. The lower panel shows the same for the second healthy control.  Sections are DAB 
stained, counterstain is haematoxylin.  
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5.3.6 TLE1 shows varied expression in CD patients with and without CD 
associated NOD2 variants 
TLE1 expression was analysed as described above in ileal resections from 10 patients with CD 
associated NOD2 variants and 10 patients without these NOD2 variants. Overall, there was 
varied staining ranging from completely negative to highly positive (Figure 48A, Figure 49A 
and Figure 50A). TLE1 expression was observed in both intestinal epithelial cells and Paneth 
cells of the intestinal crypts. Paneth cells in samples with moderate or high TLE1 expression 
showed nuclear and cytoplasmic staining (Figure 49 A and Figure 50A). Nuclear staining was 
also seen in the intestinal epithelial cells of the intestinal crypt (Figure 49) and in the lamina 
propria (Figure 48B).  
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Figure 48  A subset of ileal CD patients with and without CD associated NOD2 variants show low levels for TLE1 staining 
Four CD patients with mutant NOD2 and three CD patients with WT NOD2 showed little to no TLE1 staining in any areas of the ileum.  Sections are DAB 
stained, counterstain is haematoxylin. From left to right, image taken at 10 times magnification, image of villi at 40 times magnification and crypt taken at 
40 times magnification.  
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Figure 49 A subset of Ileal CD patients with and without CD associated NOD2 variants exhibit moderate TLE1 staining 
Four CD patients with mutant NOD2 and six CD patients with WT NOD2 showed between 20-50% of ileal cells staining positively for TLE1.  Sections are 
DAB stained, counterstain is haematoxylin. From left to right, image taken at 10 times magnification, image of villi at 40 times magnification and crypt taken 
at 40 times magnification. 
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Figure 50 A subset of Ileal CD patients with and without CD associated NOD2 variants exhibit highly positive TLE1 staining 
Four CD patients with mutant NOD2 and six CD patients with WT NOD2 showed over 50% of ileal cells staining positively for TLE1.  Sections are DAB 
stained, counterstain is haematoxylin. From left to right, image taken at 10 times magnification, image of villi at 40 times magnification and crypt taken at 40 
times magnification 
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5.4 Discussion  
In this work, I have optimised an anti-TLE1 antibody and used it to analyse TLE1 
expression in the ileum of healthy controls and CD cases. The CD patients used in this 
study were of known NOD2 status in order for us to further investigate the 
TLE1/NOD2 interaction and whether NOD2 mutations affect TLE1 expression or 
localisation. This is the first study to show the expression patterns of TLE1 in human 
ileal tissue. 
 
Overall healthy controls showed strong TLE1 staining in the intestinal crypts, 
expression was seen in both intestinal epithelial cells and Paneth cells. Both the NOD2 
mutant and NOD2 wild type ileal resections showed varied TLE1 staining; ranging 
from less than 20% positive to 85% positivity. Sections with moderate or highly 
positive TLE1 staining showed expression of TLE1 in Paneth and intestinal epithelial 
cells. 
 
The cause of the variation seen in TLE1 expression in CD cases regardless of genotype 
is not known. The sections analysed were all from uninflamed cases so this is unlikely 
to be the cause. Additional information on medical treatment and IBD markers for 
these patients e.g. fecal calprotectin would of interest to future work in order to 
determine whether TLE1 expression correlates with active disease, disease relapse or 
specific treatments. The relevant ethical review did not allow for information on the 
type of NOD2 mutation. As the L1007fsInsC mutation does not localize to the plasma 
membrane it would be interesting to analyse each of the mutations individually with 
respect to TLE1 expression and localisation in future work.  
 
Recent work in our laboratory, conducted by Helen Newbery, had identified a 
functioning NOD2 antibody. NOD2 expression is primarily in the Paneth cells of 
healthy control resections and CD patients (regardless of NDO2 status), this finding is 
line with the literature (Y Ogura et al., 2003). There are isolated epithelial cells that 
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appear to show cytoplasmic positivity. Overall NOD2 protein expression in the 
intestinal crypts is much lower than TLE1 expression.  Although expression of TLE1 
and NOD2 in the same cell types makes the interaction observed in cell lines more 
plausible it does not provide definitive evidence that NOD2 and TLE1 interact in the 
human ileum. Analysis of co-localisation of TLE1 and NOD2 was not possible in this 
study as both TLE1 and NOD2 are raised in rabbit. Cross reactivity between antibodies 
of the same species means that any results from these experiments would be 
uninterpretable. Current work in our laboratory is focused upon analysing expression 
of proteins in serial sections taken from the same sample. This may allow for analysis 
of TLE1 and NOD2 expression in the same cells. Future work may could focus on 
identification of alternative TLE1 antibodies raised in different species allowing 
analysis of co localisation of NOD2 and TLE1 with the use of fluorescently tagged 
secondary antibodies. Alternatively, there are IHC techniques that can be used when 
antibodies are raised in the same species.  Martinez et al used antibodies raised in the 
same species to analyse the protein adrenomellulin and glucagon in the rat pancreas. 
The protocol used in this work involves a stripping technique whereby slides are 
stained with one antibody and staining is visualised, the slide is then stripped for one 
minute in 2.5% KMnO4/ 5% H2SO4/ distilled H2O, 1:1:30 (vol/vol) and 0.5% Na 
metabisulfite in distilled water for 3 min. Following stripping slides are washed in 
water for two hours prior to re staining with the second primary antibody. Controls 
showed no signal from stripped sections stained with secondary antibody alone which 
suggests that the stripping was effective (Martínez, Cuttitta, & Teitelman, 1998). This 
technique may be worth trying if an alternative functioning TLE1 antibody cannot be 
found. 
As discussed, the differences in TLE1 expression between CD patients could not be 
attributed to NOD2 genotype, even once the specific type of mutation is known. It may 
be the case that other proteins are involved in the NOD2/TLE1 interaction i.e. they 
form a complex. Both NOD2 and TLE1 appear to be hub proteins; they are involved 
in many different signaling pathways and interact with hundreds of other proteins. It 
may also be of interest to use isolate the TLE1/NOD2 potential complex and use a 
combination of mass spectrometry and peptide sequencing to identify the proteins 
involved. 
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6.1 Introduction  
SNPs are single base pair changes which can be used as markers in Genome Wide 
Association (GWA) studies. They tag blocks of linkage disequilibrium, these are 
regions of DNA that are not separated by recombination. Association of a SNP with a 
particular phenotype or disease has been used to identify regions of DNA that may 
contribute to pathogenesis. The majority of the 163 IBD susceptibility loci identified 
have been found as a result of GWA studies, to date, 71 susceptibility loci for CD have 
been discovered by GWA studies (Franke et al., 2010; Jostins et al., 2012).  
In 2011, Nimmo et al typed eight SNPs in the TLE1 gene and showed that three of 
these SNPs were significantly associated with CD in a combined Scottish cohort.  The 
eight SNPs were genotyped in two independent Scottish cohorts from Edinburgh 
(controls n= 841, CD n=352) and Dundee (controls n=674, CD n=296). Three SNPs 
were significantly associated with CD in the Edinburgh cohort: rs11139315 (p=0.01), 
rs2796469 (p=0.04), rs6559629 (p=0.02). In the Dundee cohort: rs2796469 (p=0.04), 
rs6559629 (p=0.09), rs10867783 (p=0.0005), rs7856583 (p=0.02) were significantly 
associated with Crohn’s disease. When these two cohorts were combined three SNPs 
remained significantly associated with Crohn’s disease: rs11139315 (p=0.003), 
rs2796469 (p=0.004), rs6559629 (p= 4×10-4), MAF’s and p values for all TLE1 SNPs 
are shown in . The location of the eight TLE1 SNPs typed in this study is shown in 
Figure 52, the three SNPs that showed statistically significant differences in allele 
frequency are highlighted. Two of these SNPs: rs2796469 and rs6559629 tag the same 
LD block, as shown in Figure 51.  
Analysis of the NOD2 and TLE1 genotype frequencies in the aforementioned cohort 
showed that the rs6559629 TLE1 risk allele appears to increase the effects of NOD2 
mutations. In patients with only a NOD2 risk allele there was an odds ratio of 2.49, 
confidence interval 0.61-10.14, whereas in the patients with one TLE1 risk allele and 
a NOD2 risk allele an odds ratios of 10.79, confidence interval 3.01-38.64 were 
observed (Table 16).  These results have not been replicated in data from larger, UK 
IBD cohorts, suggesting this finding is only relevant to the Scottish population or it 
was an artefact of the smaller cohort used in this study (controls n=630, CD n=280). 
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 Table 15 TLE1 SNP frequencies in combined Scottish CD cohort ( adapted from (Nimmo et al, 2011)) 
TLE1 SNP allele frequency in healthy controls, all CD patients and patients with L1, L2 and L3 CD separately. L1, L2, and L3 describe the location of disease, refer 
to Table 17. Each allele as a fraction of the total number of alleles, %MAF and corresponding p values are shown. Information for the SNP with the strongest 





Controls n=1515 All CD (n = 648) L1 (n = 170) L2 (n = 188) L3 (n = 171)
TLE1 %MAF %MAF p value %MAF p value %MAF p value %MAF p value
Combined subphenotypic analysis of CD data by location
 rs11139315 36.5 41.3 0.003 39.7 0.24 40.4 0.14 39.7 0.24
 rs2796469 37.8 33.2 0.004 27.6 2 × 10−4 36 0.49 33 0.08
 rs6559629 48.5 54.5 4 × 10−4 60.6 3.1 × 10−5 48.9 0.88 56.8 0.004
 rs7045812 15.2 15.7 0.64 15.1 0.96 15.2 0.99 15.4 0.92
 rs10867783 43.2 39.9 0.05 40.1 0.28 36.8 0.02 43.5 0.91
 rs7856583 45.5 47.5 0.23 45.6 0.99 50 0.1 50.6 0.08
 rs2378591 37.6 36.8 0.6 41.1 0.21 33.3 0.11 37.4 0.92
 rs3739581 24.5 25.3 0.56 28.1 0.14 22.5 0.39 26 0.39
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Table 16 Frequency and odds ratios of TLE1 rs6559629 and NOD2 risk alleles in a combined Scottish cohort 
Number of TLE1 and NOD2 risk alleles in combined Scottish cohort, number of alleles, odds ratios and confidence intervals are shown. NOD2 and TLE1 cohort 
MAFs and percentage of the cohort with TLE1 and NOD2 risk alleles both individually and combined are shown.  
Number of risk alleles (NOD2) Number of risk alleles (TLE1) Controls (n=1272) CD (n=590) OR CI CD (L1) (n=162) OR CI
0 0 264 106 1 21 1 0.54-1.60
0 0 593 208 0.87 0.66-1.15 44 0.93 1.41-4.21
0 2 232 142 1.52 1.21-2.07 45 2.44 0.44-3.35
1 0 52 20 0.96 0.55-1.68 5 1.21 1.75-6.30
1 1 87 56 1.6 1.07-2.40 23 3.32 2.23-10.16
1 2 37 37 2.49 1.50-4.14 14 4.76 0.34-29.40
2 0 4 4 2.49 0.61-10.14 1 3.14 4.68-93.79
2 1 3 13 10.79 3.01-38.64 5 20.95
2 2 0 4 4
NOD2 carriage 14.3% 22.7% 32.1%
TLE1 carriage 74.9% 78.0% 83.3%
NOD2 +TLE1 carriage 10.0% 18.6% 28.4%
NOD2 MAF 7.5% 13.1% 19.1%
TLE1 MAF 48.0% 54.5% 61.1%
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Figure 51 Linkage Disequilibrium patterns in TLE1; gene 
Map of LD blocks in TLE1 gene constructed using data from HAPMAP release#28 and Haploview v4.2. Block one contains the rs6559629 SNP, the TLE1 SNP 























Figure 52 TLE1 SNPs associated with CD (Nimmo et al, 2011) 
The eight SNPs genotyped as part of the Nimmo et al, 2011 study are shown. The three SNPs highlighted in 
yellow were significantly associated with CD in a combined Scottish cohort. Diagram adapted from Nimmo et 
al 2011. 
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6.2 Aim 
Initial studies showed that three SNPs in TLE1 are associated with CD in a combined Scottish 
cohort (Nimmo et al., 2011).  The strongest association observed was between rs6559629 and 
CD (p= 4×10-4). This aim of this chapter was to determine whether there was a causative variant 
underlying the association of rs6559629. In order to enrich for mutations linked to the 
rs6559629 association, patients with the rs6559629 risk allele and controls without the risk 
allele were used in this study. The aim of this chapter can be broken down into several stages: 
1. Sequencing coding regions of TLE1 in a Discovery cohort 
 
2. Sequencing relevant non coding regions in a Discovery cohort 
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6.3  Methods 
6.3.1 Cohort selection 
The first stage of this involved selecting a cohort of patients to sequence. A group of 24 CD 
patients and 24 healthy controls were selected (DNA samples from Western General Hospital 
stored at the Wellcome Trust Clinical Research facility, WTCRF). Average age of healthy 
controls was 42 and 48 for CD patients (Table 19). CD patients with ileal disease ((L1 or L3) 
were chosen preferentially as the rs6559629 association was shown in patients with ileal 
disease (Nimmo et al., 2011) .Table 17 describes the Montreal classification system and Table 
18 shows the number of patients in each sub phenotypic category. These patients had 
previously been genotyped for the rs6559629 SNP. CD patients who were homozygous for the 
rs6559629 risk allele were chosen and healthy controls who were homozygous for the 
alternative allele were used in order to increase our chances of finding a mutation underlying 
the association seen between rs6559629 and CD. The cohort of 24 individuals of each 
phenotype allowed identifications of mutations present at a greater than 1% frequency in the 
population. DNA samples were provided as 20µl aliquots (2µg/ul) from samples stored at the 
Welcome Trust clinical research facility (WTCRF).   
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 Sub phenotypes 
Location L1 ileal 
L2 colonic 
L3 ileo-colonic 
Behaviour B1 non stricturing, non penetrating  
B2 stricturing 
B3 penetrating 
Table 17 Montreal classification of IBD sub phenotypes and behaviours 
Table describing disease location and behaviour sub phenotypes of CD, according to the Montreal 
classification.  
 
 B1 B2 B3 
L1 7 3 5 
L2  5 0 1 
L3 0 2 2 
Table 18 Sub phenotypic classification of CD patients in Discovery cohort 
Sub phenotypic classification of disease location and behaviour according to the Montreal 
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 Average Age Gender 
Male Females Males Females 
Healthy 
controls 
43 40 11 13 
CD patients 43 53 14 10 
Table 19 Age and genotype information for Discovery cohort 
Average age of males and females in both males and females in the Discovery cohort. Number of 
male and females in controls and CD patients is also shown. 
 
 
6.3.2 PCR and Sanger sequencing 
Each exon and intronic region to be sequenced was PCR amplified according to standard 
protocols. Figure 53 shows the structure of the TLE1 gene, each exon was amplified, purified 
and Sanger sequenced (ABI 3130 genetic analyser, Institute of Genetics and Molecular 
Medicine sequencing service, University of Edinburgh).  The same primers were used for PCR 
and sequencing. Primers were designed using Primer 3 for 500bp regions, at either side of each 
exon 50bp of intronic sequence was included in the PCR region (Untergasser et al., 2012). 
Primers were optimised using gradient PCR (55-65 ̊C) (Appendix 1).  
 
6.3.3 Data Analysis 
Sequencing data was analysed using Geneious v7.0.6. Statistical analysis was carried out in 
Excel. The Students T Test was used to generate a p value, heterozygous and homozygous 
(minor allele) individuals were grouped together i.e. the presence of one copy of the minor 
allele was used as the “risk factor” 
 
Figure 53 TLE1 gene  
Schematic diagram of TLE1 gene, exons are shows as blue boxes separated by black lines 
representing each intron. The rs6559629 SNP is shown as a purple line between introns 15 and 16. 
 
Chapter 6: Sequencing TLE1 in Crohn’s disease patients and healthy controls       147                                                                                                                                                                                                                                                                                                                                                                                                                                                         
6.4 Results 
6.4.1 Discovery Cohort  
Sequencing of TLE1 exons 
Primers for each of the TLE1 exon were designed and optimised by gradient PCR (see 
Appendix). Additional sequencing primers used for exons greater than 450bp are shown in 
brackets underneath PCR primers. Prior to sequencing, 5µl of each PCR product was run on a 
1.5% agarose gel to check for visible clear bands of PCR product at the correct size.  
 
Analysis of sequencing data revealed two exonic SNPs: rs147523347, rs114633202 (Error! 
Reference source not found.). The minor allele frequencies (MAF) of each of these SNPs 
according to the Ensembl database (European population) were: 0.006 and 0.003, respectively. 
It is important to note that any p values discussed here on do not reflect differences in allele 
frequencies in the general population as CD patients with the rs6559629 risk allele and healthy 
controls without the risk allele were chosen for this study. The SNP in exon 2, was 
heterozygous in one healthy control and two CD patients, all other patients and controls were 
homozygous for the major allele (A). The rs114633202 SNP in exon 6, was heterozygous in 
one healthy control, all other CD patients and healthy controls were homozygous for the major 
allele (A) (p=0.56). The rs372238712 SNP was homozygous for the minor allele (T) in one CD 
patient and heterozygous in one healthy control, all other individuals were homozygous for the 
major allele (C) (Error! Reference source not found.).      
 
Sequencing of non- coding regions  
Sequencing Intron 15/16 
The intron 15/16 region contains two of the three SNPs in TLE1 that are associated with CD: 
rs2796469 (p=0.004), rs6559629 (p= 4×10-4) (Nimmo et al., 2011), hence it was sequenced to 
identify any mutations underlying these associations.  
Sequence analysis revealed four SNPs in this region: rs7023704, rs2796471, rs6559629, 
rs7019824 (Error! Reference source not found.). All CD patients were homozygous for the 
minor allele (G) of the rs6559629 SNP and healthy controls were homozygous for the major 
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allele (A). All minor allele frequencies discussed were obtained from the Ensembl database 
(European population). The rs7023704 SNP had a MAF of 0.21 and was homozygous for the 
minor allele in on CD patient and two healthy controls, it was heterozygous in one CD patient 
and one CD control and homozygous for the major allele in all other individuals (p=0.65). The 
rs2796471 SNP has a minor allele frequency of 0.21, one CD patient and two healthy controls 
were heterozygous for the SNP, all other patients and controls were homozygous for the major 
allele (A) (p=0.65). The third allele, rs7019824 has a MAF of 0.1, one CD patient and one 
healthy control were heterozygous, all other individuals were homozygous for the major allele 
(C) (p=1).     
 
Sequencing Intron 16/17 
The majority of SNPs identified GWA studies are in non- coding regions as is the case with 
rs6559629, the SNP in TLE1 most strongly associated with CD. A recent research focus has 
been to try and analyse the direct functional significance of mutations in non- coding regions. 
The SuRFr pipeline was used to identify the regions of DNA, tagged by rs6559629, that may 
be of particular interest to sequence (Ryan, Morris, Porteous, Taylor, & Evans, 2014). This 
pipeline was used with the kind help of its creator Niamh Ryan. The SuRFr pipeline uses data 
from the UCSC genome browser including histone acetylation and methylation, transcription 
factor binding sites, sequence conservation and DNase 1 hypersensitivity to predict which non 
coding regions are most likely to have functional significance. The LD block tagged by 
rs6559629, shown in block 1 of Figure 51 was used as the input DNA region. The highest 
scoring region in the output within this LD block was the intron 16/17 region shown in Figure 
54. This region contained the largest number of SNPs of potential functional significance and 
also contains the start site for a predicted alternative transcript of TLE1 in addition to histone 
acetylation markings and DNAse1 hypersensitivity clusters.  
In total, nine variants were found in intron 16/17, one of which was a 7bp deletion 
(rs376377585). Six of the SNPs were present at frequencies that were statistically significantly 
different according to the student’s t test: rs376377585 (p=0.076), rs2796466 (p=0.085), 
rs911638 (p=0.085), rs2777772 (p=0.0003), rs2796464 (0.0201) and rs2796465 (p=1.93×10-
6). The MAF’s of the nine SNPs ranged from 0.002-0.12
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Table 20 SNPs found in TLE1 exons in a cohort of 24 CD patients and 24 healthy controls 
This table details the results from sequencing intron 16/17 in the previously described cohort of 24 CD patients and 24 healthy controls. The table shows 
chromosomal location, SNP ID numbers, type of variation, the number of patients and controls that are homozygous for the major or minor allele, the number of 
patients that are heterozygous and the p value for the difference in minor allele frequency between patients and controls.  
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9:81592983 rs7023704 C/G 0.22 (G) Intronic SNP 22 1 1 21 2 1 0.65 
9:81592942 rs2796471 A/G 0.21 (G) Intronic SNP 23 0 1 22 0 2 0.65 
9:81592445 rs6559629 G/A 0.48 (G) Intronic SNP 0 24 0 24 0 0 N/A 
9:81592295 rs7019824 C/T 0.10 (T) Intronic SNP 23 0 1 23 0 1 1 
Table 21 SNPs found in intron 15/16 of TLE1 in a cohort of 24 CD patients and 24 healthy controls 
This table details the results from sequencing intron 16/17 in the previously described cohort of 24 CD patients and 24 healthy controls. The table shows 
chromosomal location, SNP ID numbers, type of variation, the number of patients and controls that are homozygous for the major or minor allele, the 
number of patients that are heterozygous and the p value for the difference in minor allele frequency between patients and controls.  
In the intron 15/16 region three SNPs in addition to rs6559629 were found: rs7023704, rs2796471, rs7019824, allele frequencies were not different 
between CD patients and healthy controls. The p value for rs6559629 is not applicable as CD patients with the rs6559629 risk allele and healthy controls 



































rs376377585  GCACTGA/- NA Intronic indel 24 0 0 21 3 0 0.076 
9:81590773 rs373720466 G/A NA (A) Intronic SNP 22 0 2 22 0 2 1.00 
9:81590772 rs187303459 C/T 
0.002 
(T) 
Intronic SNP 23 0 1 24 0 0 0.32 
9:81590592 rs62578588 C/T 
0.074 
(C) 
Intronic SNP 24 0 0 23 1 0 0.32 
9:81589864 rs2796466 G/T 
0.290 
(T) 
Intronic SNP 16 5 3 10 6 8 0.085 
9:81589485 rs911638 C/T 
0.120 
(T) 
Intronic SNP 15 5 4 9 6 9 0.085 
9:81589417 rs2777772 T/G 
0.120 
(G) 
Intronic SNP 18 3 3 6 9 9 0.0003 
9:81589329 rs2796464 T/C 
0.120 
(C) 
Intronic SNP 19 3 4 9 6 9 0.02 
9:81589690 rs2796465 G/A 
0.120 
(A) 
Intronic SNP 19 3 2 8 7 9 1.93×10-6 
Table 22 SNPs found in intron 16/17 in a cohort of 24 CD patients and 24 healthy controls. 
Results from intron 16/17 sequencing in Discovery cohort. Table shows chromosomal location, SNP ID numbers, type of variation, the number of patients and controls 
that are homozygous for the major or minor allele, the number of patients that are heterozygous and the p value for the difference in minor allele frequency between 
patients and controls. The Students T Test was used to generate a p value, heterozygous and homozygous (minor allele) individuals were grouped together i.e. the 
presence of one copy of the minor allele was used as the “risk factor”. In total 8 SNPs and one deletion were found, of these variations three had statistically significant 
allele frequencies in CD patient’s vs healthy controls: rs2777772 (p=0.0003), rs2796464 (p=0.0201), rs2796465 (p=1.9337×10-8). 
 







Figure 54 Features of potential functional significance in the TLE1 intron 16/17 region. Adapted from the UCSC genome browser 
Figure showing functional SNPs of particular interest identified using SuRFr pipeline in top row and TLE1 transcripts, histone acetylation and DNase 1 
hypersensitivity clusters below, respectively. Intron 16/17 is shown in orange on the primary (top) TLE1 transcript, SNPs in intron 16/17 that were identified 
by the SuRFr pipeline are depicted by blue lines above the first TLE1 transcript. 
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6.4.2 Haploreg analysis of SNPs found in Discovery cohort 
Haploreg is a tool designed to help prioritise variants from GWA studies (Ward & 
Kellis, 2012b). It provides data on chromatin state, evolutionary conservation and 
predicted transcription factor binding sites/regulatory motif alterations. The data 
provided is based on a combination of information from the ENCODE project, 1000 
genomes project and genome browsers (UCSC, Ensembl). In this context, Haploreg 
was used as a tool to analyse whether any of the SNPs found in this Discovery cohort 
interrupted predicted transcription factor binding sites that have been implicated in 
IBD. 
 
All sixteen SNPs found in the Discovery cohort were batch input into Haploreg for 
analysis, no data was available for rs372238712, rs376377585 and rs373720466. Table 
25 shows the results from this analysis, in addition to regulatory motif alterations, 
MAF in African, Asian, American and European populations and dbSNP functional 
annotation are shown. Information from the ENCODE project/UCSC is used to 
produce promoter and enhancer histone marker information in addition to DNase 1 
hypersensitivity and proteins bound. The only SNP to be located in a predicted 
promoter region according to histone markings was rs147523347, located in exon 2 of 
TLE1. Eight of the thirteen SNPs analysed were in DNAase1 hypersensitivity sites:  
rs147523347 rs7023704 ( 11 cell types) , rs2796471 (8 cell types) , rs6559629 (4 cell 
types), rs187303459, rs62578588,  rs2796466 (1 cell type). Five proteins are predicted 
to bind to the rs147523347 region: POL2, CTCF, POL24H, and TAF. Eight of the 
thirteen SNPs analysed interrupt predicted regulatory motifs, 27 motifs are interrupted 
in total, of which three: PAX 5, RXRA and FOXJ2 are interrupted by two SNPs. Eight 
of the thirteen SNPs have MAF frequencies between 0.23 and 0.51 in European 
populations, frequencies in African , American and Asian populations are similar or 
lower. Two SNPs (rs147523347, rs7019824) have a MAF of 0.01, rs62578588 has a 
MAF of 0.08 in European populations and there is no allele frequency data available 
for rs114633202 and rs187303459. Huvec (human umbilical vein endothelial) cells 
have enhancer histone markings in the rs7023704 and rs2796471 SNP regions. 
Enhancer markings in HMEC (Human mammary endothelial cells) are seen in the 
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rs7019824 and rs6559629 SNP region. In the hepatocellular carcinoma cell line 




6.4.3 Analysis of SNPs in a European cohort 
In total, fifteen SNPs were discovered in exons 2 and 6 and introns 15/16 and 16/17 in 
a Discovery cohort of 24 CD patients and 24 healthy controls. Of these 16 SNPs, 6 of 
the SNPs found in intron 15/16 were present at different frequencies in CD patients 
and controls.  
A combined European dataset comprising 15,694 CD cases and 14,026 controls was 
analysed for the frequency of the 15 SNPs found in the Discovery Cohort. This 
dataset has been published by Franke et al, 2010.  Data for six SNPs was available, 
none of which showed significant differences between CD cases and controls (Table 
23). Data is shown for rs2796471 (p=0.15), rs6559629 (p=0.55), rs911638 (p=0.13), 
rs2777772 (p=0.43), rs2796464 (0.43) and rs2796465 (p=0.22).   
The possible epistatic interaction between NOD2 and TLE1 has been investigated in 
this cohort previously by Dr Elaine Nimmo and TLE1 has not been shown to alter the 
effect of NOD2 mutations.  
 







Table 23 TLE1 SNPs found in Discovery cohort are not associated with CD in a 
larger European Replication cohort 
TLE1 SNPs found in Discovery cohort were analysed in a larger European cohort (Franke 
et al., 2010) , p values shown are Bonferroni corrected.  
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6.4.4 Analysis of SNPs in Scottish cohort 
To further investigate these findings, the frequency of these fifteen SNPs were 
analysed in a larger Scottish Replication cohort of 393 individuals: 203 CD patients 
and 190 healthy controls. This cohort consists of Scottish patients and control data 
collected after the Nimmo et al study in 2011 and there was no overlap between 
patients and controls between the two cohorts. This cohort has been genotyped by the 
WTCRF. All 15 SNPs were analysed in this larger cohort, six SNPs met quality control 
criteria: rs2796464, rs2777772, rs911638, rs2796465, rs62578588, rs2796471 (Table 
24).The remaining SNPs either did not meet QC standards or had not been genotyped. 
The association study was conducted using PLINK v1.9 with the kind help of Dr Nick 
Kennedy (Purcell et al., 2007). Uncorrected p values for all 6 SNPs ranged from 0.65 
to 0.96 and were therefore all non- significant. Odds rations ranged from 0.99 to 1.14.  
 
The possible epistatic interaction between NOD2 and TLE1 has been investigated in 
this cohort previously by Dr Elaine Nimmo and TLE1 has not been shown to alter the 






Squared P value Odds Ratio 
rs2796464 0.26 0.0061 0.94 1.01 
rs2777772 0.26 0.049 0.82 1.04 
rs911638 0.26 0.049 0.82 1.04 
rs2796465 0.26 0.038 0.85 1.04 
rs62578588 0.077 0.208 0.65 1.14 





Table 24 Association study of SNPs found in Discovery cohort in larger 
Scottish replication cohort 
Association analysis of SNPs discovered in Discovery cohort in a larger Scottish 
replication cohort of 203 CD patients and 190 healthy controls. Minor allele 
frequency, chi squared statistics, p values and odds ratios were calculated using 
PLINK. Uncorrected p values are shown. 
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rs147523347 A G 0 0 0 0.01 
7 cell 
types 





rs114633202 A G 0.02 0 0 0      synonymous 
rs7023704 C G 0.04 0.23 0.27 0.29  Huvec 11 cell types  EBF,RXRA intronic 
rs2796471 A G 0.19 0.24 0.05 0.32  Huvec 8 cell types   intronic 
rs6559629 G A 0.49 0.49 0.6 0.51  HMEC 4 cell types  ERα,HIF1,MIZF, TATA,XBP-1 intronic 
rs7019824 C T 0.24 0.04 0.12 0.01  HMEC   Irf,NFE2,Nanog,Pax5,SP1,YY1,Zbtb3 intronic 
rs187303459 C T 0.01 0 0 0   GM12891  Irf intronic 
rs62578588 T C 0.11 0.1 0.04 0.08   Th1   intronic 
rs2796466 G T 0.34 0.33 0.03 0.44   Osteoblasts  CTCF,Foxj2,Foxp1, 
HDAC2,HNF4,Pax5,RXRA,TATA,p300 
intronic 
rs911638 C T 0.05 0.14 0 0.24  HepG2   Spz1,Zfp410 intronic 
rs2777772 T G 0.05 0.14 0 0.23  HepG2    intronic 
rs2796464 T C 0.04 0.15 0 0.24  HepG2    intronic 
rs2796465 G A 0.03 0.14 0 0.24     CEBPB,Foxj2 intronic 
Table 25 Haploreg output  
Haploreg output for 13 of the 16 SNPs discovered in the initial cohort. Data for rs372238712, rs376377585 and rs373720466 was not available. From left to right, 
column are: variant (rs ID), reference allele (major allele), alternative allele (minor allele), MAF in four populations (African, American, Asian and European) (all from 
dbSNP), promoter, enhancer markers (UCSC/Ensemble), DNase 1 hypersensitivity (UCSC/Ensemble), proteins bound (ENCODE), regulatory motif changes 
(ENCODE) and dbSNP functional annotation. 
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Figure 55 Summary of results from TLE1 sequencing 
Summary figure showing regions of the TLE1 sequenced in a cohort of 24 CD patients 
and 24 healthy controls. Results from the sequencing are summarised in the lower boxes. 
 
Chapter 6: Sequencing TLE1 in Crohn’s disease patients and healthy controls       158                                                                                                                                                                                                                                                                                                                                                                                                                                                         
6.5  Discussion 
The aim of the work described in this chapter was to identify any mutations that may 
underlie the association between the rs655629 SNP in TLE1 and Crohn’s disease in 
Scottish populations (Nimmo et al., 2011) . A Scottish cohort of 24 ileal CD patients 
and 24 healthy controls were selected as an initial Discovery cohort. To enrich for 
mutations underlying the rs6559629 association CD patients with the rs6559629 risk 
allele and healthy controls without the risk allele were selected for this cohort.  
All twenty exons of TLE1 were amplified and sequenced in the Discovery cohort, two 
SNPs were discovered: rs147523347 (p=1) and rs114633202 (p=0.56). Both SNPs 
encoded synonymous changes and the minor allele was present in both CD patients 
and healthy controls.  
 
Additionally two TLE1 introns: 15/16 and 16/17 were identified by association with 
CD and the SuRFr pipeline, respectively, as of regions of particular interest and were 
also sequenced in the Discovery cohort. Thirteen variants (including one deletion) 
were found in intronic regions of which rs2777772 (p=0.003), rs2796465 (p=0.00095) 
and rs2796464 (p=0.02) were present at different frequencies in patients and controls 
and achieved statistical significance. However, it is important to note that this 
significance does not reflect differences in the general population due to selection of 
controls and patients according to rs6559629 genotype.  
 
Where possible, each of the 15 variants found in the Discovery cohort was followed 
up in a larger Scottish (CD=203, HC=190) and European replication cohort 
(CD=15,694, HC=14,026) of 203 CD patients and 190 healthy controls. None of the 
six SNPs were present at significantly different allele frequencies in CD patient’s vs 
healthy controls in the replication cohort.  
 
In this study a case control cohort were specifically selected based on rs6559629 
genotype, therefore any statistical tests performed on the Discovery cohort are not a 
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true representation of population allele frequencies. This cohort allowed identification 
of variants in LD with the rs6559629 SNP that were not typed by the study conducted 
by Nimmo et al in 2011. This work has focused on the Scottish population, the 
rs6559629 association with CD has not been replicated in the UK (unpublished data, 
UK IBD consortium; (Franke et al., 2010)). This may be due to differences in 
ancestry/founder populations between Scottish and English populations leading to 
genetic heterogeneity. The Scottish population has been shown to have stronger 
Scandinavian influence than the English population which is reflected in differences 
in mitochondrial and Y chromosomal DNA (Capelli et al., 2003; Goodacre et al., 
2005). This is complemented by geographic differences in NOD2 genotype 
frequencies, which show that the NOD2 1007fsInsC and R702W variants are less 
common in the Scottish population than in the USA or central Europe (Arnott et al., 
2004).  
 
Figure 56 NOD2 allele frequency in Europe 
Frequency of NOD2 L1007insCfs allele across Europe, frequencies are higher in central 
and southern Europe when compared to northern Europe.  
 
 
Furthermore, the clear north-south divide in IBD incidence implies genetic differences 
between populations in addition to environmental differences. Future work could 
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involve deep sequencing of the TLE1 region in both Scottish and Scandinavian 
populations. Recent studies have focused on deep sequencing of susceptibility genes 
discovered by GWA studies in order to identify low frequency, causative variants. In 
IBD, deep sequencing has revealed rare variants in loci known susceptibility loci 
including: NOD2, IL23R and XBP1 (Balzola et al., 2012; Kaser et al., 2008).  
 
Two synonymous exonic SNPs were found in the Discovery cohort used in this study: 
rs147523347 (exon 2), rs114633202 (exon 6). Both SNPs had a low MAF as would be 
expected of a rare causative variant (between 0.0009-0.003). However, neither showed 
different allele frequencies between CD patients and healthy controls: rs147523347 
(p=1), rs114633202 (p=0.60). Data for these SNPs was not available in the much larger 
cohort of 393 (203 CD patients and 190 healthy controls). Although these SNPs are 
not present at statistically significant frequencies, follow up analyses i.e. deep 
sequencing of the TLE1 region are warranted, particularly with regard to the 
rs114633202 SNP as it was not observed in CD patients and therefore may have a 
protective effect. Both these SNPs are synonymous, however they may still be of 
functional significance, it has been shown that synonymous variants in the Multi drug 
resistance gene (MDR1) have functional consequences. MDR1 encodes an ATP 
dependant, membrane bound, drug efflux pump. Synonymous mutations in exon 26 of 
the MDR1 gene encode a rare codon which delays co translational protein folding. This  
results in a protein product with altered structure, which interacts differently with both 
drug substrates and inhibitors (Kimchi-Sarfaty et al., 2007). As these are exonic SNPs, 
even synonymous variants could have a profound effect on translation efficiency, 
translation efficiency or other factors such as transcription factor binding.  
  
In addition to the exonic SNPs discussed there were a number of promising intronic 
SNPs identified in the Discovery cohort. The indel variant, rs376377585 was seen as 
a seven base pair deletion in three healthy controls. This variant may have a protective 
effect and warrants further investigation in larger cohorts as data for this variant was 
not available in the larger European and Scottish cohorts used in this study. Other 
intronic variants of interest include those in intron 16/17 which were present at 
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statistically significant allele frequencies between cases and controls, although they 
did not show significance in the larger cohorts discussed in this study it may be of 
interest to look at the frequency of these variants in Scandinavian cohorts.  
 
A key limitation of this work is that it may have lacked the power necessary to detect 
statistically significant differences in allele frequencies. Due to the study design, the 
exact power cannot be calculated as the cohort was enriched for CD cases with the 
rs6559629 risk allele. However, if this was a standard GWA study the number of 
people needed to achieve 80% power to replicate the association between rs6559629 
and CD would be approximately 10,000 cases and controls. This is not possible in a 
Scottish cohort, however the UK replication cohort used met these criteria. Given that 
the rs6559629 SNP was not associated with CD in this cohort, it may be the case that 
the Nimmo et al finding was an artefact or that the association is a Scottish specific 
finding, as previously discussed. Additionally, the strongest association between TLE1 
and CD was seen in ileal CD patients, the European replication cohort did not have 
sub phenotypic data and therefore the TLE1 association may have been masked.  
Current projects in our laboratory involve the collection of DNA samples from Scottish 
CD patients as well as Scandinavian and other European CD patients, analysis of TLE1 
in these patients will help to determine the significance of the association between 
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The work presented in this thesis investigates the role of the TLE1 gene in Crohn’s 
disease. TLE1 was identified as a potential CD susceptibility gene by Nimmo et al 
(2011). A yeast 2 hybrid study showed that TLE1 interacts with the known CD 
susceptibility protein NOD2. Additionally an association study showed that 
polymorphisms in TLE1 were associated with CD in a Scottish cohort (healthy controls 
n=1515, CD = 648). The strongest association was observed between the rs6559629 
SNP in intron 15/16 of TLE1 and cases with ileal CD (p=3.1 ×10-5). Furthermore, the 
rs6559629 risk allele was shown to increase the effect of polymorphisms in NOD2, 
however this it is important to note that only a relatively small proportion of the cohort 
had NOD2 mutations (22.7%). 
 
It is important to note that neither the association between SNPs in TLE1 nor the 
finding that TLE1 polymorphisms increase the effect of NOD2 mutations found in CD 
have been replicated in other cohorts. For example, data from a larger UK cohort of 
4307 healthy controls and 1903 CD cases genotyped for the three NOD2 risk alleles 
and the rs6559629 SNP by the Wellcome Trust Clinical Case Consortium did not 
replicate either of these findings. Although it appears the TLE1 polymorphisms may 
not be important in CD pathogenesis in different populations, they may still be valid 
in Scottish populations as a result of different ancestral lineage of the Scottish 
population compared to the English population. It is also important to note that 
although TLE1 has not been identified by GWA studies in other UK cohorts, 
interacting partners of TLE1 have been identified such as NOD2 (Jostins et al., 2012).  
 
My work, analyses TLE1 sequence, TLE1 expression and interacting partners of TLE1 
in the context of Crohn’s disease. In this chapter, the key findings are discussed 
alongside limitations and further work needed to determine whether TLE1 plays a role 
in IBD pathogenesis. 
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7.1 TLE1 expression and localisation  
7.1.1 Key findings 
Expression and localisation of TLE1 was analysed by immunohistochemistry, in ileal 
resection samples from healthy controls and CD cases. CD cases were grouped in two 
according to whether they had a NOD2 mutation. TLE1 expression was detected in the 
nucleus and the cytoplasm. Overall, expression in CD cases varied from 70% + 
positivity to less than 20% positivity. These differences did not correspond to NOD2 
genotype. However, it is important to note that the three NOD2 mutations: R702W, 
G908R and L1007fs were grouped together in this study. Due to the low frequency of 
these mutations in the Scottish population, ethical concerns did not allow analysis of 
each genotype individually. This may have been the cause of the range of expression 
seen in the NOD2 mutant group.  
 
7.1.2 Future work: TLE1 and NOD2 function in Paneth cells 
TLE1 and NOD2 are expressed in Paneth cells of the small intestine. This expression 
is seen in both the nucleus and the cytoplasm of Paneth cells. As previously discussed, 
Paneth cells are located at the base of the small intestinal crypts and secrete 
antimicrobial peptides in order to protect the crypts from bacterial invasion. The 
autophagy protein ATG16L1, the bacterial sensor NOD2 and numerous UPR genes 
have been implicated in IBD pathogenesis. It has previously been postulated that 
autophagy, UPR defects and defects in bacterial recognition converge to cause Paneth 
cell dysfunction seen in IBD (Figure 57).  Both ATG16L1 and NOD2 variants are 
associated with Paneth cell dysfunction. Interestingly they appear to have cumulative 
effect i.e. cases with risk alleles in both genes had increased numbers of abnormal 
Paneth cells when compared to those with one risk allele (Vandussen et al., 2014). 
Increased expression of the ER stress markers GRP78 and EIF2α (phosphorylated) has 
been shown in cases with the ATG16L1 T300A risk allele. This was shown by 
immunohistochemical analysis of protein expression (Deuring et al., 2014).  
 
Results from this thesis suggest that TLE1 may be involved in the unfolded protein 
response. This is shown by differential expression of TUSC3 following TLE1 
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knockdown. TUSC3 has been implicated in the UPR; TUSC3 knockdown leads to a 
decrease in expression of both the UPR sensor, BiP and the downstream UPR 
transcriptional regulator, CHOP (Horak et al., 2014). TLE1 appears to act as a 
transcriptional co repressor for TUSC3; upon TLE1 knockdown, TUSC3 expression 
increases. The role of TUSC3 has not been shown in the gut, future work may involve 
analysing whether TLE1 influences TUSC3 expression directly and whether the TLE1 
and TUSC3 proteins interact.  
 
The NAD dependant deacetylase, SIRTUIN (SIRT1) has also been shown to interact 
with TLE1. TLE1 was identified as a potential interacting partner of SIRT1 using a 
yeast two hybrid assay; these results were confirmed in HeLa cells overexpressing 
TLE1 and SIRT1 (Ghosh et al., 2007b). SIRT1 has been implicated in both the ER 
stress response and autophagy. These are both processes that are dysregulated in IBD 
and are important to Paneth cell function. In mouse models of obesity 
immunohistochemical analysis of liver tissue shows increased SIRT1 expression leads 
to decreased expression of ER stress markers: CHOP, GRP79. Additionally SIRT1 
overexpression leads to a loss of phosphorylated EIF2α, as shown by western blotting 
for phosphorylated and unphosphorylated EIF2α isoforms (Li et al., 2011). Reduced 
expression of SIRT1 has also been shown in the colonic mucosa of IBD cases, 
particularly in the intestinal crypts, where both NOD2 and TLE1 are expressed. SIRT1 
expression is principally nuclear in the colonic mucosa, however there are also very 
low levels of cytoplasmic staining in the crypts (Melhem et al., 2015). SIRT1 over 
expression appears to stimulate autophagy in the intestinal epithelial cell line, 
HCT116. Co immunoprecipitation experiments using HeLa cells show that SIRT1 
interacts with the autophagy proteins: ATG 6, 7 and 8 (I. H. Lee et al., 2008). Results 
from this thesis suggest that TLE1 does not influence expression of SIRT1, however 
the interaction between TLE1 and SIRT1 may provide a link between TLE1, the UPR 
and autophagy.  
 
TLE1 knockdown altered expression of two predicted mTOR interactors: RIOK1 and 
CCND1. mTOR is a serine threonine kinase which is involved in numerous metabolic 
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pathways e.g. protein translation, ribosome biogenesis and cell growth. It 
phosphorylates over 800 proteins. There are numerous lines of evidence suggesting 
mTOR is involved in autophagy. Under normal conditions (non- starvation) mTORC1 
phosphorylates transcription factor EB (TFEB). Phosphorylated TFEB is retained in 
the cytoplasm. However if mTOR is inhibited, for example by nutrient starvation, 
TFEB translocates into the nucleus (Martina, Chen, Gucek, & Puertollano, 2012). 
Activated, unphosphorylated  TFEB was shown to initiate transcription of 11 out of 
51 autophagy related genes, these included: UVRAG,ATG9B and WIPI (Settembre et 
al., 2011). mTOR inhibition has also been shown to initiate autophagy in model 
organisms (Ravikumar et al., 2004). mTORC1 forms a complex with the autophagy 
proteins ULK1 and ATG13 in HEK 293T cells (Hosokawa et al., 2009).   
 
Taken together, it could be hypothesised that TLE1 may contribute to the Paneth cell 
dysfunction seen in IBD via interaction with/regulation of UPR (SIRT1 and TUSC3) 
and autophagy regulators (SIRT1). Further investigation of this by analysing 
colocalisation and of NOD2 and TLE1 along with autophagy and UPR proteins may 
help to elucidate this. The use of animal models to study the effects of TLE1 and NOD2 
knockdown on UPR and autophagy gene expression in Paneth cells may also be of 
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Figure 57 The UPR, bacterial sensing and autophagy contribute to Paneth cell 
dysfunction 
Adapted from (Van Limbergen, Radford-Smith, & Satsangi, 2014). Schematic diagram 
showing development of the ileitis from normal intestinal crypts. Autophagy, bacterial 
sensing and the ER stress response are all thought to play a role in the development of 
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7.2 Sequence analysis of TLE1  
7.2.1 Key findings  
The strategy used in this study was different to standard GWAS studies in that the 
cohort was specifically selected according to rs6559629 genotype. Additionally only 
CD cases with ileal CD were studied as this group of cases showed the strongest 
association with rs6559629. This Discovery cohort allowed identification of variants 
in LD with the rs6559629 SNP that were not typed by the study conducted by Nimmo 
et al in 2011.  A Discovery cohort of 24 CD cases and 24 ileal CD cases with the 
rs6559629 risk allele and alternative allele, respectively were chosen for this study. 
Due to this enrichment p values shown for the Discovery cohort are not representative 
for the general Scottish population and are only provided as a guideline to suggest 
differences in frequency. These frequency of these variants was then analysed in two 
replication cohorts: a Scottish cohort (203 CD cases, 190 controls) and a combined 
European cohort (6,333 CD cases, 15,056 controls). None of the variants identified 
were present at statistically different frequencies between CD cases and controls.  
 
The finding suggesting TLE1 is not associated with CD in larger European cohort 
poses the key question: is the association shown in the Nimmo et al study an artefact 
of the relatively small numbers used or is it representative of a population specific 
association? Differences between Scottish and English ancestry are discussed in depth 
elsewhere. In summary, the Scottish population has been shown to have stronger 
Scandinavian influence than the English population which is reflected in differences 
in mitochondrial and Y chromosomal DNA (Capelli et al., 2003; Goodacre et al., 
2005). This is complemented by geographic differences in NOD2 genotype 
frequencies, which show that the NOD2 1007fsInsC and R702W variants are less 
common in the Scottish population than in the USA, UK or Europe and are almost 
absent in Japan, Korea and China (Arnott et al., 2004). Furthermore, the clear north-
south divide in IBD incidence implies genetic differences between populations in 
addition to environmental differences. Low NOD2 mutation frequency in Scottish and 
Scandinavian cohorts may be a reflection of Viking ancestry compared to more 
prevalent Anglo-Saxon ancestry in England. Population specific associations have 
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been identified in other IBD susceptibility loci, for example insertion/deletion variants 
in the IGRM locus that have been associated with CD in European populations, these 
are not found in Japanese populations (Prescott et al., 2010).   
 
Although SNPs found in TLE1 were followed up in the largest available Scottish 
cohort, this cohort may still have been underpowered to detect significant differences 
in carriage frequency. These SNPs were also followed up in a larger combined cohort 
of cases and controls across Europe, results did not show any differences in carriage 
frequency. Current projects in our lab involve collection of samples from both Scottish 
and European cohorts, this will enable us to determine whether TLE1 is associated 
with CD in larger Scottish cohorts and Scandinavian cohorts. 
 
7.2.2 Future work: Deep Sequencing of the TLE1 locus 
Although the size of the Discovery cohort allowed detection of mutations at 
approximately 1% frequency in the population, it may have been underpowered to 
detect more subtle differences in the frequency of the 15 variants found in the 
Discovery cohort. The exact power of the Discovery cohort cannot be calculated due 
to study design. Additionally the size and approach used may not have allowed 
identification of rare private mutations. Furthermore, Sanger sequencing was used to 
sequence these samples, this type of sequence only produces a single read from each 
sample. The use of technology to get multiple reads would allow identification of 
mutations present in cell subtypes present at less than 1% frequency in the sample.   
 
Deep sequencing involves generating thousands of reads for the same sequence which 
allows for increased coverage and identification of rare mutations that may only be 
present in a very small proportion of the cells from which the DNA sample originates. 
An alternative approach to identifying variants underlying associations identified by 
GWAS studies involves deep sequencing of genes in larger groups of cases. More 
recently this has become more accessible due to the decrease in costs of next 
generation sequencing technologies.  
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 A recent study deep sequenced 50 known IBD susceptibility genes in a cohort of 350 
cases and controls, mutations found were then genotyped in a much larger cohort of 
16,054 Crohn’s disease cases, 12,153 ulcerative colitis cases and 17,575 healthy 
controls. Private causative and protective variants in NOD2 as well as other IBD 
susceptibility genes were identified. This study used a mixed European cohort which 
would not be appropriate for deep sequencing TLE1 as the association between CD 
and TLE1 have not been observed outside of the Scottish population, however, a study 
similar to the initial cohort would be feasible in the Scottish population.  
 
7.3 TLE1 interacting proteins   
7.3.1 Key findings: TLE1 and XBP1 
Analysis of the rs6559629 SNP in TLE1 revealed it interrupts a potential XBP1 
binding site. In this work a ChIP assay was designed optimised and implemented for 
XBP1 and results from cell lines show that exogenous XBP1 does not bind to its 
predicted binding site in TLE1.   
 
7.3.2 Future Work: TLE1 and XBP1 
The rs6559629 site is not in a known promoter region, the nearest TSS is the TLE1 
TSS which is approximately 10Kb downstream of the XBP1 recognition motif in 
intron 15/16 of TLE1. Many studies have focused on the binding of XBP1 to promoter 
regions for example XBP1 has been shown to bind to promoter regions of GPR43, 
CHOP and BECLIN1 using ChIP assays (Ang et al., 2015; Margariti et al., 2013; Shao 
et al., 2015). Although the potential binding site interrupted by rs6559629 was not 
close to a TSS it was targeted by this study as it had sequence overlap for two core 
XBP1 binding motifs. Additionally although Acosta et al suggest that many of XBP1 
binding motifs occur at transcriptional start sites, their work used proximal promoter 
arrays and hence a long range transcriptional activation mechanism for XBP1 cannot 
be ruled out. Many transcriptional regulators have been shown to have long range 
effects in addition to short range ones. For example, the transcriptional activator, 
Estrogen receptor (ER) has only 22% of its targets near TSS, the remaining targets are 
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long range targets, some of which are up to 100Kb away from a TSS. Furthermore 
these distal ER binding sites are functional and activate transcription of downstream 
genes  (Carroll et al., 2006).  Although according to this work XBP1 does not bind the 
rs6559629 site, given that XBP1 is an IBD susceptibility gene in its own right, it would 
be of future interest to explore long range effects of XBP1 to further elucidate its role 
in IBD pathogenesis.  
   
In this work binding of both the spliced and unspliced forms of XBP1 was analysed. 
Recent work has shown that the XBP1 (us) is a functional interacting protein. It has 
been shown to interact with the autophagy protein FOXO1, by co-
immunoprecipitation and colocalisation was shown using immunocytochemistry. It 
was also suggested that XBP1(us) facilitates degradation of FoxO1 by the proteasome 
(Zhao et al., 2013). Although the work presented suggests XBP1 (us) does bind to the 
same positive control regions as XBP1 spliced, it is possible that XBP1 (us) has 
different targets and mechanisms of action to XBP1 (s). As the positive control used 
in this work only worked for XBP1 (s) it could be the case that the ChIP assay did not 
accurately detect the XBP1 (us) targets. The use of high throughput technologies such 
as chip on chip to identify XBP1 (us) targets would be of interest, to identify whether 
XBP1 (us) binds to the rs6559629 site as well as to compare XBP1 (s) and XBP1 (us) 
functionality.  
 
7.3.3 Key Findings: TLE1 and NOD2 
 
In 2011, the NOD2/TLE1 interaction was identified in HEK293 cells over expressing 
NOD2 and TLE1. As part of this project attempt was made to further characterise 
this interaction in cell lines using western blotting and co immunoprecipitation 
however a functional antibody could not be identified.  
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7.3.4 Future Work: TLE1 and NOD2 
Further characterisation of this interaction to identify which regions of the proteins 
are involved in this interaction was attempted. However, this was limited by time 
constraints and a lack of a functioning TLE1 and NOD2 antibody. Further 
characterisation using the recently identified NOD2 antibody is warranted.  
 
Additionally, the direct interaction between TLE1/NOD2 has not yet been confirmed 
in human tissue samples. This is necessary to confirm that results from cell lines are 
representative of human cells. Currently this is not possible due to the fact that both 
the functional NOD2 and TLE1 antibodies available are raised in the same species 
and cannot, therefore, be used in co localisation experiments such as 
immunohistochemistry using fluorescently tagged markers.  
 
 
7.4 Future Perspectives 
7.4.1 Analysing methylation of TLE1 
This work presented in this thesis did not analyse either epigenetic changes in TLE1. 
Alterations in methylation of loci have been shown to alter transcription factor 
binding and gene expression. 
 
The rs6559629 SNP creates or destroys a potential CpG site by substitution of A to G.  
The methylation status of this CpG site may influence XBP1 binding. As previously 
discussed an appropriate pyrosequencing assay could not be designed for this site. 
Future work could use chip technology to analyse global methylation in Scottish adults 
in the rs6559629 region. The rs11190140 SNP in NKX23 was shown to be associated 
with IBD in a Pennsylvanian cohort and it also interrupted CpG site. Bisulphite 
sequencing was used to analyse the methylation status of the rs11190140 site and 
showed the C allele was methylated in a subset of IBD cases with the C allele. 
Furthermore, methylation of the site was shown to alter binding of the transcriptional 
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regulator NFAT1 in B cells using a ChIP assay (John et al., 2011).  As the methylation 
status of the rs6559629 site is not known in the cell lines used it may not accurately 
reflect the situation in IBD cases. Previous work has analysed global methylation in 
paediatric IBD cases vs controls. Four sites in TLE1 are included as part of these 
studies, these sites did not include the rs6559629 SNP and were not differentially 
methylated between cases and controls  and hence the methylation of the rs6559629 
site warrants further investigation (Adams et al., 2014).   
 
TLE1 promoter methylation is altered in hematologic malignancies. The CpG island 
located in the TLE1 promoter region (approximately 500bp from the TSS) was 
analysed by Fraga et al using a combination of bisulphite sequencing and methylation 
specific PCR.  It has been shown that the TLE1 promoter is only methylated in 
haematological cell lines; analysis of intestinal epithelial cell lines such at HCT 116 
and SW 480 are not methylated in this region (Mario F Fraga et al., 2008b). The rest 
of the TLE1 gene has not been analysed for methylation with regard to disease status. 
SNPs in the promoter region of TLE1 were not analysed as part of the Nimmo et al 
study. Recent work in our lab had analysed genome wide methylation in paediatric 
cases and controls. This work led to the identification of mir21 as differentially 
methylated between cases and controls. Furthermore, hypomethylation of the region, 
confirmed by an Illumina methylation chip and subsequent pyrosequencing, 
corresponded to increased VMP1/mir21 expression in leukocytes and inflamed 
intestinal tissue of IBD cases (Adams et al., 2014; Noble et al., 2010). A Scottish 
cohort was used in this study and was shown to be sufficiently powered to detect 
changes in methylation, a similar cohort could be used to investigate the methylation 
of the TLE1 promoter and rs655929 region. It is important to note that TLE1 is 
differentially methylated according to sex and this would need to be corrected for in a 
patient cohort (J. Liu, Morgan, Hutchison, & Calhoun, 2010).  
 
7.4.2 Summary of future work 
This thesis has raised new questions as to how TLE1 may be involved in IBD 
pathogenesis. Key questions that should be the focus of future work are listed below. 
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1. Deep sequencing of the TLE1 locus in a Scottish cohort. 
The work described in this thesis shows sequence data for TLE1 in a 
cohort of Scottish cases. This was conducted in order to identify 
mutations underlying the rs6559629 association with ileal CD. The 
study design used a small cohort enriched with CD cases enriched for 
the rs6559629 risk allele. Although some variants were identified, none 
were limited to cases or healthy controls. Recent studies have used 
cohort sizes similar to our Scottish cohort (approximately 393 cases and 
197 controls) to deep sequence known IBD susceptibility genes and 
identify rare variants underlying associations from GWAS studies. 
 
 
2. Role of TLE1 in Paneth cells 
This thesis shows that TLE1 is expressed in the Paneth cells of the small 
intestine. Colocalisation of TLE1 and NOD2 in Paneth cells has not been 
shown as both antibodies are raised in the same species. The use of 
serial sections to analyse TLE1 and NOD2 staining in the same cells is 
currently being undertaken in our laboratory. In recent years, there 
have been great advances in microscopy techniques such as super 
resolution photo activated localization microscopy (PALM). These 
techniques allow for live cell imaging and deep tissue imaging would 
be of interest to study NOD2 and TLE1 expression and localisation in 
the human gut. Although these types of microscopy are not yet 
commercially available, independent laboratories have built the 
microscopes in question. 
3. TLE1 in autophagy 
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TLE1 knockdown studies showed that TLE1 may be involved in 
autophagy and two potential TLE1 targets are predicted to interact with 
the known autophagy protein, mTOR. Further characterisation of 
potential TLE1/mTOR interactions and the mechanism by which TLE1 
would be of interest to future work as autophagy is dysregulated in 
IBD.  
4. TLE1 in the UPR 
Although XBP1 (sp) does not appear to bind TLE1, this work shows that 
TLE1 knock down alters expression of the UPR gene, TUSC3. The 
potential XBP1 (we) /TLE1 interaction and the mechanism behind 
TUSC3/TLE1 interplay may provide additional mechanisms by which 
TLE1 is involved in IBD pathogenesis.  
5. TLE1 in S1P signaling 
SGPL1 is a member of the S1pP signaling pathway and its expression is 
altered by TLE1 knockdown. This work was done at the RNA level, 
future work could look at analysing this relationship at the protein level 
in addition to investigating the mechanism by which TLE1 may be 
involved in S1P signaling 
6. Methylation analysis of TLE1 
Methylation changes in TLE1 have been associated with disease (M. F. 
Fraga et al., 2008). Work in our lab has shown differential methylation 
of genes between IBD cases and healthy controls in a Scottish cohort 
(Adams et al., 2014). The methylation status of the TLE1 promoter and 
the rs6559629 region was not investigated by this study and hence 
would be of interest in future work. Methylation analysis could be 
analysed by genome wide analysis or individual CpGs could be 
analysed by pyrosequencing. 
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Table 27 RIOK1, TUSC3, SGPL1 and CCND1 RT qPCR primers 
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XBP1 promoter 1 CTCGGCTAGAAGACACCTCC 
GTCCCAACTCCAGAGCCTC 
XBP1 promoter 2 CAGGAGGCTCTGGAGTTGG 
TGGTAGGGAGGGAACAGGAT 
XBP1 promoter 3 TTTCCCATCCTGTTCCCTCC 
GTAATTATTGCTTCCTCCTCTGC 
XBP1 promoter 4 AACCTGGAATAGTGCTGCCC 
TGGCCAGGTGTTTGTGAAAG 
XBP1 promoter 5 GCCCCTCTTTCACAAACACC 
CCTCGGCCTCCCAAAGTG 




XBP1 promoter 7 GGTATTCCCCTCCAACCCAG 
AGGTTTCAGTGAGCCGAGAT 
XBP1 promoter 8 ATCTCGGCTCACTGAAACCT 
CCATCCGGAGTGACAGAATT 
XBP1 promoter 9 TCAGTCTGGAAAGCTCTCGG 
CTCGGCGTCCATTGGTCC 
XBP1 promoter 10 CATAGCCACGGTCCTGAAAC 
AGCAGAACTTTAGGGGTCCC 
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Rs6559629 site primer set 1 
TGCACAAGGGCAATTTCTCC 
GGAGAGCCTCTGTAAACCACT 
Rs6559629 site primer set 2 
AGTGGTTTACAGAGGCTCTCC 
AACCAGCTCTCTCAGGTCTC 
Rs6559629 site primer set 3 
GGAGACCTGAGAGAGCTGG 
AGAGATCCGAACATGTCCCA 
Rs6559629 site primer set 4 
TGGGACATGTTCGGATCTCT 
GGTGAAACCCCGTCTCTACT 
Rs6559629 site primer set 5 
GTTTCACCATGTTAGCCAGAATG 
AGGCAGACACCACACCAG 
Table 29 rs6559629 site RT qPCR primers used for ChIP 
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TLE1 Exon number Primer Sequence Optimum annealing temp (°C) PCR product length (bp) 
Forward Reverse 
Exon 1 AACCTCGCTCCCCTTTG AAATTAAGAGTTTCGGCCC 59.3 819 
Exon 2 TCGTTTTCAGCCACTTCTAAC GAGACTCCACACGCCAC 59.3 400 
Exon 3/4 GAAGTGCAAATATGTGAGGC CAAGAAGCAACCCTTGATG 61 400 
Exon 5 CCATTTTATACACATTTCCAGAG CCATTTCTACAGTGTGCCC 61 360 
Exon 6 CATTCTCAGTTTTTCTTTCCC CACACACGTAAAGCCATC 55.9 335 
Exon 7/8 CATGTCTGTTTTCCCCTG CCTCTTATCTCATTGTTTGCTC 61 423 
Exon 9 ATTGCAAAGTCAGGGTCTC CCGGCAGAAGCATAATTTAC 61 497 
Exon 10 CAAACTGATAGAGAGCCTGC AGAAGTTGCAAGAGGTCCC 61 313 
Exon 11 GTACAACCCCAACCCG CTCAAGCAGCAAAACCC 55 374 
Exon 12 GAAAATTGGCTGAGGGAG CGTACATTTCATATTTGTAGGGC 55.9 370 
Exon 13 CCCTAGAAGCCTTACCCTTTC AGACTGGGCGTCTTTGTC 56.7 455 
Exon 14 GGGGATCTGTGAGTTTCTAA GACACCAGAAATCTCCTTTGG 55.9 318 
Exon 15 TTTGCACCAGCAGTAAATG CAGGAAACAGAAGGGGC 55 538 
Exon 16 CCATGAAACACCACTCTTAACTC CATGCCTGGCATTCAAG 55.9 474 
Exon 17 CACGGTCCAAAACTAACAAC CAGCCCTGATCTCGTTTGTT 55.9 350 
Exon 18  AGTCTGGACTTGGCTGATTAC TATTGCATCCAGCTGCTC 55.9 331 
Exon 19  GTCCTTAGGGCATGATAGTTC TAGACTGTAGCCTTCTTGTCCC 56.7 431 
Exon 20 GTCCTTAGGGCATGATAGTTC TAGACTGTAGCCTTCTTGTCCC 56.7 431 
Table 30 Primer details for TLE1 exon sequencing 
PCR/ sequencing primer sequences, optimal annealing temperature and PCR product length for each of the TLE1 exons  
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2 Appendix 2: Patient Information 
 Average Age Gender 
Male Females Males Females 
CD cases without 
NOD2 variants 
30 29 3 7 
CD cases with NOD2 
variants 
30 34 3 7 
Table 33 Patient information for IHC study 
 Average Age Gender 
Male Females Males Females 
Healthy 
controls 
54 54 10 14 
CD cases 66 64 12 12 
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